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Abstract 
 
Herpes simplex virus type I (HSV-1) is a large, enveloped DNA virus which belongs 
to the Herpesviridae family. HSV-1 is a highly infectious human pathogen that contacts 
mucosal surfaces to initiate infection and causes a range of diseases from mild cold 
sores to keratitis and encephalitis. A growing number of studies point to a sex difference 
in the prevalence and severity of viral infections. However, the role for sex in herpes 
infection is unclear due to the complexity of factors involving in the manifestation of 
HSV diseases. Furthermore, many primary infections are asymptomatic, contributing 
to the difficulty of studying HSV infections in humans. The neurotropic properties of 
HSV make it harder to reach information from infected humans for investigating the 
immune mechanisms controlling reactivation of latent infection within sensory ganglia 
or central nervous system. Therefore, mouse models have been used extensively to 
understand multiple aspects of HSV pathogenesis. However, the molecular basis 
underpinning cross-species differences between humans and mice in response to HSV-
1 infection is unknown. In this thesis, we asked whether these two factors, sex and 
species, may influence HSV-1 replication. Much progress towards these goals has been 
made using reductionist approaches such as in vitro cell cultures and in many situations 
this is the only way that cell-intrinsic mechanisms can be dissected. 
 
We demonstrated that HSV-1 can adapt to specific sex and generate different mutations 
due to selective pressure derived from different sexes. Next, profiling of male and 
female transcriptomic programs revealed that the cytosolic sensing pathway is induced 
to a greater degree in female primary mouse skin cells (female cells), correlating with 
higher yields of infectious virions in male counterparts (male cells). In addition, female 
cells distinctively reactivated Xist, a critical component of X-inactivation, to silence the 
expression of the transcriptional repressor on the X chromosome, which thereby 
maintained higher innate immune responses and further explains the different growth 
phenotypes in HSV-1 replication between the two sexes. Collectively, we propose a 
model in which HSV-1 triggers a sex-specific regulation of antiviral response in the 
cytosolic sensing signalling via the control of Xist. 
 
During investigation of the sex difference, we coincidently found that viperin, an 
interferon-stimulated gene (ISG), is upregulated in mouse but not in all tested human 
cells, which is related to previous findings in the field and encouraged us to 
comprehensively study human-mouse differences in HSV-1 infection. We show that 
the growth kinetics of HSV-1 differed substantially in human and mouse cells. A 
viii 
 
computational pipeline was developed to analyse the cross-species RNA sequencing 
data, revealing over 60% of differentially regulated pathways between these two hosts 
in cell cultures. Strikingly, mouse cells upregulated more genes in the antiviral pathway 
driven by ISGs. To identify the key factor that influences the cross-species difference, 
we identified that Janus kinase 1 (Jak1) is essential for contributing to the human-mouse 
difference in HSV-1 replication. Lastly, we utilized virus mutants to show that HSV-1 
vhs plays an important role to regulate JAK1 expression and therefore activation 
between human and mouse cells.  
 
In summary, this thesis has expanded our understanding on basic differences of cell 
cultures that sex and species can affect scientific interpretations in virus infection. 
Furthermore, the results presented in this study provide rich resources to translate data 
between the two sexes or mouse experiments into the human disease. 
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1.1 Herpes simplex virus 
 
The herpes simplex virus (HSV) belongs to the family Herpesviridae and subfamily 
Alphaherpesvirinae. All viruses within the Herpesviridae share similar characteristics, 
such as particle morphology and have a large double-stranded (ds) DNA genome 
(Roizmann et al., 1992; Davison et al., 2009). Herpesviruses are classified as well by 
their similarities in gene arrangement and, particularly, by sequence similarity in the 
proteins that they encode. Thus, predicted protein sequence similarlity is certainly is an 
important defining characteristic of the alphaherpesviruses as well as all mammalian 
and avian herpesviruses. Viruses within the Alphaherpesvirinae can cause diseases in 
a wide range of animals, including humans, non-human primates, birds and fish 
(Davison, 2002). HSV-1 infection cycle occurs in lytic, latent and reactivation phases 
(Section 1.1.3). During the latent phase, there is no detectable infectious virus, whereas 
during lytic or reactivation phases, HSV-1 is transmissible (Stevens and Cook, 1971; 
Koelle and Corey, 2008). 
 
1.1.1 HSV-1 virion and genome 
 
The three-dimensional capsid structure has been investigated by electron 
cryomicroscopy at 8.5 angstrom resolution (Zhou et al., 2000). HSV-1 particles are 
approximately 150-200 nm in diameter (Grunewald et al., 2003). The outer surface of 
the nucleocapsid is icosahedral and is made up of 162 capsomeres. A lipid envelope 
containing glycoprotein spikes surrounds the capsid. The HSV-1 nucleocapsid is 
surrounded by a tegument and enclosed in an envelope formed from host cytoplasmic 
membranes. There are 11 different HSV-1 glycoproteins that protrude through the 
HSV-1 envelope (van Genderen et al., 1994; Grunewald et al., 2003).  
  
The dsDNA genome is tightly packed into the nucleocapsid (Booy et al., 1991). The 
genome of HSV-1 is around 153 kb and has approximately 68% GC content. During 
HSV-1 infection, the virus expresses at least 74 proteins, although it has been 
speculated that there are about 94 putative open reading frames (ORFs) in the HSV-1 
genome (Rajcani et al., 2004; McGeoch et al., 2006). The HSV-1 genome can be mainly 
divided into two major segments: unique long (UL) and unique short (US) regions 
(Figure 1-1). The UL region encodes around 56 distinct genes and the US region 
contains at least 12 ORFs (McGeoch et al., 1988; Watson et al., 2012). Each region is 
flanked by a pair of inverted repeats, named internal repeats (IRL or IRS), that are 
located at the junction between UL and US, as well as terminal repeats (TRL or TRS) 
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that are located at both ends of the genome. Two functional origins of replication are 
present, OriL in the middle of UL and two copies of OriS in the IRS and TRS, respectively 
(Stow, 1982). Additionally, the “a” sequence is a short repeat found at each terminus 
of the genome and also located as an inverted copy at the junction of the IRL and IRS 
components (Wagner and Summers, 1978). 
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Figure 1-1. Schematic diagram of HSV-1 genome. The HSV-1 genome can be 
majorly classified into two unique linked segments named UL and US. TRL and IRL are 
inverted repeats flanking UL and IRS and TRS are inverted repeats flanking US. The 
“a” region is a terminal redundancy found at the genome termini. 
  
IRLTRL IRS TRSUSUL
a a a
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1.1.2 HSV-1 epidemiology and diseases 
 
1.1.2.1 HSV-1 epidemiology 
 
HSV-1 is one of the most wide-spread human pathogens. The seroprevalence rates are 
approximately 90% worldwide and around 76.5% in Australia (Wentworth and 
Alexander, 1971; Cunningham et al., 2006). Interestingly, age, sex and demography 
may influence prevalence of the disease (Howard et al., 2003). Earlier studies reported 
that the HSV-1 prevalence among females in Australia is higher than among males 
(Roest et al., 2001). One study reported that the HSV-1 prevalence among females was 
80%, which was significantly higher than the prevalence in males (71%) (Cunningham 
et al., 2006). More recent global estimates of the prevalence and incidence HSV-1 
infections have suggested that the prevalence varies widely by region and there is no 
statistically significant difference in prevalence between males and females among all 
age groups (Looker et al., 2015a). Contradictory conclusions among these publications 
may be due to different sample sizes, sample selection criteria and laboratory detection 
methods. Nevertheless, the high HSV-1 prevalence together with the broad spectrum 
and severity of HSV diseases highlights the importance of investigating the 
pathogenesis of HSV-1 so as to relieve the substantial medical burden resulting from 
HSV diseases. 
  
1.1.2.2 Oral herpes 
 
HSV-1 transmission primarily occurs via damaged skin or mucosal surfaces. Oral 
herpes infection is mainly transmitted by oral-to-oral contact through HSV-1 virions in 
saliva. Both primary lytic HSV-1 infection and subsequent reactivation events can be 
asymptomatic or symptomatic, depending on a range of factors, presumably including 
the immunological status of the host (Bustamante and Wade, 1991; Ramchandani et al., 
2016). 
 
The vast majority of symptomatic oral herpes manifest as mild cold sores and fever 
blisters, typically occurring around the mouth (Fatahzadeh and Schwartz, 2007). 
Symptoms often start with small blisters which eventually break open and produce 
sores and then heal themselves within a few weeks (Johnston and Corey, 2016). Mild 
or asymptomatic HSV-1 infection is most common.  
 
1.1.2.3 Ocular herpes 
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Another major clinical problem caused by HSV-1 infections that involve the eye. 
Ocular herpes generally affects the top layer of the cornea and is usually cleared without 
any permanent problems. However, stromal keratitis is developed when the lesion gets 
into the layers of the cornea. This may result in scarring and loss of vision, especially 
with recurrent diseases (Chernakova et al., 2014; Zhu and Zhu, 2014). Recurrent ocular 
herpes is a major problem and a reason for repeated corneal transplants (Remeijer et al., 
2009; Al-Dujaili et al., 2011). 
 
1.1.2.4 Genital herpes 
 
HSV-1 can also be transmitted to the genital area. Importantly, an increase in the 
frequency of genital herpes caused by HSV-1, compared with HSV-2 infection, has 
been reported over the past decades (Reina et al., 2005; Wald, 2006). Individuals who 
already have HSV-1 oral herpes are unlikely to be subsequently infected with genital 
herpes. However, it is possible to have concurrent oral and genital infections with an 
identical strain of HSV-1 in humans (Embil et al., 1981). Genital HSV affects 
approximately 20-65% of pregnant women and most of them are unaware of the 
infection (Corey and Wald, 2009). Additionally, the increased incidence of HSV-1 
isolated from genital herpes lesions could be explained by the lower prevalence of 
HSV-1 among children, leaving them susceptible to HSV-1 later in life (Gutierrez, 
2007). There is an increased prevalence of oral-genital contact, rather than genital-
genital sex, among adolescents, thus raising the risk of transmission of genital HSV-1 
(Wald, 2006).  
 
1.1.2.5 Neonatal herpes 
 
Transmission of HSV diseases to neonates is the most severe consequence of maternal 
genital herpes. Around 0.2-0.39% of all pregnant women shed HSV in the genital tract 
near the time of delivery, regardless of previous history of recurrent HSV infection 
(Pinninti and Kimberlin, 2014). Neonatal herpes can also happen after contact with 
people with cold sores soon after birth. Although neonatal HSV infections remain 
uncommon, there is only a 40% survival rate in untreated cases (Corey and Wald, 2009).  
  
1.1.2.6 Herpes simplex Encephalitis  
 
Severe manifestations, such as encephalitis may occur in some cases (Burcea et al., 
2015; Slifer and Jennings, 2015). In addition, HSV-1 can affect the central nervous 
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system, resulting in herpes simplex encephalitis (HSE) (Whitman et al., 1946). HSE 
prevalence is 2 cases per million people per year of HSE and is responsible for about 
10% of the 20,000 annual viral encephalitis cases in the United States (Levitz, 1998; 
Kuroda, 2015). HSE is associated with more than 50% mortality in untreated cases and 
most of the patients are affected by reactivation of an earlier infection (Whitley, 1988; 
Steiner and Benninger, 2013; Singh et al., 2016).    
 
1.1.3 HSV-1 life cycle 
 
The HSV-1 life cycle can generally be divided into three stages: lytic infection, latency 
and reactivation (Figure 1-2). The virus initiates replication in mucous membranes or 
the epidermis of broken skin as a primary infection site (Boehmer and Nimonkar, 2003; 
Rahn et al., 2017). At these peripheral sites, HSV-1 gains access to the termini of nerves, 
followed by retrograde transport to neuronal cell bodies. The virus is capable of 
traveling back to skin during lytic infection and thus, infecting more cells near primary 
infection sites and causing larger skin lesions (Thompson and Sawtell, 2000; Shimeld 
et al., 2001). With the spread of lesions on the skin surface, it is likely that more 
innervating axonal endings are infected. Hence, virus replication in primary sensory 
neurons contributes to the initial lesion size and subsequently, the spread of virus within 
peripheral neurons (Smith, 2012).  
 
The adaptive immune response can clear HSV-1 primary lytic infection in the 
peripheral sites and ganglia within a few days (Simmons et al., 1992; Chew et al., 2009). 
However, during latent infection, HSV can deposit its genome within neurons and thus, 
establish a lifelong latent infection (Stevens, 1975; Rock and Fraser, 1983; Hill et al., 
1996; Nicoll et al., 2012). Latency is considered to occur when there is a stable reservoir 
of viral DNA without producing infectious virus (Lachmann, 2003; Grinde, 2013). 
Only when certain environmental or physiological stimuli occur, such as stress or 
immunosuppression, will the virus reactivate and return to the lytic cycle, thereby 
producing progeny virions. During the reactivation phase of infection, HSV-1 progeny 
travels down the axon towards the skin and manifests at the initial site of infection. 
(Fraser and Valyi-Nagy, 1993; Suzich and Cliffe, 2018).  
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Figure 1-2. HSV-1 life cycle (primary lytic infection, latency and reactivation). (A) 
The primary lytic infection occurs at the periphery and is initiated in the epithelial cells 
where HSV-1 replicates to produce viral progeny. Viral infection within the cell body 
is productive (filled star). Virus can enter the nerve endings innervating the primary 
infection site. (B) Latency is established by some viruses persist in the sensory neurons 
without production of infectious virus (unfilled star). (C) While latency is disrupted 
with a certain stimulus, HSV-1 can reactivate and initiate productive infection in both 
the primary infection site and neurons. 
 
1.1.4 HSV-1 gene expression  
A. Primary lytic infection
B. Latency
C. Reactivation
Epithelial cells
Peripheral 
nervous 
system 
Epithelial cells
Peripheral 
nervous 
system 
Epithelial cells
Peripheral 
nervous 
system 
Sensory neuron cell body
Sensory neuron cell body
Sensory neuron cell body
10 
 
 
During lytic infection, HSV-1 gene expression occurs in an ordered and time-dependent 
cascade. All HSV-1 protein-coding genes can be classified into three categories: 
immediate-early (IE or α), early (E or β or delayed early) and late (L or γ) genes (Honess 
and Roizman, 1974; Lehman and Boehmer, 1999; Weller and Coen, 2012). The late 
genes are the final group of genes in the cascade. Late gene expression peaks between 
six and twelve hours post-infection (Stingley et al., 2000; Harkness et al., 2014). HSV-
1 transcripts are encoded by the host cell RNA polymerase II transcription machinery, 
and contain 5’ 7-methyl G caps as well as 3’ polyadenylation. Expression is regulated 
by viral proteins that either enhance or suppress the machinery (Ben-Zeev and Asher 
Y'Becker, 1976; Beck and Millette, 1982).  
 
1.1.4.1 HSV-1 gene expression and virus replication during lytic infection 
 
Upon the binding of HSV-1 particles to receptors on the cell surface, the viral envelope 
fuses with the cell membrane and the viral nucleocapsid enters into the cytoplasm. It is 
transported along cytoplasmic microtubules with the help of the motor protein complex 
(Dohner et al., 2002). The HSV-1 capsid is transported to the nuclear pore and the viral 
DNA genome is released into the nucleus in an importin-dependent manner (Sodeik et 
al., 1997; Ojala et al., 2000). Transcription of initial HSV-1 genes is controlled by the 
viral transactivator VP16 acting on the RNA pol II machinery, a late viral protein 
packaged into virion as a tegument component, interacting with the cellular proteins 
octomer binding protein (Oct1) and host cell factor (HCF). The VP16-Oct1-HCF 
interactions induce RNA polymerase II-dependent transcription (Triezenberg et al., 
1988a; Stern and Herr, 1991; Wilson et al., 1993). There are five IE proteins expressed 
by HSV-1, including ICP0, ICP4, ICP22, ICP27 and ICP47. IE genes, such as ICP0 
and ICP4, are expressed within one to two hours post-infection (Harkness et al., 2014). 
ICP0 acts to inhibit the cellular innate immune response and ICP4 is a primary viral 
transcription factor that can negatively regulate the expression of IE genes and stimulate 
the expression of early genes (Persson et al., 1985; Cai and Schaffer, 1992; Yang and 
Courtney, 1995). IE protein synthesis is followed by early gene expression between 
four and seven hours post-infection (Harkness et al., 2014). In general, the products of 
early genes are essential for replication of the viral genome (Honess and Roizman, 1974; 
Challberg, 1986). Both ICP4 and ICP27 also have the ability to promote transcription 
of late genes, which mainly encode structural proteins of HSV-1 or those assisting viral 
assembly (Pizer et al., 1986; Newcomb et al., 2006).  
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The late genes are the final class of genes in the HSV-1 gene expression cascade. HSV-
1 late genes predominantly functions in viral assembly and release of infectious 
particles. They mainly encode structural proteins and many of which form a part of the 
virion with other functions, such as the immunomodulatory protein ICP34.5 and the 
virion host shut-off protein (vhs) (Smiley, 2004; Wilcox and Longnecker, 2016). The 
late genes are subdivided into two classes (γ1 and γ2) based on the requirement for 
DNA replication (Gruffat et al., 2016). Expression of the γ1 genes follows that of the 
early genes and expression of the γ2 genes is dependent on the completion of lytic DNA 
amplification. In addition to the TATA box, the presence of initiator elements which 
overlap the initiation start site, plays an essential role for the regulation of late genes 
(Steffy and Weir, 1991; Guzowski and Wagner, 1993).  
 
At least three HSV-1 proteins, such as ICP4, ICP27 and ICP8, are required for the 
proper expression of the γ1 and γ2 genes. ICP4 interacts with initiator elements in late 
promoters and transactivates late gene expression (Grondin and DeLuca, 2000; 
Zabierowski and DeLuca, 2004). In addition to ICP4, ICP27 has been found to regulate 
the late viral gene, including gC and UL47 (Jean et al., 2001). The ability of ICP27 to 
promote late gene expression has found to be at the mRNA transcription level, as ICP27 
interacts directly with the C-terminal domain of RNA polymerase II (Sandri-Goldin 
and Mendoza, 1992; Zhou and Knipe, 2002). Furthermore, HSV-1 early protein ICP8, 
a single stranded DNA-binding protein, plays a role in late viral gene expression 
(Gruffat et al., 2016). Both the accumulation of late gC mRNA and late protein 
synthesis in cells expressing a dominant negative form of ICP8 indicates ICP8 has 
inhibitory effects on late viral gene expression (Gao and Knipe, 1991; Chen and Knipe, 
1996). 
 
At least seven HSV-1 proteins, including UL6, UL15, UL17, UL25, UL28, UL32 and 
UL33, support the excision of unit-length genomes and their subsequent encapsidation 
(Preston et al., 1983; Beard et al., 2002). The mature virion is transported out of the cell 
by exocytosis (Homa and Brown, 1997). The capsid acquires its first envelope when it 
buds through the inner nuclear membrane, but it will lose the first envelope while 
leaving the nucleus (Homa and Brown, 1997). In the cytosol, the virus gains its final 
envelope studded with viral glycoproteins from cytoplasmic vesicles through the ER-
Golgi intermediate compartment membranes (Homa and Brown, 1997; Baines, 2011). 
After the mature virus exits the cell through fusion with the plasma membrane, HSV-1 
spreads to and infects other susceptible cells, such as epithelial cells or neurons 
innervating the primary site of infection. 
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1.1.4.2 Latency-associated transcripts and lytic genes in latency 
 
It has been proposed that during latent infection, DNA remains in a non-replicating and 
quiescent state in the neuronal nuclei until receiving outside stimulation to reactivate 
(Perng and Jones, 2010; Thellman and Triezenberg, 2017). Latency-associated 
transcripts (LATs) are transcribed from a locus within the repeat regions flanking the 
HSV-1 UL sequence. This transcription produces an 8.3 kb transcript. Subsequently, 
the LAT undergoes sequential splicing events to produce a 2.0kb, then a 4.5kb stable 
intron (Zabolotny et al., 1997). Functionally, LATs have an anti-apoptotic function and 
a role in epigenetically regulating lytic genes (Gupta et al., 2006; Bloom et al., 2010). 
In addition, several microRNA (miRNA) sequences have been identified within LATs 
(Cui et al., 2006; Umbach et al., 2008; Jurak et al., 2010). Despite LAT’s various 
functions and its abundance during latent infection, it is generally accepted that LATs 
are not the key gene to establish latency, maintain latency or induce reactivation (Javier 
et al., 1988; Sedarati et al., 1989; Steiner et al., 1989). Originally, it was widely agreed 
that HSV-1 gene expression is silent during latency. However, with the improvement 
of experimental methods, recent reports have indicated that spontaneous molecular 
reactivations and certain viral transcripts can be detected during latency (Feldman et al., 
2002; Ma et al., 2014). For example, transcripts of the IE gene ICP4 are found in the 
ratio of one to seven molecules of RNA in latently-infected cells, as compared to the 
viral genome in 20% of ganglia (Kramer and Coen, 1995; Feldman et al., 2002). 
Furthermore, several studies have revealed that lytic gene expression in HSV-1 latency 
is correlated with host gene regulation (Nicoll et al., 2016; Russell and Tscharke, 2016; 
Cliffe and Wilson, 2017). This also indicates that managing HSV latency engages 
active cellular responses to viral activity (Ma et al., 2014; Russell and Tscharke, 2016). 
Nevertheless, there is still debate over gene expression during reactivation. This 
situation may occur because the various models of reactivation are triggered by 
different cellular stimuli and popular models employ rodents or rodent neurons that 
may not reflect the natural virus-host interaction (Du et al., 2011; Webre et al., 2012).  
 
1.2 Recognition of HSV-1 in host cells 
 
During the initial microbial infection, host cells utilise pathogen-recognition receptors 
(PRRs) to sense pathogen-associated molecular patterns (PAMPs). PAMPs are 
microbe-derived molecules of pathogens such as nucleic acids, proteins and lipids 
(Akira and Hemmi, 2003; Akira and Takeda, 2004). The recognition of PAMPs by 
PRRs results in activation of signalling pathways that work to control microbial 
replication (Akira et al., 2006). Multiple mechanisms of nucleic acid sensing exist to 
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trigger innate immune responses against HSV-1. Therefore, HSV-1 has evolved 
strategies to counteract host sensors and the cellular signalling pathway (Ma and He, 
2014).  
 
1.2.1 Toll-like receptors (TLRs) 
 
The first discovered and well-characterised PRRs were the Toll-like receptor (TLRs) 
(Medzhitov et al., 1997). TLRs are located in the plasma membrane and endosomal 
vesicles. TLRs bind with microbial elements and can induce early antiviral cellular 
responses and stimulate the secretion of  mediators to activate nearby cells (Kawai and 
Akira, 2011). The role of each TLR in HSV-1 infection remains controversial and likely 
contributes to virus control in a cell-specific manner. Three TLRs have been found to 
be important in HSV-1 infection, namely TLR2, TLR3 and TLR9 and each of them will 
be discussed below. 
 
1.2.1.1 TLR2 
 
TLR2 is the predominant sensor located on the plasma membrane that engages in 
antiviral defences (Beutler, 2009). TLR2 has been shown to be capable of detecting a 
broad range of herpesviruses, including HSV-1, cytomegalovirus (CMV), Epstein-Barr 
virus (EBV) and varicella-zoster virus (VZV) (Aravalli et al., 2005; Wang et al., 2005; 
Szomolanyi-Tsuda et al., 2006; Gaudreault et al., 2007). The activation of TLR2 by 
HSVs is primarily induced by the binding of viral envelope glycoproteins (gH/gL) to 
TLR2. Downstream signalling after receptor ligation induces nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) activation, type I interferon (IFN) 
production and interleukin-10 (IL-10) secretion (Gianni et al., 2013; Cheshenko et al., 
2014). Yet, the specific downstream consequence of inducing TLR2 is virus strain- and 
infection route-dependent. Only certain laboratory strains and clinical isolates of HSV-
1 lead to the TLR2-dependent pathway (Sato et al., 2006). Sensing intraperitoneal and 
ocular HSV-1 infection via TLR2 can be detrimental to the host due to severe 
inflammatory responses with excessive secretion of cytokines in the brain. Reduced 
mortality and proinflammatory cytokine production have been observed in TLR2-
deficient neonatal and adult mice infected with HSV-1 (Kurt-Jones et al., 2004; Finberg 
et al., 2005; Kurt-Jones et al., 2005).  
 
1.2.1.2 TLR3 
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TLR3 is an endosomal TLR and well-studied for its ability to recognise dsRNA, and 
thus, induce expression of type I IFN and inflammatory cytokines (Jensen and Thomsen, 
2012; Perales-Linares and Navas-Martin, 2013). During HSV-1 infection, viral dsRNA 
is detectable and serves as the ligand for TLR3, although the mechanism is still unclear 
(Jacquemont and Roizman, 1975; Hayashi et al., 2006). Several reports have used that 
deletion or mutation of TLR3, resulting in defective signalling to study its function. For 
example, a single amino acid substitution (P554S) impairs the dsRNA binding activity 
and dimerization of TLR3, which was associated with the development of herpes 
simplex encephalitis (Zhang et al., 2007; Guo et al., 2011). However, the deficiency in 
TLR3 in patients did not increase the susceptibility for other viral infection and the 
efficiency of spread of HSV-1 in the periphery (Zhang et al., 2007; Guo et al., 2011). 
Together, this suggests that TLR3 may be dispensable for antiviral responses in the skin 
in humans. Similarly, the type I IFN signalling mediated by TLR3 in HSV is cell-
specific. For example, when stimulated with dsRNA or HSV, human TLR3-deficient 
peripheral blood mononuclear cells (PBMC) and leukocytes still generate type I IFN 
(Guo et al., 2011). However, this was not observed in human fibroblasts (Guo et al., 
2011). In addition to IFN signalling, TLR3 has been shown to be upstream of the 
activation of several transcription factors, including NF-κB, Jun amino-terminal kinase 
(JNK) and p38, both in immortalised and in primary human corneal epithelial cells (Li 
et al., 2006). In the murine model, HSV replicates more efficiently in TLR3-deficient 
neurons and astrocytes, indicating that TLR3 is essential for the intrinsic immunity of 
type I IFN to HSV-1 in the central nervous system (Lafaille et al., 2012; Reinert et al., 
2012). However, TLR3 signalling is not required for type I IFN production in murine 
macrophages during HSV-1 infection (Malmgaard et al., 2004). These results indicate 
the redundant role of TLR3 in various cell types and suggest that there may be a human-
mouse difference in the utilisation of TLR3 as an antiviral factor against HSV-1 
infection.  
 
1.2.1.3 TLR9 
 
TLR9 is one of the endosomally localised PPRs, just like TLR3, 7 and 8 (Yang et al., 
2005). In mice, TLR9 is broadly expressed in different cell types, while its expression 
is restricted to dendritic cells (DCs) and B cells in humans (Takeuchi and Akira, 2010). 
TLR9 recognizes CpG-rich DNA, which is abundant in the HSV genome and is 
assumed to be the most potent stimulator of innate immune responses (Bauer et al., 
2001; Chockalingam et al., 2009). The previous literature has shown that TLR9-/- mice 
are more susceptible to HSV-1 infection (Lima et al., 2010; Boivin et al., 2012). Further, 
macrophages derived from these mice have a defective ability to produce inflammatory 
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cytokines when treated with CpG DNA (Zolini et al., 2014). In addition, mice pre-
treated with a TLR9 agonist intranasally were reported to have higher survival rates and 
reduced HSV viral loads in the brain (Boivin et al., 2008). TLR9 signalling causes the 
activation of interferon regulatory factor 7 (IRF7), leading to the expression of type I 
IFN in both human and mouse DCs (Lund et al., 2003; Lim et al., 2007). In agreement 
with this, reduced type I IFN produced from pDCs and impaired nature killer (NK) cell 
activation in TLR9-deficeint mice has been shown (Lund et al., 2003). However, other 
studies have indicated that the role of TLR9 in vivo is dose-dependent and TLR9 did 
not contribute to virus control in the corneal infection model when mice were infected 
with high doses of HSV-1 (Wuest et al., 2006). Moreover, previous data have revealed 
that even in epithelial cells that are deficient in TLR9, the DNA-dependent immune 
responses can still be induced, implying that multiple mechanisms of DNA sensing 
exist and that the role of TLR9 is redundant (Conrady et al., 2012). 
 
1.2.2 Cytosolic DNA sensors 
 
Since HSV fuses its envelope with the plasma membrane and the capsid is released 
directly into the cytoplasm, cytosolic sensors are also activated during HSV infection 
(Unterholzner et al., 2010). The accumulation of viral nucleic acids in the cytoplasm, 
including both DNA and RNA as well as commonly observed PAMPs, contributes to 
innate immune recognition (Ablasser et al., 2009).  
 
1.2.2.1 DNA-dependent activator of IRFs (DAI) 
 
DAI was the first identified DNA sensor in the cytosol and also the first one found to 
recognise HSV-1 (Takaoka et al., 2007). DAI has the ability to recognize cytoplasmic 
DNA and depletion of DAI correlates with increased HSV replication in vitro (Pham et 
al., 2013). Although DAI was initially characterized for its ability to directly interact 
with DNA, recent evidence from HSV1, VACV and MCMV indicates that newly 
synthesized transcripts during infection are the most likely PAMP for DAI under 
natural conditions. When small interfering RNA (siRNA) was used to reduce the 
expression level of DAI, IFN responses were restricted in HSV-1 infection (Takaoka et 
al., 2007). However, other studies have revealed that cells derived from DAI-deficient 
mice, including macrophages and mouse embryonic fibroblasts, respond normally to 
DNA viruses and immunostimulatory DNA (Ishii et al., 2006; Wang et al., 2008b; Furr 
et al., 2011). These findings indicate that DAI may act specifically in certain cell types 
or have redundancy in detection of HSV genome.  
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1.2.2.2 Cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) 
synthase (cGAS) 
 
Another cytosolic DNA sensor, cGAS, interacts with DNA through its amino-terminal 
domain and can detect HSV genomes (Ablasser et al., 2013; Li et al., 2013; Xiao and 
Fitzgerald, 2013). While responding to DNA, cGAS can produce cGAMP which 
activates stimulator of interferon genes (STING)-dependent IFN production through 
direct interaction in macrophages and lung fibroblasts (Li et al., 2013). The depletion 
of cGAS results in reduced IFN levels, interferon-stimulated gene (ISG) expression and 
IRF3 activation during HSV-1 infection (Schoggins et al., 2014). Consistent with 
observations in vitro, cGAS-/- mice were found to be more vulnerable to HSV-1 
infection (Li et al., 2013).  
 
1.2.2.3 IFN-inducible protein 16 (IFI16) 
 
IFI16 is a member of the pyrin and HIN-domain (PYHIN) family and is a microbial 
DNA sensor that participates in the IRF3-mediated pathway (Schattgen and Fitzgerald, 
2011; Orzalli et al., 2012). Lack of IFI16 expression in mouse macrophages and human 
fibroblasts leads to a reduction in IRF3 and NF-κB activation (Diner et al., 2015; Orzalli 
et al., 2015). IFI16 senses DNA through a sequence-independent mechanism and is 
localised in both the nucleus and the cytoplasm, dependent on the cell type (Li et al., 
2012). The cellular location of IFI16 may support different strategies to recognise viral 
DNA. While normally the nucleocapsid protects the HSV-1 DNA through cytoplasmic 
transit to the nucleus. The nucleocapsid can be subject to proteosomal degradation. The 
release of HSV genome DNA into the cytoplasm after degradation of the viral capsid 
is critical for IFI16 to detect HSV-1 in human macrophages (Horan et al., 2013). 
Moreover, nuclear IFI16 recognises HSV-1 infection upon release of encapsidated viral 
DNA into the nucleus during HSV-1 replication in human fibroblasts. This is inhibited 
by the viral nuclear ICP0 protein by promoting IFI16 degradation (Orzalli et al., 2012). 
A previous study has also shown that IFI16 may play an essential role in controlling 
HSV-1 infection in vivo as higher HSV-1 titres were detected in the corneal tissue of 
IFI16-deficient mice as compared to wild-type mice (Conrady et al., 2012). 
 
1.2.3 Retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) 
 
RNA polymerase III plays an essential role in linking DNA sensing to RNA recognition. 
Although RNA polymerase III does not directly sense DNA, it produces ligands to 
stimulate cytosolic RNA sensors. RNA polymerase III resides in the cytosol and 
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transcribes AT-rich DNA into the uncapped 5’-triphosphate form of dsRNA that can 
be recognised by cytosolic RNA sensors (Ablasser et al., 2009; Valentine and Smith, 
2010). Consequently, the recognition of RNA results in the induction of type I IFN, the 
secretion of cytokines and the stimulation of ISGs via several signalling pathways (Chiu 
et al., 2009). RIG-I-like receptors, namely cytosolic RNA sensors, include RIG-I and 
melanoma differentiation-associated gene 5 (MDA5). RLRs are expressed in most cell 
types and can be directly induced by IFN treatment (Szabo et al., 2012). RIG-I 
preferentially senses short dsRNA (<300 bp) having a 5’ triphosphate (5’-ppp), and 
MDA5 recognises long dsRNA (>1000 bp). Although RLRs were initially discovered 
for their role in detecting RNA, later studies showed that they also function to directly 
sense DNA (Cheng et al., 2007; Chow et al., 2018). There is a predicted helicase-like 
domain in RIG-I that can interact with B form DNA. In addition to B form DNA, RIG-
I can bind to other immunogenic DNAs, such as HSV-1 genome DNA and synthetic 
stimulatory DNA (Choi et al., 2009). The RNA-RLR pathway has been found to 
activate IRF3 and NF-κB, while the DNA-RLR pathway primarily induces expression 
of IRF3 and therefore type I IFN and ISGs (Choi et al., 2009).  
 
Knockdown studies of RIG-I or MDA5 with siRNA in macrophages indicated that 
MDA5, rather than RIG-I, is the major mediator recognising HSV-1 due to the 
strikingly reduced IFN-β and IFN-λ levels with cells lacking MDA5 expression 
(Melchjorsen et al., 2010). MDA5 and its adaptor protein mitochondrial antiviral 
signalling protein (MAVS) are required for producing IFNs in primary human 
macrophages during HSV-1 infection (Melchjorsen et al., 2010). Upon stimulation of 
type I IFN receptor (IFNAR) knockout cells with foreign DNA, overexpression of RIG-
I and MDA5 in these cells was found to selectively rescue high level of type I IFN 
mRNA expression, in the absence of signalling from the association between IFN and 
its receptors (Choi et al., 2009). Therefore, these studies provide evidence that RLRs 
are critical for type I IFN expression in an IFNAR-independent manner.  
 
1.3 Downstream signalling pathways after sensing HSV-1 
 
Both membrane-bound receptors (e.g., TLRs) and cytosolic sensors (e.g., DAI, cGAS, 
RLRs) signal through adaptors to transduce their signals to the nucleus (Figure 1-3). 
The myeloid differentiation primary response (MyD) 88 and TIR-domain-containing 
adapter-inducing interferon-β (TRIF) are two primary adaptors interacting with the 
intracellular domain of TLR (Takeda and Akira, 2004; Piras and Selvarajoo, 2014). 
MyD88 associates with the cytoplasmic fragments of TLRs via interaction between 
individual Toll/IL-1 receptor (TIR) domains and this process further induces expression 
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of inflammatory cytokines such as tumour necrosis factor (TNF)-α, IL-1, IL-6 and IFN-
γ through activation of transcriptional factors NF-κβ and IRF3 (Takeuchi et al., 2000; 
Akira et al., 2001). TRIF has a major role in TLR3-, TLR4-dependent and MyD88-
independent signalling which elicits expression of IFNs and numerous ISGs through 
activation of IRF3, TANK-binding kinase 1 (TBK1) and IKKε (Kawai et al., 2001; 
Doyle et al., 2002). As for RLRs, RIG-I and MDA5 recognise cytosolic nucleic acid 
ligands and then signal to the adaptor protein, MAVS (Reikine et al., 2014; Wu and 
Hur, 2015). Signals from RLRs are then transferred to TBK1 and IκB kinases, leading 
to the phosporylation of several transcription factors, including IRF3, IRF7 and NF-κB 
(Melchjorsen et al., 2010; Xing et al., 2012a). After activation, NF-κB and IRFs are 
translocated into the nucleus and transactivate the expression of type I IFN, as well as 
other inflammatory cytokines and ISGs (Schneider et al., 2014; Chen et al., 2015a). 
Moreover, Wang et al. showed that high levels of activated IRF3 expression are 
sufficient for induction of IFN-β in NF-κB knockout MEFs, indicating IRF3 can induce 
type I IFN transcription independent of NF-κB (Wang et al., 2010b; Wang et al., 
2010c). In the DNA sensing pathway, STING is an essential adaptor protein involved 
in the regulation of signal transduction, either by directly binding to exogenous DNA 
or via receiving signals from other sensors like cGAS and IFI16 (Barber, 2014; Bhat 
and Fitzgerald, 2014; Hansen et al., 2014). Activated STING recruits TBK1 and IRF3 
to from a complex. The formation of this complex promotes phosphorylation of both 
TBK1 and IRF3, resulting in an increase in the expression of type I IFN and ISGs 
(Ishikawa et al., 2009; Ishikawa and Barber, 2011; Tanaka and Chen, 2012). Lastly, 
cell death is a downstream consequence of PRR activation and HSV-1 employs ICP6 
to block both caspase 8 (Casp 8) and Z-DNA Binding Protein 1 activation in human 
cells (Guo et al., 2018). 
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Figure 1-3. Nucleic acid recognition pathways. Pathogen-derived RNA or DNA is 
sensed via TLR and/or nucleic acid-sensors. Upon endosomal translocation, viral RNA 
and DNA are recognized by endosomally expressed TLR7, TLR8 and TLR9. The 
adaptor molecule MyD88 is essential for driving the production of type I IFNs. Viral 
RNA is also sensed by RLRs through MAVS, a CARD-containing adaptor protein. 
RLRs/MAVS then interacts with TBK1 and activates IRFs. Viral DNA can be 
recognised by DNA sensors. Upon DNA stimulation, STING translocates from the 
membrane of endoplasmic reticulum the cytoplasmic punctate structure, where it 
interacts with TBK1 and then activates IRFs to trigger type I IFN production.  
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1.3.1 Canonical IFN signalling pathway 
 
After viral PAMPs are sensed by various host PRRs and the antiviral signal is 
transduced to transcription factors that promote IFN production (Su et al., 2016). IFN 
is secreted from the producing cell and acts in an autocrine and paracrine manner to 
amplify cell-intrinsic antiviral responses and ultimately reduce virus replication. 
Secreted IFNs bind to IFNAR, a heterodimeric transmembrane receptor, and this 
interaction actives receptor-associated protein tyrosine kinases such as Janus kinase 1 
(JAK1) and tyrosine kinase 2 (TYK2) (Krishnan et al., 1997; Schindler et al., 2007). 
Diverse pathways downstream can be induced, leading to multiple biological effects. 
In canonical IFN signalling, phosphorylated JAK1 and TYK2 further phosphorylate the 
signal transducer and activator of transcription 1 (STAT1) and STAT2 proteins, 
resulting in dimerization, nuclear translocation and association with IRF9 to form the 
ISG factor3 (ISGF3) complex (Levy et al., 1989). ISGF3 interacts with specific DNA 
sequences, known as IFN-stimulated response elements (ISREs), in numerous ISGs. 
Thus, this step activates the transcription of ISGs. Several hundred ISRE-driven ISGs 
have been found to be induced by viral infections (Schoggins et al., 2011; MacMicking, 
2012). In addition to the canonical IFN signalling pathway, type I IFN can activate 
STAT homodimers which interact with a distinct gamma-activated sequence, 
commonly related to IFN-γ-mediated signalling (Ahmed and Johnson, 2006).  
 
IFN responses have been shown to have an important role in combating HSV-1 
infection. The expression of IFNs has been shown to correlate with resistance to HSV 
infection in vivo (Wrzos et al., 1990; Halford et al., 1997). The presence of IFN 
expression and functional IFNAR is required to control virus spread from peripheral 
sites to the central nervous system by reducing virus replication in trigeminal ganglia 
(Leib et al., 1999; Luker et al., 2003). Additionally, more severe skin lesions, 
characterised by extensive oedema and loss of lymphatics, occur in IFNAR-deficient 
mice, compared with wild-type mice, during HSV-1 infection (Bryant-Hudson et al., 
2013). IFNs activate various ISGs to protect the host from HSV-1 lytic infection (Su et 
al., 2016). For example, ISG15-deficient mice had increased susceptibility to HSV-1 
infection (Lenschow et al., 2007). Moreover, promyelocytic leukemia protein (PML), 
another ISG, was found to mediate the anti-HSV state induced by exogenous IFNs, 
which counteracts the activity of ICP0 (Chee et al., 2003; Everett et al., 2006). IFNs 
not only restrict lytic infection of HSV1, but also control HSV-1 latency. 
Supplementation with IFN-γ was found to control HSV-1 reactivation in ex vivo 
trigeminal ganglion cultures (Liu et al., 2001).  
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1.3.2 IFN-independent mechanisms 
 
Aside from IFN induction, entry of certain pathogens into the cell at the initial stage of 
infection can stimulate host cell innate responses through IRFs, in the absence of IFNs. 
Activated IRFs act as transcriptional activators to upregulate expression of a subset of 
ISGs (Nicholl et al., 2000; Mossman et al., 2001). The activation of IRF family 
members, especially IRF1 and IRF3, directly induces this response in epithelial cells 
and fibroblasts (Chin and Cresswell, 2001; Collins et al., 2004; Stirnweiss et al., 2010). 
Mossman et al. (Mossman et al., 2001) used an HSV-1 mutant, which cannot induce a 
functional level of IFN expression, together with other soluble cytokines as a model to 
investigate antiviral activity in an IFN-independent manner. The data indicated that 
HSV-1-infected cells can induce an IFN-independent antiviral state and induce 
expression of ISGs, including myxovirus resistance 1 (MX1), MX2, IFN-stimulated 
protein (ISG15), IFN-induced protein 65 (IFIT1), IFN-induced transmembrane protein 
(IFITM1) and OAS family members (OAS2 and OAS3) (Mossman, 2002). Another 
study also showed that HSV-1 virions can activate ISG15, ISG54, IFI56, MX1 and 
IFITM1 expression in the absence of protein synthesis and de novo viral gene 
expression (Nicholl et al., 2000). These antiviral responses are not dependent on IFN 
itself or JAK/STAT signaling components that are triggered by IFN in human 
fibroblasts (Nicholl et al., 2000). Therefore, despite the importance of IFN being shown, 
IFN-independent pathways are likely to remain important in some cell types. 
 
1.4 Regulation of viperin and its role in innate antiviral responses 
 
The ISGs mentioned in the previous section were not investigated in this thesis. 
However, due to our experimental results (Section 4.2), we chose to examine viperin. 
For this reason, this molecule is introduced here in detail. Viperin is an ISG, encoded 
by radical S-adenosyl methionine domain containing 2 (RSAD2) gene, with broad 
spectrum inhibition of virus replication, including both DNA and RNA viruses (Seo et 
al., 2011a; Helbig and Beard, 2014). However, due to limited studies, the mechanism 
and whether viperin is essential for controlling HSV-1 infection remains unclear. 
Viperin was initially identified as an ISG in human macrophages and a 
cytomegalovirus-inducible gene in human fibroblasts (Zhu et al., 1997; Chin and 
Cresswell, 2001). Therefore, viperin is also known as cytomegalovirus-induced gene 5 
(cig5). The viperin protein is highly conserved across species from humans to fish 
(Duschene and Broderick, 2012). Human viperin is composed of 361 amino acids with 
a predicated molecular size of 42 kDa (Figure 1-4). Viperin is divided into three distinct 
domains: an N-terminal domain that has varied length and sequence between species, a 
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highly conserved central domain with a motif containing cysteine residues (CxxxCxxC) 
and a C-terminal domain that shows similarity across species. An amphipathic helix 
located from residue 9 to 42 in the N-terminus of viperin can associate with the 
cytosolic surface of the endoplasmic reticulum (Hinson and Cresswell, 2009b). The N-
terminus is also capable of interacting with lipid droplets (Hinson and Cresswell, 
2009a). Motifs homologous to the radical S-adenosyl-L-methionine (SAM) domain 
were shown in the central domain. The interaction between these motifs and iron-
sulphur clusters, a characteristic function of radical SAM enzymes, has been shown 
(Shaveta et al., 2010). The role of the conserved C-terminus is not yet clearly defined, 
but it appears to act as a necessary fragment for suppression of replication of viruses in 
the Flaviviridae, such as dengue virus (DENV) and Zika virus (ZIKV) (Jiang et al., 
2008; Helbig et al., 2013). 
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Figure 1-4. Schematic diagram of  known domains in viperin. The N-terminal 
domain (9-42 aa) is important for localization of viperin to the cytosolic surface of the 
endoplasmic reticulum. The central domain (71-182 aa) is conserved and contains a 
binding motif with cysteine residues. The C-terminal domain (218-361 aa) is relatively 
highly conserved. 
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Viperin expression is induced by all types of IFNs (α, β and γ), as well as some 
microbial PAMPs, dsRNA, dsDNA and lipopolysaccharide (LPS) (Severa et al., 2006; 
Hinson et al., 2010). Viperin induction can generally be divided into two major routes: 
IFN-mediated and IFN-independent pathways (Boudinot et al., 2000). The induction of 
viperin expression in an interferon-dependent manner occurs after the ligation of 
PAMPs with PRRs and subsequent downstream IFN production. One consequence of 
IFN-stimulation is the assembly of ISGF3, a multi-protein complex with DNA binding 
functionality, within the cytoplasm and ISGF3 translocation to the nucleus. Within the 
nucleus, ISGF3 binds to the internal ribosome entry site within the viperin promoter, 
thus inducing viperin expression. (Severa et al., 2006). Viperin expression can also be 
regulated in an IFN-independent manner. Studies with several viruses, such as human 
cytomegalovirus (HCMV), Japanese encephalitis virus (JEV) and vesicular stomatitis 
virus (VSV), show upregulated viperin expression in infected cells independently of 
IFNs (Boudinot et al., 2000; Boehme et al., 2004; Chan et al., 2008). Mechanistically, 
IFN-independent viperin induction occurs after the ligation of viral dsRNA and RLRs, 
subsequent recruitment to peroxisomal MAVS and IRF1/3-dependent ISG expression 
(DeFilippis et al., 2006; Dixit et al., 2010; Stirnweiss et al., 2010). During reovirus and 
influenza virus infection, peroxisomal MAVS was found to produce rapid IFN-
independent viperin expression early after infection, while mitochondrial MAVS 
activated an IFN-dependent expression of viperin to maintain a stable antiviral 
environment with delayed kinetics in the presence of IFNs (Dixit et al., 2010).  
 
Viperin has been shown to inhibit DNA and RNA viruses by diverse mechanisms. In 
Herpesviridae, viperin affects replication of both HCMV and HSV in different ways. 
Envelope glycoprotein B (gB) from HCMV can directly induce expression of different 
ISGs, including viperin (Chin and Cresswell, 2001; Boehme et al., 2004). Human 
fibroblasts expressing viperin show a reduction in HCMV production, indicating that 
viperin is a potential antiviral against HCMV (Chin and Cresswell, 2001). HCMV 
vMIA protein can interact with viperin, resulting in the redistribution of viperin from 
endoplasmic reticulum to mitochondria. The iron-sulphur binding motifs in the central 
domain of viperin play an essential role in associating with mitochondrial trifunctional 
protein (TFP). This interaction then leads to cytoskeleton disruption and enhancement 
of HCMV infectivity (Chin and Cresswell, 2001; Seo et al., 2011b). Ectopically 
expressed viperin did not inhibit the replication of wild-type virus in HEK239 cells 
(Shen et al., 2014). Reduced virus replication was found only where the virus did not 
express UL41 due to that UL41 reduces accumulation of viperin mRNA (Shen et al., 
2014). 
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1.5 Herpesviral proteins that evade DNA sensing and the IFN pathway 
 
As a large virus with a slow replication rate compared to those of RNA viruses in vivo, 
it is essential for HSV-1 to establish infection within the first few replication cycles 
(Rathinam and Fitzgerald, 2011; Christensen and Paludan, 2017). In order to evade 
sensing from host cells and the subsequent innate immune responses, HSV-1 has 
evolved various viral proteins (Friedman, 2003; Su et al., 2016). Different viral proteins 
can aim redundantly at the same signalling pathway, and these gene products can also 
be multifunctional (Wadd et al., 1999; Smith et al., 2005; Kawaguchi, 2013).  
 
1.5.1 ICP0 
 
ICP0, an IE protein of HSV-1, is a strong inhibitor of TLR-mediated cellular signalling. 
Daubeuf et al. reported that ICP0 binds to ubiquitin-specific-processing protease 7 
(USP7) and USP7 is then translocated from the nucleus to cytoplasm (Daubeuf et al., 
2009). Within the cytoplasm, USP7 deubiquitinates TNF receptor-associated factor 6 
(TRAF6) and inhibitor of κB kinase (IKK), leading to the reduced activation of 
mitogen-activated protein kinase (MAPK) via TLR signalling (Daubeuf et al., 2009). 
Others have shown that ICP0 inhibits TLR2 signalling by targeting the adapter protein 
MyD88 for degradation, abolishing NF-κB signalling (van Lint et al., 2010). Another 
function of ICP0 is the inhibition of expression of ISGs (Lanfranca et al., 2014). For 
instance, the RING finger domain of ICP0 has been found to interact with IRF3 and 
IRF7, disrupting induction of ISG expression (Lin et al., 2004). It has also been reported 
that ICP0 sequestered nuclear IRF3, promoting IRF3 degradation, and thus suppressing 
transcription of IFN-β and ISGs (Melroe et al., 2007). Additional studies have shown 
that in human foreskin fibroblasts, nuclear localisation of ICP0 is critical for inhibition 
of the IFI16-induced IRF3 signalling pathway through degradation of IFI16. (Paladino 
et al., 2010). 
 
1.5.2 ICP27 
 
Another IE protein of HSV-1, ICP27, has been found to be involved in a wide range of 
HSV-1 biological functions, such as viral gene expression, virion release and the export 
of viral mRNA (Sekulovich et al., 1988; Tian et al., 2013; Park et al., 2015). In addition, 
it induces host-cell shutoff by decreasing cellular mRNA stability and inhibiting host 
splicing machinery (Hardwicke and Sandri-Goldin, 1994). In addition to these broad 
antiviral activities, ICP27 helps HSV-1 to evade type I IFN signalling through 
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inhibition of the activation of IRF3 and STAT1 (Melchjorsen et al., 2006; Johnson et 
al., 2008). Melchjorsen et al. showed that ICP27-deletion in HSV-1 led to higher levels 
of IRF3, NF-κB and cytokine production in infected human monocyte-derived 
macrophages and dendritic cells, as compared to wild-type virus (Melchjorsen et al., 
2006). These data indicate that ICP27 protein mediated suppression of cytokine 
expression through effects on IRF3 and NF-κB in HSV-1 infection. Another report 
found that ICP27 is necessary for blocking STAT1 phosphorylation at early infection 
time points, preventing nuclear translocation (Johnson et al., 2008). A recent study 
discovered a new role of HSV-1 ICP27 in regulating the cGAS/STING pathway 
(Christensen et al., 2016). An interaction between ICP27 and the STING-TBK1 
complex inhibited TBK1-mediated phosphorylation of IRF3 and induction of ISGs 
(Christensen et al., 2016). Thus, ICP27 may play a key role in suppressing IFN  and 
IFN-independent responses to HSV-1 infection. 
 
1.5.3 ICP34.5 
 
ICP34.5, a neurovirulence factor of HSV-1, is well known for its regulation of innate 
antiviral responses in host cells (Melchjorsen et al., 2009; Rosato and Leib, 2015). 
HSV-1 ICP34.5 has been found to recruit protein phosphatase 1 to dephosphorylate 
eukaryotic translation initiation factor 2 (eIF2α). This process blocks the translational 
arrest effect of eIF2α, thus supporting virus replication in infected cells (He et al., 1997). 
Furthermore, ICP34.5 directly interacts with beclin1 to prevent autophagy, which 
functions to deliver viral molecules to endosomes (Orvedahl et al., 2007; Into et al., 
2012). Hence, the inhibition of autophagy by ICP34.5 may offset the recognition of 
viral DNA and RNA by endosomal TLRs. In addition, ICP34.5 controls the activity of 
TBK1 (Verpooten et al., 2009). The interaction between ICP34.5 and TBK1 prevents 
TBK1 associating with IRF3, thus inhibiting subsequent expression of IFNs and ISGs 
(Ma et al., 2012). In agreement with this finding, levels of IRF3 phosphorylation and 
type I IFN were found to be higher in cells infected with the ICP34.5-deletion virus 
compared with wild-type HSV-1 (Verpooten et al., 2009). ICP34.5 has also been 
identified as suppressing NF-κB signalling by dephosphorylating IKK, resulting in 
decreased inflammatory cytokine production (Jin et al., 2011). 
 
1.5.4 virion host shutoff (vhs; UL41) 
 
HSV-1 encodes a ribonuclease, UL41, also referred to as the virion host shutoff protein 
(vhs). HSV-1 vhs is a component of the tegument and digests both host and viral 
mRNAs after viral entry. This restricts translation of host mRNA contributing to the 
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shutdown of cell-intrinsic immune responses (Smiley, 2004). In the absence of vhs, 
HSV-1 is attenuated with reduced infection in corneal in vivo (Strelow and Leib, 1995). 
However, the consequence of a lack of vhs activity in cell culture is dependent on cell 
type (Dauber et al., 2011). With respect to cytosolic sensing, in cells infected with a 
vhs null mutant, viral RNA accumulated, acting as an increased pathogen signal 
(Pasieka et al., 2008). Concurrently, vhs is critical for reducing the activation of the 
RNA-sensing pathways via MyD88- and TLR3-independent pathways in both human 
and mouse DCs (Cotter et al., 2010). However, the target of vhs is not the TLR agonist 
for these sensors, indicating that an inhibitory effect may occur at some point upstream 
of the pathway (Cotter et al., 2010). Another study has showed that vhs selectively 
suppresses expression of several components in the nucleic acid-sensing pathway in 
epithelial cells, including TLR2, TLR3 RIG-I and MDA5 (Yao and Rosenthal, 2011). 
HSV-1 vhs also reduces signalling by the cGAS/STING-mediated pathway by reducing 
mRNA and subsequent protein levels of cGAS (Su and Zheng, 2017). In terms of IFN 
responses, vhs-null HSV-1 shows a growth deficit with smaller plaques, and as 
expected, increased sensitivity to the effect of IFNs (Read et al., 1993; Pasieka et al., 
2008). When compared to wild-type HSV, the vhs mutant was found to cause greater 
activation of IRF3. HSV-1 vhs has also been found to disrupt IFN-related antiviral 
immunity by targeting multiple proteins, such as dsRNA-activated protein kinase 
(PKR), ribonuclease L (RNase L) and JAK1 due to its ribonuclease activity (Murphy 
et al., 2003; Chee and Roizman, 2004; Duerst and Morrison, 2004). Pasieka et al. 
(Pasieka et al., 2008) revealed that the presence of vhs activity affects the 
phosphorylation of eIF2α in a PKR-dependent manner because the phosphorylation of 
eIF2α is increased during HSV-1 infection lacking vhs function as compared to wild-
type virus. Further, another study indicated that downregulation of JAK1 and STAT2 
occur in cells infected with wild-type HSV-1, but both JAK1 and STAT2 expression 
are restored in cells infected with vhs-defective virus, suggesting that the vhs protein is 
involved in counteracting the JAK/STAT2-mediated IFN signalling pathway (Chee and 
Roizman, 2004). Taken together, the results summarized above indicate that vhs has 
multiple mechanisms by which if interferes with cytosolic sensing and IFN signalling 
pathways. 
 
1.5.5 Us3 
 
Us3, a multifunctional serine/threonine kinase, participates in the egress of viral 
particles from the nucleus, the regulation of the cytoskeleton and the inhibition of 
apoptosis (Leopardi et al., 1997; Mettenleiter, 2002; Kato et al., 2011). Us3-deletion 
HSV-1 mutant triggers activation of IRF3, secretion of type I IFN and expression of 
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TLR3, indicating that Us3 interrupts the TLR3 pathway and its downstream expression 
of IFNs (Piroozmand et al., 2004; Peri et al., 2008). Moreover, Us3 interferes with 
TLR2 signalling, inhibiting the TLR2-associated NF-κB pathway and the subsequent 
induction of cytokines (Sen et al., 2013).  
 
1.5.6 Us11 
 
HSV-1 Us11 also plays an important role during the capsid assembly and egress process 
(Mettenleiter, 2002). Studies have shown that Us11 inhibits the RNase L antiviral 
pathway and PKR-mediated protein synthesis (Poppers et al., 2000; Khoo et al., 2002; 
Sanchez and Mohr, 2007; Lussignol et al., 2013). An association has been reported 
between the C-terminal RNA-binding domain of Us11 and endogenous RIG-I and 
MDA5. This association prevents RIG-I and MDA5 from binding to their adapter 
protein MAVS, resulting in downregulation of the RLR signalling pathway (Xing et al., 
2012b).  
 
1.5.7 Other HSV-1 inhibitors 
 
HSV-1 serine protease VP24 has been shown to occlude both the interferon stimulatory 
DNA- and cGAS/STING-mediated IFN signalling pathway by interfering with IRF3 
promoter activation, without blocking the function of the NF-κB promoter (Zhang et 
al., 2016). Mechanistically, VP24 prevents the association between IRF3 and TBK1 
through physical interaction of VP24 with IRF3. This interaction inhibits the 
phosphorylation and dimerization of IRF3 (Zhang et al., 2016). In addition, both HSV-
1 UL24 and UL36 inhibit the cGAS/STING-induced DNA sensing pathway by 
interfering the NF-κB activation (Xu et al., 2017; Ye et al., 2017). UL24 inhibits the 
interferon stimulatory DNA- and cGAS/STING-mediated NF-κB signalling pathway, 
which is correlated with reduced production of IFNs and IL-6. These data suggest that 
UL24 blocks cGAS/STING-mediated NF-κB activation via the interaction between 
UL24 and endogenous p65 and p50 proteins. This association decreases p65 and p50 
translocation, thus affecting NF-κB transcription (Xu et al., 2017). Ubiquitin-specific 
protease UL36 is another protein interrupting cGAS/STING-mediated NF-κB 
signalling (Ye et al., 2017). Overexpression of UL36 reduces cGAS/STING-induced 
IFNs and activation of the NF-κB promoter by restraining IκBα degradation through 
the deubiquitinase activity of UL36 and this blocks the activation of NF-κB (Ye et al., 
2017). 
 
1.6 The effect of sex on the immune system 
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Sex refers to biological characteristics that determine male and female, such as 
reproductive organs, arrangement of chromosomes and sex hormones. The 
physiological differences arising from sex may affect the control and clearance of 
microbes, and the difference in anatomical structure between the two sexes can 
influence exposure and transmission of infectious diseases (Guerra-Silveira and Abad-
Franch, 2013; Nhamoyebonde and Leslie, 2014). Based on available literature reviews, 
in general, the prevalence of infections are usually higher among males than females. 
However, females face more severe disease outcomes associate with immunopathology, 
suggesting that sex differences matter in the pathogenesis of infectious diseases 
(Fischer et al., 2015; Klein et al., 2015).  
 
1.6.1 Mechanisms of sex differences in immune responses 
 
1.6.1.1 Sex steroids 
 
Several mechanisms have been proposed to underline differences in immune function 
between the sexes (Klein et al., 2015; Ghosh and Klein, 2017; Roved et al., 2017). The 
most well-established hypothesis is the action of sex steroids (De Leon-Nava et al., 
2009; Guerra-Silveira and Abad-Franch, 2013). Specifically, estrogen and testosterone 
affect the function of the immune cells (Fish, 2008; Xia et al., 2009). These steroid 
hormones bind to their receptors in the cytoplasm and form the steroid-receptor 
complex that move to the nucleus and associate with hormone response elements in the 
promoter regions of sets of genes in DCs, macrophages and lymphocytes (Sakabe et al., 
1990; De Leon-Nava et al., 2009). Direct interactions between sex steroids and their 
respective receptors further modulate cellular signalling via IRFs and NF-κB 
(Hewagama et al., 2009). Therefore, the production of different cytokines and 
chemokines is differentially regulated between the two sexes (Hewagama et al., 2009).  
 
1.6.1.2 Incomplete X chromosome inactivation 
 
Another mechanism for the sex-based differences in immunological reactions involves 
the sex chromosomes (Migeon, 2007). Females possess two X chromosomes, one from 
each parent, while males have only one X chromosome from the mother. Compared to 
the Y chromosome, which only carries about 100 genes, the X chromosome harbours 
approximately 1100 genes and some of them play crucial roles to mediating immune 
responses, such as TLRs and interleukin receptors (Libert et al., 2010). During the early 
stage of embryogenesis in females, gene expression from one of the X chromosomes is 
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shut down to avoid a double dosage of these proteins in females (Brown et al., 1991). 
This process is called X chromosome inactivation and is driven by the long non-coding 
RNA Xist. (Senner and Brockdorff, 2009; Pontier and Gribnau, 2011). This process 
generates cellular mosaicism in females, which means that the X chromosome from 
paternal or maternal origin is expressed in different cells (Migeon, 2007). As a result, 
deleterious mutations cause whole cell populations in males to lose their functions, but 
only around half of the cells are affected in females. Cellular mosaicism not only 
protects females against the consequence of disadvantageous gene mutations, but also 
supports the ability of females to counteract various microbial infections by adding 
diversity. However, the disadvantage may be that females are at higher risk than males 
of developing immunopathology resulting from excessive and prolonged activation of 
the immune system (Klein, 2012). In addition to cellular mosaicism, some immune-
related genes have been found to be expressed at a higher level in females, as compared 
to males, due to incomplete X-inactivation (Wang et al., 2016b). For example, TLR7, 
which is encoded by a gene on the X chromosome, is present in females at a higher 
level than males owing to incomplete X-inactivation. Greater TLR7 expression has 
been noted in a large proportion of DCs, B lymphoctyes and monocytes (Souyris et al., 
2018a; Souyris et al., 2018b). These findings suggest that overexpression of TLR7 is a 
potential factor to the risk of systemic lupus erythematosus, an autoimmune disease 
with strong female bias (Subramanian et al., 2006; Deane et al., 2007). 
 
1.6.1.3 X chromosome encoded miRNAs 
 
In addition to incomplete X chromosome inactivation, it is proposed that the X 
chromosome contains a high intensity of miRNAs which are involved in modulating 
immune responses (Pinheiro et al., 2011; Bianchi et al., 2012). For instance, mir-223 
has the ability to downregulate LPS-induced IFN signalling in splenic lymphocytes and 
can also inhibit TLR4- or TLR3-triggered inflammatory responses (O'Neill et al., 2011; 
He et al., 2014). Moreover, previous studies have shown that both mir-351 and mir-448 
expression can be induced by IFN-β, and subsequently act to inhibit HCV replication 
(Pedersen et al., 2007; Pinheiro et al., 2011; Shrivastava et al., 2015). To date, there are 
no reports suggesting that spontaneous mutations in these miRNAs can influence sex 
differences in immune reactions, but many researchers still believe that dysregulation 
of miRNAs expression on the X chromosome may partly explain differences in 
immunity between the sexes (Pinheiro et al., 2011).  
 
1.6.2 Sex-specific differences in HSV-1 infection 
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Sexual dimorphism in immune responses has been observed during herpesvirus 
infection. Several studies have reported that mortality rates are higher in male mice 
when they are infected with HSV-1 by the corneal route or intranasal injection (Han et 
al., 2001; Lundberg et al., 2003; Brown et al., 2004). In contrast, Geurs et al. (Geurs et 
al., 2012) showed that in systemic viral infections, female mice are more susceptible to 
large dsDNA viruses such as HSV-1 and CMV due to differential regulation of IFNAR 
signalling between the two sexes. The inconsistent results described above may be 
explained by different infection routes, strains of HSV-1 and mice, which have been 
noted to exhibit variation in HSV-1 pathogenesis (Perng et al., 2001; Kastrukoff et al., 
2012; Wang et al., 2013a).  
 
Female mice infected by HSV-1 intraperitoneally produce more antibodies than their 
male counterparts, and castration significantly enhances antibody production in male 
mice due to the effect of sex hormones (Knoblich et al., 1983). In addition, CD4+ T cell 
activity and glycoprotein D (gD)-dependent humoral immune responses are higher in 
females than in males during clinical trials of the HSV-1 vaccine (Zhang et al., 2008). 
This observation is correlated with results from the gD-based HSV-2 vaccine which 
showed a significant sex-bias in protection and there was 73% efficacy in females but 
only 11% in males (Stanberry et al., 2002). Similar results have been reported for other 
members of the herpesvirus family. For example, serological screening of EBV 
antibodies via indirect immunofluorescence or by enzyme-linked immunosorbent assay 
(ELISA) has indicated that males are more likely to be EBV-seronegative than females 
in a prevelance study (Wagner et al., 1994). Women infected with CMV can also 
produce a higher number of IL-2-secreting cells and greater levels of INFs and IL-2 
compared to similarly infected men (Villacres et al., 2004). In summary, these results 
suggest that there are sex differences in host immune responses to herpesviruses 
whereby females may display more protective responses than males, but the 
mechanisms behind this remain poorly understood.  
 
1.7 Differences between mouse and human immunity 
 
Over the past century, mice have developed into the premier mammalian model system 
for biomedical research because they have many similarities to humans in terms of 
anatomy, physiology and genetics (Emes et al., 2003). Mice and humans share around 
95% similarity in their genomes and have many genetic diseases in common. 
Additionally, only about 300 genes are unique to one species or the other (Guigo et al., 
2003; Cheng et al., 2014). However, there remain significant differences between mice 
and humans in terms of their innate and adaptive immune systems (Haley, 2003). This 
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section describes broad differences in immunity between these two species at the 
beginning (Section 1.7.1), including innate immune responses and antiviral ISGs, and 
then illustrates human-mouse differences in HSV-1 infection in Section 1.7.2. 
 
1.7.1 Cytokines and innate immune responses 
 
1.7.1.1 Cytokines 
 
The expression and function of cytokines and innate proteins may be different in 
different species. For instance, IL-13 induces switching expression of the Ig isotype in 
B lymphocytes in humans, from IgM to IgE, but not in mice (Tangye et al., 2002; 
Kracker and Radbruch, 2004). Moreover, the signals leading to the development of Th 
cells in CD4+ T cells are different between mice and humans. In humans, type I IFNs 
promote Th1 development and can activate STAT4 by gathering the IFNAR complex 
dependent on STAT2. However, the C-terminal domain of the STAT2 protein in mice 
has been altered due to a minisatellite insertion in this gene. This further disturbs the 
ability of STAT2 to activate STAT4 (Farrar et al., 2000). In addition, Th2 cells release 
IL-10 in mice, while in humans, IL-10 is produced by Th1 and Th2 cells (Del Prete et 
al., 1993). Lastly, mouse IL-7 and IL-7 receptors are essential for differentiation of 
immature T cells and B cells. However, deficiency of IL-7 receptors causes the arrest 
of T-cell development, but not B-cell development, in humans (Peschon et al., 1994; 
Roifman et al., 2000).  
 
1.7.1.2 TLRs 
 
Recent studies indicate that TLR orthologues are differently expressed in mice and 
humans, including the expression of varied TLR transcripts in different cell types and 
differing functions on cellular activation (Bryant and Monie, 2012). For example, TLR2 
mRNA is low or undetectable in mouse blood cells. However, constitutive levels of 
TLR2 expression have been shown in peripheral blood leukocytes in humans 
(Matsuguchi et al., 2000; Zarember and Godowski, 2002). Furthermore, during 
proinflammatory stimuli, the mouse TLR2 promoter is active and induced rapid TLR2 
expression in macrophages. By contrast, it is difficult to activate TLR2 promoters of 
human monocytic cell lines by LPS (Musikacharoen et al., 2001; Haehnel et al., 2002). 
Other studies have also found that TLR9 is expressed on all mouse myeloid cells, 
plasmacytoid DCs and B cells, whereas in humans, TLR9 is primarily located on 
plasmacytoid DCs and B cells (Kadowaki et al., 2001; An et al., 2002). 
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1.7.1.3 MX proteins 
 
1.7.1.3.1 Cellular localization of MX proteins 
 
A typical example of a human-mouse difference in ISGs is the MX proteins. MX 
proteins, belonging to the family of interferon-induced GTPases, act differently during 
virus infection in mice and humans. Both human and mouse MX1 proteins are able to 
reduce viral protein expression in influenza (Pavlovic et al., 1992). However, the 
distinct cellular distribution of MX1 provides different strategies to inhibit virus 
replication. Human MX1 protein accumulates in the cytoplasm and has been found to 
interfere in both influenza viral protein synthesis and genome amplification (Zurcher et 
al., 1992a). An explanation for this is that the MX1 protein probably intercepts the 
intracytoplasmic transport of viral mRNA or the translocation of newly synthesised 
viral proteins to the nucleus. In contrast, mouse MX1 is primarily localised in the 
nucleus (Stranden et al., 1993). Nuclear localisation of mouse MX1 is essential to 
counteracting influenza virus infection, based on the data showing that cytoplasmic 
variants of mouse MX1 protein were inefficient in inhibiting both influenza virus and 
VSV (Zurcher et al., 1992c).  
 
1.7.1.3.2 Antiviral activity of MX proteins 
 
Further, the primary influenza viral transcript levels of the three polymerase genes PB1, 
PB2 and PA were found to be significantly lower in stably transfected cell lines 
expressing MX1 protein (Verhelst et al., 2012). These results suggest that mouse MX1 
inhibits the mRNA synthesis of the influenza virus dependent on the location of the 
MX1 protein in the cells. In addition to restricting replication of RNA viruses, the 
cytoplasmic human MX1 protein has been found to have broad antiviral activities 
against large DNA viruses, such as African swine fever virus (ASFV) and HSV 
(Netherton et al., 2009; Ku et al., 2011). Another member of the MX family has also 
been reported to show human-mouse differences. Mouse MX2 has been shown to reside 
in the cytoplasm and exhibit antiviral activity against VSV and Hantaan virus (Zurcher 
et al., 1992b; Jin et al., 2001). However, no antiviral activity has been discovered in 
human MX2 protein to date.  
 
1.7.2 Human-mouse differences in HSV-1 infection 
 
1.7.2.1 IFN-stimulated genes 
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In the innate immune responses, several genes, including Mda5, Mx2 and members in 
the guanylate nucleotide binding protein (Gbp), are upregulated in mouse embryonic 
fibroblasts, but these genes are significantly downregulated by HSV-1 infection in 
primary human fibroblasts (Pasieka et al., 2006; Peng et al., 2008). In addition to the 
human-mouse difference in the expression level of innate proteins, a controversial 
relationship between MX1 and HSV-1 has been identified. Originally, human MX1 
protein was reported to have no ani-HSV-1 activity when MX1-transfected mouse 3T3 
cells were infected (Pavlovic et al., 1990). Later, another study showed that HSV-1 
titres were decreased in human HEK293 cells transiently overexpressed with MX1 (Ku 
et al., 2011). These contradictory results may be due to the use of different cell types 
and methods to express the MX1 protein or to a difference between species. 
 
1.7.2.2 Necroptosis 
 
HSV-1 suppresses necroptosis in human cells (Guo et al., 2015b; Guo et al., 2018), but 
it induces necroptosis in mouse cells (Dufour et al., 2011a; Dufour et al., 2011b; Yu 
and He, 2016). Necroptosis is a mechanism to eliminate pathogens in infected cells by 
disrupting cellular membrane in a programmed manner, thus distinct from necrosis (Du 
et al., 2013; Yu and He, 2016). Necroptosis occurs when Casp8 and apoptosis is 
inhibited, but the cell death pathways are activated by stimuli, such as viral nucleic 
acids and viral proteins (Orzalli and Kagan, 2017). When Casp8 is inhibited, TNF 
signalling induces the formation of a protein complex known as the necrosome, which 
includes receptor interacting protein-1 and -3 (RIP1 and RIP3) (Holler et al., 2000; Cho 
et al., 2009). Activated RIP3 recruits and phosphorylates mixed lineage kinase-like 
(MLKL), and MLKL forms a pore-like structure on the cell membrane, resulting in cell 
lysis and membrane leakage (Orzalli and Kagan, 2017; Nailwal and Chan, 2019).  
 
Host cells use this strategy to overcome both DNA and RNA virus infection (Galluzzi 
et al., 2017). This is because necroptosis mediates the release of intracellular damage-
associated molecular patterns, including IL-1, uric acid and DNA, leading to the 
recruitment of proinflammatory cell types to sites of infection (Huang et al., 2015; 
Nogusa et al., 2016). HSV-1 ICP6 normally blocks apoptosis and necroptosis in human 
cells and that just the opposite is seen in mice (Huang et al., 2015; Yu et al., 2015). 
HSV-1 can inhibit apoptosis and Casp8 activity, resulting in necroptosis as an 
alternative death pathway during HSV-1 infection in human cells (Dufour et al., 2011a; 
Dufour et al., 2011b). Additionally, HSV-1 replication in RIP3 knockout mouse cells 
was elevated because necroptosis does not correctly proceed (Huang et al., 2015). 
Furthermore, the RIP homotypic interaction motif (RHIM) domain of the UL39 protein 
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in both HSV-1 and HSV-2 associates with RHIM domain in the RIP1/3 complex, 
triggering necroptosis in HSV-1-infected mouse cells (Yu et al., 2015). RHIM domains 
of RIP1 and RIP3 are required for the interaction with the UL39 protein (Huang et al., 
2015). On the contrary, the UL39 protein cannot induce necroptosis in human cells 
(Guo et al., 2015b). The UL39 protein was found to be sufficient to interrupt the RIP1-
RIP3 association in a UL39- and RHIM-dependent manner, protecting human cells 
from HSV-1 induced necroptosis (Guo et al., 2015b). The data above suggest that the 
sequence of the RHIM domain in the UL39 protein and RIPs may determine whether 
the interaction is pro-necroptotic or anti-necroptotic in different species. HSV-1 has 
evolved a method to evade necroptosis-mediated antiviral signalling in humans, but 
sequence differences between human and mouse proteins which interact with UL39 
result in species-specific discrepancies.  
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1.8 Aims of this thesis 
 
Species and sex differences are either ignored or poorly studied in HSV-1 infection. 
Both of these factors are amenable to characterisation by RNA sequencing analysis, 
leading to further dissection. Thus, the aims of this thesis were: 
 
1. To determine whether there are sex-related differences in virus replication and 
transcriptional regulation during HSV-1 infection of cells in cultures (Chapter 3). 
 
2. To discover potential antiviral factors acting as an ideal marker for the sex-specific 
responses (Chapter 4).  
 
3. To examine potential mechanisms that drive sex-specific responses in HSV-1-
infected cells (Chapter 5) 
 
4. To characterise the pathways that are differentially regulated between primary human 
and mouse skin cells (Chapter 6). 
 
5. To identify key genes in the host and virus that contribute to the human-mouse 
differences in HSV-1 replication (Chapter 6). 
 
 
37 
 
  
38 
 
 
 
 
 
 
 
Chapter 2. Materials and Methods 
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2.1 Materials 
 
2.1.1 Buffers and solvents 
 
EDTA: 0.5 M ethylenediaminetetraacetic acid in deionised water (pH 8.0).  
 
1x TAE buffer: 1 mM EDTA (pH 8.0), 20 mM glacial acetic acid and 40 mM Tris 
base in deionised water. 
 
1x ThermoPol buffer: Diluted from 10x ThermoPol buffer (New England Biolabs) in 
deionised water. 
 
TE buffer: 1 mM EDTA and 10 mM Trizma base (pH 8.0) in deionised water. 
 
1x T4 DNA ligase buffer: Diluted from 10x T4 DNA ligase buffer (New England 
Biolabs) in deionised water. 
 
RSB buffer: 1.5 mM magnesium chloride (Ajax FineChem), 10 mM potassium 
chloride (Sigma-Aldrich) and 10 mM Trizma base (Sigma-Aldrich) in deionised water. 
 
PBS: Phosphate-buffered saline obtained from Sigma-Aldrich. 
 
PBS-T: PBS with 0.1% Tween-20 detergent. 
 
FACS-PBS: PBS with 2% foetal bovine serum (FBS; Serana, Australia). 
 
1 M Tris, pH 6.8: 1 M Trizma base (Sigma-Aldrich) in deionised water (pH 6.8). 
 
1.5M Tris, pH 8.8: 1 M Trizma base (Sigma-Aldrich) in deionised water (pH 8.8). 
 
Cycloheximide: 100 mg/mL cycloheximide (Sigma-Aldrich). 
 
Acetone (Merck). 
 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich). 
 
Ethanol (Merck). 
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Methanol (Merck). 
 
Nuclease free water (Ambion). 
 
Sterile water (Baxter healthcare). 
 
2.1.2 Media for cell culture 
 
CMC-MEM: 0.4% (w/v) medium viscosity sodium carboxymethyl cellulose (CMC; 
Sigma) in Minimum Essential Medium (MEM) supplemented with 2 mM L-glutamine 
and 2% FBS. 
 
DMEM: Dulbecco’s modified eagle medium (DMEM; Invitrogen), supplemented with 
2 mM L-glutamine (Life Technologies) and 2% (v/v) or 10% (v/v) FBS (Serana, 
Australia).  
 
MEM: Minimum essential medium (MEM; Invitrogen) supplemented with 5 mM 
HEPES (Life Technologies), 2 mM L-glutamine (Invitrogen), 50 μM 2-
mercaptoethanol (Gibco) and 2% (v/v) or 10% (v/v) FBS (Serana, Australia).  
 
2.1.3 Media for bacterial culture 
 
Luria-Bertani (LB) medium: 5 g yeast extract (Bacto), 10 g sodium chloride (Merck) 
and 10 g tryptone (Bacto) in 1 L deionised water. 
 
LB-agar plates: 10 g tryptone (Bacto), 5 g yeast extract (Bacto), 10 g sodium chloride 
(Sigma-Aldrich) and 15 g Bacto-agar (Bacto) in 1 L deionised water. To make LB-agar 
plates with antibiotics, ampicillin (Sigma-Aldrich) or kanamycin (Sigma-Aldrich) was 
added to a final concentration of 100 μg/ml before pouring. 
 
SOC medium: Super optimal broth with catabolite repression (SOC) medium 
(Invitrogen). 
 
Antibiotics:  100 μg/ml ampicillin (Sigma-Aldrich) or 100 μg/ml kanamycin (Sigma-
Aldrich) in deionised water . 
 
60% (v/v) Glycerol: 60% (v/v) glycerol (Sigma-Aldrich) in deionised water. 
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2.1.4 Reagents for molecular biology 
 
10% SDS: 10% (w/v) sodium dodecyl sulfate (SDS; Sigma-Aldrich). 
 
Bovine Serum Albumin (BSA; Sigma-Aldrich). 
 
Transfer buffer: 6 g/L Trizma base (Sigma-Aldrich), 3 g/L glycine (Bacto) and 10% 
(v/v) methanol (Merck) in deionised water. 
 
1x Laemmli buffer: 3 g/L Trizma base (Sigma-Aldrich), 19 g/L glycine and 1% (v/v) 
SDS with the pH adjusted to 8.3. 
 
40% Acrylamide/Bis solution: 40% acrylamide and bis acrylamide (29:1) solution 
(Biorad). 
 
Tween 20 (Sigma). 
 
Bromophenol blue (Biorad). 
 
Tetramethylethylenediamine (N-N-N’-N’-tetramethylethylenediamine; TEMED; 
Biorad). 
 
10% ammonium persulfate: 10% (w/v) ammonium persulfate (APS; Biorad) in 
deionised water. 
 
5x Western blot loading buffer: 15 ml stock solution containing 3 ml 20% SDS, 3.75 
ml Tris buffer (1 M, pH 6.8), 9 mg bromphenol blue, 2.4 ml 2-mercaptoethanol, 4.5 ml 
glycerol. 
 
Tris-glycine Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE): Recipes for stacking and resolving gels for SDS-PAGE are described in Table 
2-1 and Table 2-2. 
 
Table 2-1. Resolving gel for Tris-glycine SDS-PAGE in 10 ml. 
 10% 12% 15% 
Deionised water 4.8 ml 4.3 ml 3.5 ml 
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40% 
acrylamide/bis 
solution 
2.5 ml 3.0 ml 3.8 ml 
1.5 M Tris, pH 8.8 2.5 ml 2.5 ml 2.5 ml 
10% APS 100 μl 100 μl 100 μl 
10% SDS 100 μl 100 μl 100 μl 
TEMED 4 μl 4 μl 4 μl 
 
Table 2-2. 5% (v/v) stacking gel for Tris-glycine SDS-PAGE in 4 ml. 
Deionised water 2.9 ml 
40% 
acrylamide/bis 
solution 
0.5 ml 
1 M Tris, pH 6.8 0.5 ml 
10% APS 40 μl 
10% SDS 40 μl 
TEMED 4 μl 
 
Protein marker: Prestained protein ladder (10 to 180 kDa; Thermo Scientific). 
 
Nitrocellulose membrane (NC membrane): 0.20 µm pore-size nitrocellulose 
membrane (Biorad). 
 
Enzyme-linked chemiluminescence (ECL) substrate: Clarity Western ECL substrate 
(Biorad ) and Amersham ECL prime Western blotting detection reagent (GE 
Healthcare). 
 
Agarose for DNA gel electrophoresis: 1.0% or 2.0% (w/v) UltraPure Agarose (Life 
Technologies) in 1x TAE Buffer. 
 
Plasmid miniPrep kit (Favorgen). 
 
Plasmid midiPrep kit (Invitrogen). 
 
Gel and PCR clean-up kit: Wizard SV gel and PCR clean-up system (Promega). 
 
qPCR mastermix: 2x Power SYBR green master mix (Applied Biosystems). 
 
Qubit assays: Qubit RNA HS assay (Life Technologies). 
 
Bioanalyser: Agilent 2100 Bioanalyser (Agilent Technologies). 
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High Sensitivity DNA Kit: Agilent High Sensitivity DNA kit (Agilent Technologies). 
 
RNA analysis kit: Agilent RNA 6000 Nano kit (Agilent Technologies). 
 
Whole transcriptome analysis (RNA-Seq) kit: TruSeq stranded total RNA library 
preparation kit (Illumina). 
 
Whole genome sequencing kit: Nextera XT DNA library preparation kit (Illumina). 
 
Big Dye terminator: Big Dye terminator for DNA sequencing (Life Technologies) 
with 5x reaction buffer supplied by Biomolecular Resource Facility, John Curtin School 
of Medical Research, ANU. 
 
DNA markers: 100 bp (New England Biolabs) and 1 kb DNA markers (New England 
Biolabs).  
 
6x DNA gel loading buffer (New England Biolabs). 
 
Deoxyribonucleotide triphosphate mix: 10 mM deoxyribonucleotide triphosphate 
(dNTP) mix (Bioline). 
 
siRNAs. 
 
Table 2-3. siRNAs used in this thesis. 
Ref_mRNA_ID Gene_Symbol Assay ID Source 
NM_001290729 Taf1 503338 Thermo 
Scientific 
NM_001079513 Zbtb33 SASI_Mm02_00293002  Sigma-Aldrich 
NM_001113354 Phf8 SASI_Mm02_00307463  Sigma-Aldrich 
NM_027382 Hdac8 SASI_Mm01_00107278  Sigma-Aldrich 
NM_007922 Elk1 SASI_Mm01_00163817  Sigma-Aldrich 
NM_008224 Hcfc1 SASI_Mm01_00051349  Sigma-Aldrich 
NM_008390 Irf1 SASI_Mm01_00151781 Sigma-Aldrich 
NM_016849 Irf3 SASI_Mm02_00323626 Sigma-Aldrich 
NM_016850 Irf7 SASI_Mm01_00188289 Sigma-Aldrich 
NM_020256 Zbtb33 SASI_Mm01_00171874  Sigma-Aldrich 
NR_001463 Xist SASI_Mm02_00352381 Sigma-Aldrich 
NM_021384 Viperin SASI_Mm01_00031984 Sigma-Aldrich 
NM_006777 Zbtb33 SASI_Hs01_00199087 Sigma-Aldrich 
NR_001564 Xist SASI_Hs02_00375151 Sigma-Aldrich 
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NM_080657 Viperin SASI_Hs02_00362416 Sigma-Aldrich 
Universal negative control NA SIC001 Sigma-Aldrich 
 
In-Fusion HD cloning kit (Clontech). 
 
Phusion DNA polymerase: Phusion DNA polymerase (New England Biolabs). 
 
Taq DNA Polymerase: Taq DNA Polymerase (New England Biolabs). 
 
Restriction enzymes: Various restriction endonucleases (New England Biolabs). 
 
DNA gel staining solution: GelRed staining solution (Biotium), 1 in 10,000 diluted in 
deionised water. 
 
Lipofectamine transfection kit: Lipofectamine 2000 (Life Technologies). 
 
Nucleofector transfection kit: Nucleofector kits for primary fibroblasts (Lonza). 
 
Nuclear and cytoplasmic extraction reagents: Nuclear extraction kit (Abcam; 
ab113474). 
 
Paraformaldehyde: 16% paraformaldehyde (PFA) in deionised water (Electron 
Microscopy Sciences). 
 
cDNA synthesis kit: SuperScript VILO cDNA synthesis kit (Life Technologies).  
 
DNase: DNase I, RNase free (Ambion). 
 
Phenol:chloroform: Phenol:chloroform:isoamyl alcohol (25:24:1 ratio; Sigma-
Aldrich). 
 
IGEPAL: IGEPAL CA-630 (Sigma-Aldrich). 
 
RNA extraction kits: Two RNA isolations kits were used: the RNAqueous micro kit 
(Ambion) for small scale RNA isolation from sorted cells and the TRIzol reagent 
(Invitrogen) for medium scale RNA extraction from cultured cells. 
 
T4 DNA ligase: 400 units/μl T4 DNA ligase (New England Biolabs). 
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Sodium acetate: 3 M sodium acetate (Merck) in deionised water. 
 
2.1.5 Reagents for cell culture and virology 
 
Crystal violet staining solution: 2.5% (v/v) crystal violet (Sigma-Aldrich) in 20% 
(v/v) ethanol. 
 
Collagenase solution: 0.5% (w/v) Type IV Collagenase (at least 160 units/ml; 
Worthington) in deionised water. 
 
Trypsin: 0.05% (w/v) trypsin with 0.53 mM EDTA (Invitrogen). 
 
Foetal bovine serum (Serana, Australia). 
 
100x MEM NEAA: MEM Non-Essential Amino Acids Solution (NEAA; Gibco), 
diluted as appropriate. 
 
2-Mercaptoethanol: 55 mM 2-Mercaptoethanol in Dulbecco's Phosphate Buffered 
Saline (DPBS; Gibco). 
 
Penicillin streptomycin solution: Penicillin streptomycin solution (10,000 U/ml; 
Gibco), diluted as appropriate. 
 
Geneticin solution: Geneticin solution (50 mg/ml; G418; Gibco), diluted as 
appropriate.  
 
2.1.6 Reagents for infection of mice 
 
Avertin: 2.5% (v/v) 2-methyl-butanol (Sigma-Aldrich) and 12.5 mg/ml 2,2,2-
tribromoethanol (Sigma-Aldrich) in deionised water.  
 
Veet depilatory cream: Veet depilatory cream for sensitive skin (Reckitt Benckiser). 
 
2.1.7 Plasmids 
 
All plasmids in this thesis were isolated using a MiniPrep or MidiPrep kit (Section 
2.2.2.1). Plasmids used during this thesis are listed in Table 2-4. Plasmids produced 
during this thesis are described in Table 2-5. 
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Table 2-4. Plasmids used in this thesis. 
Plasmid name Description Source 
pSSmCB The plasmid contains an mCherry gene 
under the control of the Vaccinia virus 
(VACV) strong synthetic promoter. 
(Dobson et al., 2014) 
lentiCRISPR v2 The plasmid contains two expression 
cassettes, hSpCas9 and the chimeric guide 
RNA. It can be digested by the BsmBI 
restriction enzyme and a pair of annealed 
oligos can be cloned into the single guide 
RNA scaffold. 
A gift from Dr. Gaétan 
Burgio (Burgio, 2018) 
p3x FLAG-
CMV-14 
The plasmid encodes three adjacent 
FLAG epitopes downstream of the 
multiple cloning sites. It is used to 
establish expression of transient or stable 
intracellular C-terminal 3x FLAG fusion 
proteins in mammalian cells. 
A gift from Professor 
Wei-Li Hsu (Tseng et 
al., 2015) 
 
Table 2-5. Plasmids generated in this thesis. 
Plasmid name Description 
lentiCRISPRmCherry lentiCRISPR v2 vector with the coding 
sequence of the mCherry fluorescent protein 
under the control of the EFS-NS promoter. 
p3xFLAG-viperin p3xFLAG-CMV-14 with the full-length 
coding sequence of mouse viperin fusion 
with three adjacent FLAG epitopes. 
p3xFLAG-viperin-Δ9-42 p3xFLAG-CMV-14 with the mouse viperin 
deleted of 9 to 42 amino acid residues fusion 
with three adjacent FLAG epitopes. 
p3xFLAG-viperin-Δ71-182 p3xFLAG-CMV-14 with the mouse viperin 
deleted of 71 to 182 amino acid residues 
fusion with three adjacent FLAG epitopes. 
p3xFLAG-viperin-Δ218-361 p3xFLAG-CMV-14 with the mouse viperin 
deleted of 218 to 361 amino acid residues 
fusion with three adjacent FLAG epitopes. 
lentiCRISPRmCherry-Mb21d1 
(cGAS) 
Contains a guide RNA designed to target the 
Mb21d1 (cGAS) coding sequence inserted 
into lentiCRISPRmCherry.  
lentiCRISPRmCherry-Ifih1 (Mda5) Contains a guide RNA designed to target the 
Ifih1 (Mda5) coding sequence inserted into 
lentiCRISPRmCherry. 
lentiCRISPRmCherry-Ddx58 (Rig-
I) 
Contains a guide RNA designed to target the 
Ddx58 (Rig-I) coding sequence inserted into 
lentiCRISPRmCherry. 
lentiCRISPRmCherry-Tbk1 Contains a guide RNA designed to target the 
Tbk1 coding sequence inserted into 
lentiCRISPRmCherry. 
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lentiCRISPRmCherry-Tlr3 Contains a guide RNA designed to target the 
Tlr3 coding sequence inserted into 
lentiCRISPRmCherry. 
lentiCRISPRmCherry-Tlr4 Contains a guide RNA designed to target the 
Tlr4 coding sequence inserted into 
lentiCRISPRmCherry. 
lentiCRISPRmCherry-Zbtb33 Contains a guide RNA designed to target the 
Zbtb33 coding sequence inserted into 
lentiCRISPRmCherry. 
lentiCRISPRmCherry-Rsad2 
(Viperin) 
Contains a guide RNA designed to target the 
Rsad2 (viperin) coding sequence inserted 
into lentiCRISPRmCherry. 
lentiCRISPRmCherry-human-Mx1 Contains a guide RNA designed to target the 
human Mx1 coding sequence inserted into 
lentiCRISPRmCherry. 
lentiCRISPRmCherry-human-Jak1 Contains a guide RNA designed to target the 
human Jak1 coding sequence inserted into 
lentiCRISPRmCherry. 
lentiCRISPRmCherry-mouse-Mx1 Contains a guide RNA designed to target the 
mouse Mx1 coding sequence inserted into 
lentiCRISPRmCherry. 
lentiCRISPRmCherry-mouse-Jak1 Contains a guide RNA designed to target the 
mouse Jak1 coding sequence inserted into 
lentiCRISPRmCherry. 
p3xFLAG-HSV-1-VP16 p3xFLAG-CMV-14 with the coding 
sequence of HSV-1 VP16 
p3xFLAG- HSV-1-ICP34.5 p3xFLAG-CMV-14 with the coding 
sequence of HSV-1 ICP34.5 
 
2.1.8 Oligodeoxynucleotides 
 
Oligodeoxynucleotides used in this thesis were synthesised and purified by Sigma-
Aldrich and are listed in Table 2-6, Table 2-7, Table 2-8 and Table 2-9. Working stocks 
of 10 pmol/μl (10 μM) were prepared in deionised water and stored at -20°C. Primer 
sets for qPCR for the detection of human or mouse genes (Table 2-7) were acquired 
from the GETprime online tool (http://bbcftools.epfl.ch/getprime/). Guide RNA (Table 
2-8) was designed based on the ATUM CRISPR gRNA design tool 
(https://www.atum.bio/eCommerce/cas9/input). 
 
Table 2-6. Oligodeoxynucleotides used for InFusion and ligation-based cloning. 
Primer name Sequence (5’-3’) 
IF-mCherry-F CGCCACCCGCGACGACGTCATGGTGAGCAAGGGCGAGGA 
IF-mCherry-R CGGCCCTGGGGACGTCGTCTTACTTGTACAGCTCGTCC 
viperin-KpnI-F TCAAGGTACCATGCTAGTGCCCACT 
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viperin-XbaI-R CGTATCTAGAGCACCAGTCCAGCTTCAG 
Δ9-42 viperin-
KpnI-F 
TCAAGGTACCATGCTAGTGCCCACTGCTCTAGCT 
GGGAAGGAACAGCCACAGGT   
Δ71-182 
viperin-F 
ACTCAGCGCACAACCGATGAACAGGTTAAT 
Δ71-182 
viperin-R 
ATTAACCTGTTCATCGGTTGTGCGCTGAGT 
Δ218-361 
viperin-XbaI-R 
CGTATCTAGACTTGAAAGCCACCTTGT 
HSV-1-VP16- 
HindIII-F 
TCCGAAGCTTATGGACCTCTTGGTCGACG 
HSV-1-VP16- 
XbaI-R 
CGCGTCTAGAGTACCCACCGTACTCGTCA 
 
Table 2-7. Oligodeoxynucleotide primers used for qPCR. 
Primer name Sequence (5’-3’) 
mouse-Mb21d1 (cGAS)-F CATGTGAAGATTTCTGCTCCT 
mouse-Mb21d1 (cGAS)-R TCACAAGATAGAAAGCACCTG 
mouse-Ifih1 (Mda5)-F CTGTGACCACAGAATCAGAC 
mouse-Ifih1 (Mda5)-R TGTTGCTGTTATGTCCAAGAC 
mouse-Ddx58 (Rig-I)-F AATTTGGAAAGACGGTTCACC 
mouse-Ddx58 (Rig-I)-R GTCAGGAACAGGTTGTGGT 
mouse-Tbk1-F GAAGAGTGGATGAGAAAGATGC 
mouse-Tbk1-R TTCCTCTTCGATATCGAAACAC 
mouse-Rsad2 (Viperin)-F CTCAAACAGGCTGGTTTGG 
mouse-Rsad2 (Viperin)-R CTTGCCCAAGTATTCACCC 
mouse-Irf1-F AAACCAAGAGGAAGCTGTG 
mouse-Irf1-R GGTCATCAGGTAGGGTAGAG 
mouse-Irf3-F CTACACTCTGTGGTTCTGC 
mouse-Irf3-R GTAGGAACAACCTTGACCA 
mouse-Irf7-F CTTGGATCTACTGTGGGCC 
mouse-Irf7-R CTTGCCAGAAATGATCCTGG 
mouse-Zbtb33-F AGTAACAACACAGCAACACAG 
mouse-Zbtb33-R TCACTTCCGAAATAGCAACAG 
mouse-Xist-F AGACTACAGGATGAATTTGGAG 
mouse-Xist-R ACTCTTCACTCCTCTAAATCCA 
human-Rsad2 (Viperin)-F GTGGTTCCAGAATTATGGTGAG 
human-Rsad2 (Viperin)-R ATAAGGACATTGACTTCCTCGT 
human-Zbtb33-F GAGCGACGTTTAAAGAAGGG 
human-Zbtb33-R TTCTACTCTCCATGCCTGC 
human-Xist-F CGGGTCTCTTCAAGGACATTTAGCC 
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human-Xist-R GCACCAATACAGAGGAATGGAGGG 
human-Tbk1-F GGAAACAGTTATTATCGCTGAC 
human- Tbk1-R AGGCAGAGTTTCTTGTAACTC 
human-Jak1-F TCAGCATTAACAAGCAGGAC 
human-Jak1-R AGGGACACAAAGGACAAGG 
human-Mx1-F TAATAAAGCCCAGAATGCCA 
human-Mx1-R TTAGAGTCAGATCCGGGAC 
human-Mx2-F TTGAGATCATCGTGCATCAG 
human-Mx2-R GGATAATTTCCATGGCTTTCTG 
human-Eif2ak2-F ACATACCGTCAGAAGCAGG 
human-Eif2ak2-R GAAATGTAAACCTCCTATCATGTGG 
human-Mapk1-F CTATTTGCTTTCTCTTCCACAC 
human-Mapk1-R CAATAAGTCCAGAGCTTTGGA 
human-Stat2-F GCTATGATGGAGAAGCTGG 
human-Stat2-R CTGGATCTTATATCGGAAGCAG 
mouse-Jak1-F TATCTGTTTGCACAGGGAC 
mouse-Jak1-R TATCATGTCCGTCTTGCTC 
mouse-Mx1-F TGCTGTACTGCTAAGTCCA 
mouse-Mx1-R GAAGTGAAGTCGGATCAGG 
mouse-Mx2-F CACATCTGTAAATCTCTTCCTCTG 
mouse-Mx2-R TACCGTACTTCTGCAGCTC 
mouse-Eif2ak2-F GCTCGTCTATGACAAGTAATGG 
mouse-Eif2ak2-R CGAGACCGTTCGTAAACAC 
mouse-Mapk1-F GATCTCAAGATCTGTGACTTTGG 
mouse-Mapk1-R TACGTACTCTGTCAAGAACCC 
mouse-Stat2-F TGATCTCTAACAGACAGGTGG 
mouse-Stat2-R CTGCATTCACTTCTAAGGACTC 
mouse-18srRNA-F GCAATTATTCCCCATGAACG  
mouse-18srRNA-R GGCCTCACTAAACCATCCAA 
human-18srRNA-F CTACCACATCCAAGGAAGCA 
human-18srRNA-R TTTTTCGTCACTACCTCCCCG 
 
Table 2-8. Oligodeoxynucleotides used for cloning guide RNA into 
lentiCRISPRmCherry vector.  
Oligo name Sequence (5’-3’) 
gRNA-Mb21d1 (cGAS)-F CACCGGCGGACGGCTTCTTAGCGCG 
gRNA-Mb21d1 (cGAS)-R AAACCGCGCTAAGAAGCCGTCCGCC 
gRNA- Ifih1 (Mda5)-F CACCGCAGCAGCAGTTCTGCCGCGC 
gRNA- Ifih1 (Mda5)-R AAACGCGCGGCAGAACTGCTGCTGC 
gRNA-Ddx58 (Rig-I)-F CACCGCTGACTGCCTCCGTCGGCGT 
gRNA-Ddx58 (Rig-I)-R AAACACGCCGACGGAGGCAGTCAGC 
gRNA-Tbk1-F CACCGTTAGACCCTTCGAGGGGCCT 
gRNA-Tbk1-R AAACAGGCCCCTCGAAGGGTCTAAC 
gRNA-Rsad2 (Viperin)-F CACCGTGTCATTAATCGCTTCAACG 
gRNA-Rsad2 (Viperin)-R AAACCGTTGAAGCGATTAATGACAC 
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gRNA-Tlr3-F CACCGCTTTCACACGTGCAGTCGAA 
gRNA-Tlr3-R AAACTTCGACTGCACGTGTGAAAGC 
gRNA-Tlr4-F CACCGCACGTCCATCGGTTGATCTT 
gRNA-Tlr4-R AAACAAGATCAACCGATGGACGTGC 
gRNA-Zbtb33-F CACCGACCGAAAATTCCGGGCCCAT 
gRNA-Zbtb33-R AAACATGGGCCCGGAATTTTCGGTC 
gRNA-human-Jak1-F CACCGCACTGACTGCTCATTGTCGT 
gRNA-human-Jak1-R AAACACGACAATGAGCAGTCAGTGC 
gRNA-human-Mx1-F CACCGAGCCCAGAATGCCATCGCCG 
gRNA-human-Mx1-R AAACCGGCGATGGCATTCTGGGCTC 
gRNA-mouse-Jak1-F CACCGTACAGACTGTTCGTTGTCAT 
gRNA-mouse-Jak1-R AAACATGACAACGAACAGTCTGTAC 
gRNA-mouse-Mx1-F CACCGGCCTGCCATCGCTGTCATTG 
gRNA-mouse-Mx1-R AAACCAATGACAGCGATGGCAGGCC 
 
Table 2-9. Oligodeoxynucleotides used for Sanger sequencing. 
Primer name Sequence 
hU6 GAGGGCCTATTTCCCATGATT 
CMVIE CGCAAATGGGCGGTAGGCGTG 
 
2.1.9 Escherichia coli strains 
 
In this thesis, two strains of E. coli were utilised, including α-Select Chemically 
Competent Cells (Gold Efficiency, Bioline) and One Shot Stbl3 Chemically Competent 
E. coli (Invitrogen). α-Select cells were generally used for cloning most vectors. Stbl3 
cells were used to reduce the frequency of homologous recombination of long terminal 
repeats in lentiviral expression vectors. 
 
2.1.10 Mice 
 
Six-week-old male or female specific pathogen-free C57BL/6 mice were obtained from 
the Australian Phenomics Facility (Canberra, Australia). All mice were maintained in 
the containment suite at the John Curtin School of Medical Research, ANU. All 
experiments were approved by the ANU Animal Ethics and Experimentation 
Committee under protocol A2014/025 and A2017/39.  
 
For preparation of primary mouse skin fibroblasts, three-day-old C57BL/6, Balb/c or 
IFNAR knockout mice (a gift from Dr. Si Ming Man) (Man et al., 2015) were obtained 
from the Australian Phenomics Facility (Canberra, Australia). Further details on the 
preparation of the primary mouse skin fibroblasts are provided in Section 2.2.18. 
 
2.1.11 Cells 
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The cells used in this thesis are listed in Table 2-10. Cells were maintained in culture 
flasks at 37oC with 5% CO2 and were subcultured twice a week as described in Section 
2.2.17. 
 
Table 2-10. Cells used in this thesis. 
Cell Origin Property Split ratio Sex 
HEK293 Human embryonic kidney 
cells transformed with 
human adenovirus 5 DNA 
Adherent 1 in 12 Female 
HFF Human foreskin fibroblasts Adherent 1 in 8 Male 
MRC5 Human lung fibroblasts Adherent 1 in 8 Male 
Male cells 
(MF) 
Mouse skin fibroblasts Adherent 1 in 6 Male 
Female cells Mouse skin fibroblasts Adherent 1 in 6 Female 
IFNAR-/- 
(Male) 
Mouse skin fibroblasts Adherent 1 in 6 Male 
IFNAR-/- 
(Female) 
Mouse skin fibroblasts Adherent 1 in 6 Female 
HeLa Human cervical cancer 
cells 
Adherent 1 in 10 Female 
Vero African green monkey 
kidney epithelial cells 
Adherent 1 in 8 Female 
V27 Vero cells that were stably 
transfected to contain the 
HSV ICP27 gene preceded 
by the neo gene conferring 
resistance to Geneticin 
Adherent 1 in 8 Female 
BSC-1 African green monkey 
kidney epithelial cells 
Adherent 1 in 6 NA 
M2-10B4 Mouse bone marrow/stroma 
fibroblasts 
Adherent 1 in 8 Female 
 
2.1.12 Viruses 
 
Viruses used in this thesis are listed in Table 2-11. 5dl1.2, ΔSma and LJS1 were gifts 
from Professor James Smiley, Department of Medical Microbiology and Immunology, 
University of Alberta, Edmonton, Canada (Corcoran et al., 2006). All viruses were 
grown and titres were determined in Vero cells, except 5dl1.2 and LJS1, for which V27 
cells were used.  
 
Table 2-11. Viruses used in this study. 
Virus name Description Reference 
HSV-1 KOS Wild-type HSV-1 strain KOS (Smith, 1964) 
53 
 
HSV-1 pICP47 HSV-1 strain KOS 
expressing an GFP/Cre 
cassette under the control of 
the ICP47 promoter from the 
UL3/UL4 intergenic region 
(Russell and Tscharke, 
2016) 
5dl1.2 (HSV-1 ICP27 
mutant) 
HSV-1 strain KOS containing 
ICP27 null mutant 
(McCarthy et al., 
1989) 
ΔSma (HSV-1 vhs 
mutant) 
HSV-1 strain KOS containing 
a 588-nucleotide deletion in 
the UL41 gene (vhs) 
(Read et al., 1993) 
VACV Western Reserve 
(WR) 
Wild-type Vaccinia strain WR (Parker et al., 1941) 
CPXV  Cowpox virus strain Brighton 
Red 
A gift from Dr. Klaus 
Früh (Alzhanova et 
al., 2014) 
 MCMV Murine cytomegalovirus 
strain Smith 
A gift from Dr. Si 
Ming Man (Man et al., 
2016) 
 
2.1.13 Antibodies 
 
The commercially available antibodies used in this study are listed in Table 2-12. All 
the antibodies were used to perform Western blotting. Anti-rabbit IgG-horseradish 
peroxidase (HRP) or anti-mouse IgG-horseradish peroxidase (HRP) was used as the 
secondary antibody for Western blotting. Other antibodies were used as the first 
antibodies. 
 
Table 2-12. Antibodies used in this thesis. 
Name Host Source 
Anti-rabbit IgG-HRP Goat Abcam (ab97051) 
Anti-mouse IgG-HRP Goat Abcam (ab6789) 
Anti-mouse-MB21D1 
(cGAS) 
Rabbit Cell Signalling (#31659) 
Anti-mouse-IFIH1 
(MDA5) 
Rabbit Abcam (ab69983) 
Anti-mouse-DDX58 
(RIG-I) 
Rabbit Cell Signalling (#3743) 
Anti-mouse-TBK1 Rabbit Cell Signalling (#3504) 
Anti-mouse-TBK1p Rabbit Cell Signalling (#5483) 
Anti-mouse-IRF1 Rabbit Abcam (ab186384) 
Anti-mouse-IRF3 Rabbit Cell Signalling (#4302) 
Anti-mouse-IRF7 Rabbit Abcam (ab62505) 
Anti-mouse-RSAD2 
(Viperin) 
Mouse Abcam (ab107359) 
Anti-mouse-β-CATENIN Rabbit Cell Signalling (#9582) 
Anti-mouse-ZBTB33 Mouse Abcam (ab12723) 
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Anti-human/mouse-JAK1 Rabbit Cell Signalling (#3344) 
Anti-human/mouse-
JAK1p 
Rabbit Cell Signalling (#74129) 
Anti-FLAG Mouse Sigma (F3165) 
Anti-GAPDH Rabbit Cell Signalling (#5174) 
Anti-HSV1 gB Mouse Abcam (ab6506) 
 
2.2 Methods 
 
2.2.1 Growth and maintenance of bacteria 
 
E.coli was grown in liquid LB or on LB-agar plates supplemented with the appropriate 
antibiotics at 37oC overnight. Bacterial stocks were stored in glycerol solution (600 μl 
of overnight culture in 400μl 60% glycerol) at -80 oC. 
 
2.2.2 DNA extraction and purification 
 
2.2.2.1 Plasmid DNA isolation 
 
Most plasmid DNA was extracted from 1.5 ml of overnight liquid bacterial cultures 
using the Favorgen plasmid MiniPrep kit according to the manufacturer’s instructions. 
DNA was eluted in 40 μl of elution buffer. 
 
If a large amount of DNA was required, plasmid DNA was isolated from 200 ml of 
liquid bacterial cultures using the Invitrogen MidiPrep kit according to the 
manufacturer’s instructions. DNA was eluted in 1 ml of elution buffer. 
 
2.2.2.2 PCR products and purification of linearized plasmids 
 
PCR products and linearized plasmids obtained from restriction enzyme digestion were 
purified using the Wizard SV gel and a PCR clean-up kit from Promega, according to 
the manufacturer’s instructions. The DNA was eluted in 40 μl of elution buffer. 
 
In some experiments, DNA was isolated from an agarose gel to ensure that PCR 
products and linearized plasmids of the desired size were extracted. DNA fragments of 
the correct size were excised from the gel. Wizard SV gel and a PCR clean-up kit was 
used to purify DNA fragments from the agarose gel, according to the manufacturer’s 
instructions. 
 
2.2.2.3 Extraction of HSV genomic DNA for whole genome sequencing (WGS) 
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To generate HSV-1 DNA for use in WGS, male or female cells at 80% confluence were 
infected with the indicated viruses at an multiplicity of infection (MOI) of 0.01 for 48 
hours. The cells were collected by centrifuging at 2,000 rpm (rmax: 207.8 mm) for 10 
minutes at 4oC and the supernatant was stored on ice. The harvested cells were lysed 
with RSB buffer with 0.5% (v/v) IGEPAL and were incubated for 10 minutes on ice. 
The cellular debris was pelleted by centrifuging at 2,000 rpm (rmax: 207.8 mm) for 10 
minutes at 4°C. All of the collected supernatants were pooled and pelleted by 
centrifuging at 14,000 rpm (rmax: 63 mm) for 90 minutes at 4°C. The pellet was 
resuspended in 0.5 ml TE buffer with 50 μg/ml proteinase K, and was incubated for 5 
minutes at room temperature. An equal volume of phenol:chloroform was added into 
this sample. The mixture was gently inverted until evenly mixed, and was then 
centrifuged at 14,000 rpm (rmax: 63 mm)for 10 minutes. The aqueous phase was again 
extracted with phenol:chloroform two times. The final aqueous phase was precipitated 
with a 0.1 volume of 3 M sodium acetate and two volumes of 100% ethanol. The DNA 
was collected by centrifuging at 14,000 rpm (rmax: 63 mm) for 30 minutes and the pellet 
was washed with 70% ethanol. The final pellet was resuspended in 100 μl TE buffer. 
 
2.2.3 Polymerase chain reaction 
 
Standard PCR was performed primarily for molecular cloning in this study. Phusion 
high-fidelity DNA polymerase (New England Biolabs) was used according to the 
manufacturer’s instructions. PCRs were performed in 20 μl or 50 μl reaction volume 
using an ABI Veriti 96-well Thermocycler. The final reaction contained 1x Phusion HF 
buffer, 1 unit Phusion high-fidelity DNA polymerase, 200 μM dNTPs, 0.5 μM forward 
primer, 0.5 μM reverse primer and 2 μl template DNA (either purified plasmids 
(Section 2.2.2) or diluted cDNA reversely transcribed from RNA of male mouse skin 
fibroblasts (Section 2.2.4) in a 20 μl reaction. In this study, Phusion HF buffer was 
replaced with the Phusion GC buffer while amplifying HSV-1 gene. The samples were 
run on a PCR machine using the following conditions: 
 
a. Initial denaturation: 98oC for 5 minutes 
b. Amplification  
 30 cycles of  
  Denaturation: 98oC for 10 seconds 
  Annealing: 60-65oC for 30 seconds (depending on Tm of primers) 
  Extension: 72oC for 30 seconds per kb 
c. Final extension: 72oC for 10 minutes 
56 
 
d. Hold at 4°C 
 
2.2.4 RNA isolation 
 
2.2.4.1 Total RNA isolation from sorted cells 
 
For sorted cells, RNA was extracted using the RNAqueous micro kit (Ambion).  Sorted 
cells (Section 2.2.27) were mixed with 200 μl of the lysis buffer immediately to protect 
the RNA from degradation. RNA was extracted from the mixture following the 
manufacturer’s instructions. DNase treatment was performed post-elution by 
incubating samples with DNase I and 1x DNase I buffer (Ambion) at 37oC for 30 
minutes. Samples were stored at -80°C until required. 
 
2.2.4.2 Total RNA isolation from cultured cells 
 
For general cultured cells, RNA was isolated using the TRIzol reagent (Invitrogen). 
Cells were harvested and collected by centrifugation at 1,200 rpm (rmax: 207.8 mm) for 
10 minutes. The supernatant was then removed and 1 ml of the TRIzol reagent was 
added into every 1 x 106 cells. After incubation of the mixture at room temperature for 
5 minutes, RNA was isolated according to the manufacturer’s instructions. Briefly, an 
equal volume of phenol:chloroform was added into this mixture and the mixture as 
gently inverted to evenly mix the samples. The two phases were then separated by 
centrifugation at 14,000 rpm (rmax: 63 mm) for 10 minutes. The aqueous phase was 
extracted with phenol:chloroform one more time. The resulting aqueous phase was 
precipitated with isopropanol (0.5 ml of isopropanol per 1 ml TRIzol reagent). The 
RNA was collected by centrifuging at 14,000 rpm (rmax: 63 mm) for 30 minutes and the 
pellet was washed with 70% ethanol. The final pellet was resuspended in 50 μl TE 
buffer. 
 
2.2.5 Determining nucleic acid quantity 
 
For general determination of DNA or RNA concentration, 2 μl of sample was measured 
by Nanodrop spectrophotometer (Thermo Scientific). To obtain a more accurate 
concentration of nucleic acid for use in qPCR analysis, a Qubit fluorometer (Life 
Technologies) was applied. For detecting RNA intact number before constructing 
RNAseq libraries or DNA library size distributions, the Agilent RNA 6000 Nano Kit 
(Agilent Technologies) or the Agilent High Sensitivity DNA Kit (Agilent 
Technologies) was used following the manufacturer’s instructions. 
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2.2.6 cDNA synthesis 
 
cDNA was synthesised using the SuperScript VILO cDNA synthesis kit (Invitrogen) 
according to the manufacturer’s instructions. Briefly, 100, 300 or 500 ng of RNA was 
mixed with 4 μl of 5x VILO Reaction Mix and 2 μl of 10x SuperScript III Enzyme, and 
was filled up to 20 μl with nuclease-free water. The reaction was performed by 
incubation at 25°C for 10 minutes and then at 42°C for 60 minutes, followed by 
termination at 85°C for 5 minutes. 
 
2.2.7 Construction of standard curve for qPCR analysis 
 
p3xFLAG-viperin plasmid was isolated as described in Section 2.2.2.1. DNA quantity 
was measured by Qubit assay (Life Technologies), as mentioned in Section 2.2.5. The 
mass in nanograms was converted to copy numbers based on the formula below: 
 
 
 
X: amount of DNA (ng); 
N: length of dsDNA;  
660 g/mole: average mass of 1 bp dsDNA. 
 
The DNA was diluted in 10-fold serial dilutions to the desired concentration in order to 
construct the standard curve.  
 
2.2.8 qPCR analysis 
 
Human or mouse qPCR primer sets were designed by the GETprime online tool to 
amplify specific transcripts (http://bbcftools.epfl.ch/getprime/). Samples were diluted 
1:3, 1:5 or 1:10 with nuclease-free water before performing qPCR on a 7900HT Fast 
Real-Time PCR System (Applied Biosystems). The qPCR reaction was performed by 
mixing 0.5 μM forward primer, 0.5 μM reverse primer, appropriated diluted sample and 
5 μl of 2x Power SYBR green PCR master mix (Applied Biosystems) in 10 μl total 
volume. The qPCR assays were performed using the following program: 
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a. Initial denaturation: 95oC for 10 minutes 
b. Amplification and detection 
 40 cycles of  
  Denaturation: 95oC for 15 seconds 
  Annealing and Extension: 60oC for 30 seconds 
c. Dissociation curves detection 
 1 cycle of  
  Denaturation: 95oC for 15 seconds 
  Annealing: 60oC for 15 seconds 
  Extension: 95oC for 15 seconds 
 
Dissociation curves were run to determine the accuracy of the amplified products. 
Sequence Detection System v2.4 software from Applied Biosystems was used to 
analyse Ct and Tm values. Expression levels of each gene were normalised to 18srRNA 
and then differential expressions were determined by the 2 -ΔΔCt method. 
 
2.2.9 Restriction enzyme digestion 
 
Restriction enzyme digestion was used to linearize plasmids for cloning. Digests were 
performed according to the manufacturer’s instructions (New England Biolabs). In 
brief, each restriction digestion reaction contained 1x NEBuffer, 100 ng/μl purified 
plasmids and 0.2 unit/μl restriction enzymes, in a total volume of 20 μl. The reactions 
were incubated at the recommended temperature overnight.  
 
2.2.10 Agarose gel electrophoresis 
 
To visualise the resulting DNA fragments digested by restriction enzymes or the PCR 
products, the DNA fragments were separated by running gel electrophoresis on 0.8, 1.0 
or 2.0% agarose TAE gels in 1x TAE buffer. DNA ladder was loaded into the first well 
of each gel and used to indicate a molecular size. DNA was mixed with 6x DNA loading 
dye and the mixture was loaded into the wells. Gels were run at 110 V for 30 minutes 
using horizontal electrophoresis apparatuses (Bio-Rad). Gels were stained after 
electrophoresis with GelRed staining solution (Biotium) for 20 minutes. DNA 
fragments were visualised and photographed using the Gel Doc XR System (Biorad).  
 
2.2.11 Annealing of single-stranded oligonucleotides 
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Oligonucleotides shown in Table 2-8 were annealed with their complementary 
oligonucleotides to generate short double-stranded DNA inserts encoding guide RNA 
for cloning into lentiCRISPRmCherry vectors (Section 2.2.12). Briefly, 1 μl (100 μM) 
of each complementary single-stranded oligonucleotide was mixed with 1.5 μl of 10x 
T4 DNA ligase buffer and 8.5 μl deionised water. The sample was then incubated at 
95°C for 5 minutes, followed by ramping down to 25oC at 5oC/min. The annealed 
oligonucleotides were then stored at 4°C before use. 
 
2.2.12 Molecular cloning 
 
Two different methods were used for construction of plasmids in this thesis: standard 
ligation of digested, amplified or annealed DNA and InFusion cloning (Clontech).  
 
2.2.12.1 Ligation for molecular cloning 
 
T4 DNA ligase and its buffer, both obtained from New England Biolabs, were used to 
ligate linearized plasmids with annealed oligonucleotides (Section 2.2.11 and Table 2-
13) or PCR products after restriction digest with enzymes producing complementary 
overhanging sequences (Table 2-14).  
 
For ligation of annealed oligonucleotides with linearized plasmids, the annealed 
oligonucleotides from Section 2.2.11 were diluted into sterile water at a 1:100 ratio. 
Briefly, a 12 μl reaction contained 1 μl of the diluted oligonucleotides, 50 ng of BsmBI 
digested plasmid, two units of T4 DNA ligase and 1x T4 DNA ligase buffer. The 
reaction was incubated at 16oC for two hours and was then used for transformation 
(Section 2.2.13). Plasmids generated by this method are shown in Table 2-13. 
 
For ligation of PCR products after enzyme digestion with linearized plasmids (Table 2-
14), the reaction contained 50 ng of vector DNA, a 2:1 molar ratio of insert to vector 
DNA, two units of T4 DNA ligase and 1x T4 DNA ligase buffer in a total volume of 
12 μl. The reaction was incubated at room temperature for 16 hours and was then used 
for transformation (Section 2.2.13). DNA fragments of viperin with deletion of residues 
71 to 182 were built by overlap extension PCR (Heckman and Pease, 2007). In short, 
two separate rounds of PCRs were applied to produce the upstream or downstream 
sequences of the deletion region from p3xFLAG-viperin plasmids. Afterwards, 
products of the two separate PCR reactions having 15-bp overlaps were then used as 
the template for the next round of PCR using the outermost primers to construct the 
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final insert DNA fragments. These insert fragments were digested by corresponding 
restriction enzymes and ligated with the linearized p3xFLAG-CMV-14 vector. 
 
Table 2-13. Plasmids constructed by ligation of annealed oligonucleotides. 
Plasmid produced Restriction 
enzyme (s) 
Vector details  Insert details 
  Parental plasmid oligo 1 oligo 2 
lentiCRISPRmCherry-
Mb21d1 (cGAS) 
BsmBI lentiCRISPRmCherry gRNA-Mb21d1 
(cGAS)-F 
gRNA-Mb21d1 
(cGAS)-R 
lentiCRISPRmCherry-
Ifih1 (Mda5) 
BsmBI lentiCRISPRmCherry gRNA- Ifih1 
(Mda5)-F 
gRNA- Ifih1 
(Mda5)-R 
lentiCRISPRmCherry-
Ddx58 (Rig-I) 
BsmBI lentiCRISPRmCherry gRNA-Ddx58 
(Rig-I)-F 
gRNA-Ddx58 
(Rig-I)-R 
lentiCRISPRmCherry-
Tbk1 
BsmBI lentiCRISPRmCherry gRNA-Tbk1-F gRNA-Tbk1-R 
lentiCRISPRmCherry-
Tlr3 
BsmBI lentiCRISPRmCherry gRNA-Tlr3-F gRNA-Tlr3-R 
lentiCRISPRmCherry-
Tlr4 
BsmBI lentiCRISPRmCherry gRNA-Tlr4-F gRNA-Tlr4-R 
lentiCRISPRmCherry-
Zbtb33 
BsmBI lentiCRISPRmCherry gRNA-Zbtb33-F gRNA-Zbtb33-R 
lentiCRISPRmCherry-
Rsad2 (Viperin) 
BsmBI lentiCRISPRmCherry gRNA-Rsad2 
(Viperin)-F 
gRNA-Rsad2 
(Viperin)-R 
lentiCRISPRmCherry-
human-Jak1 
BsmBI lentiCRISPRmCherry gRNA-human-
Jak1-F 
gRNA-human-
Jak1-R 
lentiCRISPRmCherry-
human-Mx1 
BsmBI lentiCRISPRmCherry gRNA-human-
Mx1-F 
gRNA-human-
Mx1-R 
lentiCRISPRmCherry-
mouse-Jak1 
BsmBI lentiCRISPRmCherry gRNA-mouse-
Jak1-F 
gRNA-mouse-
Jak1-R 
lentiCRISPRmCherry-
mouse-Mx1 
BsmBI lentiCRISPRmCherry gRNA- mouse -
Mx1-F 
gRNA- mouse -
Mx1-R 
 
Table 2-14. Plasmids constructed by ligation of products of restriction digest. 
Plasmid produced Restriction 
enzyme (s) 
Vector details Insert details   
  Parental plasmid Template 
DNA 
Forward primer Reverse primer 
p3xFLAG-viperin KpnI and XbaI p3xFLAG-CMV-14 MF cDNA viperin-KpnI-F viperin-XbaI-R 
p3xFLAG-viperin-
Δ9-42 
KpnI and XbaI p3xFLAG-CMV-14 p3xFLAG-
viperin 
Δ9-42 viperin-
KpnI-F 
viperin-XbaI-R 
p3xFLAG-viperin-
Δ71-182 
KpnI and XbaI p3xFLAG-CMV-14 p3xFLAG-
viperin 
viperin-KpnI-F 
and Δ71-182 
viperin-F 
viperin-XbaI-R 
and Δ71-182 
viperin-R 
p3xFLAG-viperin-
Δ218-361 
KpnI and XbaI p3xFLAG-CMV-14 p3xFLAG-
viperin 
viperin-KpnI-F Δ218-361 
viperin-XbaI-R 
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p3xFLAG-HSV-1-
VP16 
HindIII and 
XbaI 
p3xFLAG-CMV-14 HSV-1 
genomic 
DNA 
HSV-1-VP16- 
HindIII-F 
HSV-1-VP16- 
XbaI-R 
p3xFLAG-HSV-1-
ICP34.5 
HindIII and 
XbaI 
p3xFLAG-CMV-14 Synthesized by GenScript 
 
2.2.12.2 In-Fusion cloning 
 
In-Fusion cloning is a ligation-independent cloning method which was applied to 
directly insert PCR products into a linearized vector by recombination. The plasmids 
that were generated using the In-Fusion cloning method are shown in Table 2-15. In 
brief, the insert used for In-Fusion cloning was amplified by PCR from plasmid DNA 
using a high fidelity polymerase. These primers had 15 nucleotide extensions at their 
5’ end homologous to the vector sequence.  
 
In this thesis, a 2:1 molar ratio of insert to vector was used in a total volume of 10 μl 
containing 1x In-Fusion reaction buffer, 1 μl In-Fusion enzyme and deionised water. 
The reaction was performed by incubating at 37oC for 15 minutes, followed by 50oC 
for 15 minutes, and was then used for transformation (Section 2.2.13). 
 
Table 2-15. Plasmids constructed by In-Fusion cloning. 
Plasmid produced Restriction 
enzyme (s) 
Vector details Insert details   
  Parental plasmid Template DNA Forward primer Reverse primer 
lentiCRISPRmCherry Tth111I lentiCRISPR v2 pSSmCB IF-mCherry-F IF-mCherry-R 
 
2.2.13 Transformation  
 
In total, 3 μl of In-Fusion reaction or 10 μl ligation mixture was mixed with 50 μl of α-
Select Chemically Competent E. coli (Bioline) or 50 μl of One Shot Stbl3 competent 
cells (Invitrogen). The reaction was incubated on ice for 30 minutes and was then heat 
shocked at 42oC using a water bath for 90 seconds, followed by incubation on ice for 2 
minutes. Next, 900 μl SOC medium was added into the transformed cells and the 
mixture was incubated at 37oC with shaking for one hour. Then, 200 μl of the 
transformed cells were plated onto LB-agar plates with the appropriate antibiotics (100 
μg/ml of ampicillin or 100 μg/ml of kanamycin) and incubated at 37oC overnight. 
Plasmids from colonies were isolated (Section 2.2.2.1) for confirmation by restriction 
digest of plasmid DNA and Sanger sequencing (Section 2.2.14).  
 
2.2.14 Sanger sequencing 
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Sanger sequencing reactions were performed using Big Dye Terminator (Life 
Technologies). Each 20 μl reaction contained 1 μl Big Dye terminator, 3.5 μl reaction 
buffer, 3.2 pmol appropriate primer and template DNA (150-300 ng of purified 
plasmid). Primers used Sanger sequencing in this thesis are shown in Table 2-9 and 
Table 2-16. The PCR conditions for Sanger DNA sequencing are described below: 
 
a. Initial denaturation: 94°C for 5 minutes 
b. Amplification and detection 
 30 cycles of: 
  Denaturation: 96°C for 10 seconds 
  Annealing: 50°C for 5 seconds 
  Extension: 60°C for 4 minutes 
c. Hold at 4°C 
 
DNA products from Sanger sequencing reactions were precipitated by adding 80 μl of 
solution containing 3.75 μl sodium acetate (3M), 62.5 μl 100% ethanol and 13.75 μl 
deionised water. After incubation at room temperature for 15 minutes, samples were 
centrifuged at 14,000 rpm (rmax: 63 mm) for 20 minutes and then washed with 250 μl 
70% ethanol. The extension products were air dried and sent to the Biomolecular 
Resource Facility (John Curtin School of Medical Research, ANU) for sequencing. 
 
Table 2-16. Primers used in Sanger sequencing. 
Primer name Used to sequence 
hU6 lentiCRISPRmCherry; 
lentiCRISPRmCherry-Mb21d1 (cGAS); 
lentiCRISPRmCherry-Ifih1 (Mda5); 
lentiCRISPRmCherry-Ddx58 (Rig-I); 
lentiCRISPRmCherry-Tbk1; 
lentiCRISPRmCherry-Tlr3; 
lentiCRISPRmCherry-Tlr4; 
lentiCRISPRmCherry-Zbtb33; 
lentiCRISPRmCherry-Rsad2 (Viperin); 
lentiCRISPRmCherry-human-Mx1; 
lentiCRISPRmCherry-human-Jak1; 
lentiCRISPRmCherry-mouse-Mx1; 
lentiCRISPRmCherry-mouse-Jak1 
CMVIE p3xFLAG-viperin; 
p3xFLAG-viperin-Δ9-42; 
p3xFLAG-viperin-Δ71-182; 
p3xFLAG-viperin-Δ218-361; 
p3xFLAG-HSV-1-VP16 
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2.2.15 RNA sequencing (RNA-seq) 
 
HFF, MRC5, male and female cells were infected with HSV-1 pICP47 at an MOI of 
0.5. Four or eight hours post-infection, GFP-positive cells were collected by FACS Aria 
II (BD Biosciences; Section 2.2.27). Total RNA was extracted from sorted cells using 
an RNAqueous micro total RNA isolation kit (Ambion), according to the 
manufacturer’s instructions (Section 2.2.4). RNA concentrations were first detected 
using a Nanodrop spectrophotometer (Thermo Scientific; Section 2.2.5) and then RNA 
integrities were checked using an Agilent 2100 Bioanalyzer (Agilent Technologies; 
Section 2.2.5). Only those samples with an RNA integrity number (RIN) greater than 
8.5 were kept for RNA-seq library preparation. 
 
The TruSeq stranded total RNA library kit (Illumina) was used for library preparation 
with 1 μg RNA as input for each sample in this study, according to the manufacturer’s 
instructions. Both cytoplasmic and mitochondrial rRNAs were removed using the Ribo 
Zero Gold kit (Illumina). In order to minimise PCR bias, only eight cycles were run to 
enrich fragment-ligated adaptors. The PCR conditions are shown below: 
 
a. Initial denaturation: 98oC for 30 seconds 
b. Amplification  
 8 cycles of  
  Denaturation: 98oC for 10 seconds 
  Annealing: 60oC for 30 seconds 
  Extension: 72oC for 30 seconds 
c. Final extension: 72oC for 5 minutes 
d. Hold at 4°C 
 
Before mixing barcoded libraries in equimolar concentrations, these libraries were 
analysed for length and concentration using the Agilent 2100 Bioanalyzer (Agilent 
Technologies). A NextSeq 500 system was executed in the high output stage to produce 
400 million single-end reads of length 1x 75 bps in a lane.  
 
2.2.16 Viral whole genome sequencing 
 
In order to identify genotype differences in serial passage viruses (Section 2.2.23), 
WGS was applied for detection of single nucleotide polymorphism (SNPs) or small 
insertions and deletions (INDELs) in the HSV-1 genome. Briefly, 1 ng of viral DNA 
(Section 2.2.2.3) was used as the input for the Nextera XT DNA library preparation kit 
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(Illumina), following the manufacturer’s guide. This kit uses an engineered 
transposome to tagment dsDNA and then these fragments are tagged with adapter 
sequences. Eight cycles of PCR were used to amplify the insert DNA and the 
thermocycler conditions are shown below: 
 
a. Initial denaturation: 95oC for 30 seconds 
b. Amplification  
 8 cycles of  
  Denaturation: 95oC for 10 seconds 
  Annealing: 55oC for 30 seconds 
  Extension: 72oC for 30 seconds 
c. Final extension: 72oC for 5 minutes 
d. Hold at 4°C 
 
This PCR step also added index adapter sequences on both ends of the DNA, which 
enables sequencing of pooled libraries on Illumina sequencing platforms. A MiSeq 
system (Illumina) was performed to produce 50 million pair-end reads of length 2x 300 
bps in a lane.  
 
2.2.17 Maintenance of mammalian cells 
 
Details of the mammalian cells used during this study are provided in Table 2-10. All 
cell cultures were incubated at 37oC with 5% CO2. Cells were subcultured two times a 
week at a certain ratio (Table 2-10). To subculture mammalian cells from a culturing 
flask, media were removed and washed with PBS. The cells were then treated with 
0.05% trypsin (Invitrogen) in PBS at 37oC until the cells detached. After removing the 
residual trypsin by aspiration, the cells were diluted in appropriate culture media and 
then transferred into new culturing flasks (Nunc) or plates (Corning). Cell numbers 
were counted using a hemocytometer after staining with trypan blue solution.  
 
2.2.18 Preparation of mouse skin fibroblasts 
 
Three-day-old C57BL/6, Balb/c or IFNAR knockout mice (a gift from Dr. Si Ming 
Man) (Man et al., 2015) were obtained from the Australian Phenomics Facility 
(Canberra, Australia). In general, three male and three female mice were ordered every 
time, and each mouse was treated as a different biological replicate. Mice were culled 
by decapitation at the time they arrived. Each mouse was skinned immediately after 
decapitation and the skin was placed in a separate petri dish with 2 ml PBS. These skins 
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were minced with a scalpel until the pieces were around 1 mm in size. Next, 5 ml of 
0.5% (w/v) collagenase (Worthington) was added into each of the petri dishes. Samples 
were collected into falcon tubes, mixed gently, and then incubated at 37oC for 20 
minutes. Samples were pelleted by centrifugation at 800 rpm (rmax: 207.8 mm) for five 
minutes and then washed with PBS once. After the residual supernatant was removed, 
5 ml 0.05% trypsin (Invitrogen) was added into each tube and then incubated at 37oC 
for 20 minutes. Cells and debris were collected by centrifugation at 800 rpm (rmax: 207.8 
mm) for five minutes, then were resuspended in 6 ml of appropriate medium and cells 
from each mouse were placed in separate 25 cm2 flasks (Nunc). 
 
The original cell culture medium was removed and replaced with mouse skin fibroblast 
medium (DMEM with 10% FBS, 1% MEM NEAA, 1% penicillin streptomycin 
solution and 2 mM L-glutamine) once every day for the first three days. Cells were split 
and transferred into 75 cm2 flasks at day four post-processing. After transferring mouse 
fibroblasts into 75 cm2 flasks, cells were cultured as described in Section 2.2.17. Mouse 
skin fibroblasts can generally be subcultured 10-12 times with normal abilities of 
differentiation and replication. All experiments were approved by the ANU Animal 
Ethics and Experimentation Committee under protocol A2014/025 and A2017/39.  
 
2.2.19 Transfection 
 
2.2.19.1 Lipofectamine method 
 
HEK293 cells were transfected with plasmid DNA using Lipofectamine 2000 at a 1:2 
ratio of DNA (μg) to Lipofectamine solution (μl). For each well to be transfected in 
the24-well plate, DNA and Lipofectamine were added to 80 μl of DMEM without FBS, 
mixed evenly, and then incubated for 20 minutes at room temperature. After cell culture 
medium was removed and replaced with 300 μl of DMEM without FBS, the 
transfection mix was then dripped on HEK293 cell monolayers at around 80% 
confluence. After six hours incubation at 37oC with 5% CO2, the transfection mix was 
removed and replaced with 500 μl of DMEM with 10% FBS. 
 
2.2.19.2 Nucleofector ion method 
 
A Nucleofector transfection kit (Lonza) was employed to transfect plasmid DNA or 
siRNA into cells, according to the manufacturer’s guide. In brief, medium was removed 
from cells and then cells were washed once with PBS. For harvesting, the cells were 
then treated with 0.05% trypsin at 37oC until detached. Appropriate medium with FBS 
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was added into the flasks to neutralise the trypsinisation reaction and the cell density 
was determined using a hemocytometer. Next, 1 x 106 of each cell was pelleted by 
centrifugation at 500 rpm (rmax: 207.8 mm) for 10 minutes at room temperature and then 
was resuspended in the solution containing 82 μl of basic Nucleofector solution for 
mammalian fibroblasts (Lonza), 18 μl supplement (Lonza) and 2 μg plasmid DNA or 
50 pmol siRNA. The mixture was placed into the supplied certified cuvettes and 
transfected using the U-023 program in the Nucleofector 2b Device (Lonza). Once the 
program was finished, 500 µl of the culture medium was added into the cuvette and the 
sample was gently transferred into a well of the six-well plate. The transfected cells 
were incubated at 37oC with 5% CO2 until analysis. 
 
2.2.20 Preparation of HSV-1 stock 
 
To prepare a HSV-1 master stock, a 75 cm2 flask of confluent Vero cells was infected 
with HSV-1 (MOI around 0.01) in 4 ml of MEM without FBS and these cells were then 
incubated at 37oC with 5% CO2 for one hour. The inoculum was replaced with 8 ml 
MEM with 2% FBS and incubated at 37oC with 5% CO2 for four days. Cells were then 
collected by centrifugation at 800 rpm (rmax: 207.8 mm) for 5 minutes at 4°C. The 
supernatant was kept and centrifuged at 14,000 rpm (rmax: 152.5 mm) for 90 minutes at 
4°C to harvest the supernatant-associated virus. In the meantime, the cell pellet was 
resuspended in a total volume of 500 μl MEM without FBS (cell-associated virus), and 
the cell pellet was then sonicated for 60 seconds at ~80% power. The cells were pelleted 
by centrifugation at 800 rpm (rmax: 207.8 mm) for 10 minutes at 4°C. The supernatant 
containing the cell-associated virus was then kept and pooled with the supernatant-
associated virus. This master stock was titrated as described in Section 2.2.21.  
 
To prepare a working stock, three 175 cm2 flasks were infected with the master stock 
at an MOI of 0.01 in 8 ml of MEM without FBS and they were then incubated at 37oC 
with 5% CO2 for one hour. The inoculum was replaced with 16 ml MEM with 2% FBS 
and incubated at 37oC with 5% CO2 for three days or until full cytopathogenic effect 
was observed. The virus working stock was harvested as described for the master stock. 
Working stocks were aliquoted into 50 μl and titrated before use. 
 
2.2.21 Plaque assays for the titration of HSV-1, VACV, CPXV and MCMV 
 
Plaque assays were used to determine viral titres of new virus stocks, serial passages of 
viruses, samples from growth curves or organs from infected mice. For all HSV-1 
viruses, except 5dl1.2, the titres were determined on confluent Vero cells. Titres of 
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5dl1.2 were measured on V27 cell monolayers. For VACV and CPXV, viral titres were 
determined by plaque assays in BSC-1 cells. Titres of MCMV were determined by 
plaque assays in M2-10B4 cells. 
 
Duplicate 10-fold serial dilutions of samples were prepared in MEM without FBS. 
Medium was removed from two six-well plates with confluent Vero, V27, BSC-1 or  
M2-10B4 cell monolayers and 0.5 ml of the virus dilutions was added to the wells and 
incubated for 90 minutes at 37oC with 5% CO2. Plates were gently rocked every 15 
minutes to ensure the monolayer remained covered by inoculum during infection. After 
incubation for 60 minutes, the infectious medium was removed and replaced with 2 ml 
of MEM with 2% FBS and 0.4% CMC (CMC-MEM) in each well. For plaque 
formation, the cells were incubated at 37oC with 5% CO2 for 72 hours. Medium was 
then aspirated and the cells were stained with 1 ml crystal violet solution for 10 minutes 
at room temperature. The crystal violet staining solution was removed and the plates 
were air dried. The stained plates were counted using a light microscope at 10x 
magnification. The number of plaques was counted and the titre in plaque forming unit 
(PFU) per ml was calculated according to the dilution factor and duplicate titrations 
were then averaged. If duplicates differed by more than two-fold, the titration was 
repeated. 
 
2.2.22 Virus growth curves 
 
2.2.22.1 Single step growth curves 
 
Confluent monolayers of HFF, MRC5, male or female cells in six-well plates were 
infected with the virus at an MOI of 5 in 500 μl of MEM without FBS for one hour at 
37oC with 5% CO2. The inoculum was then removed and the cell monolayer was 
washed once with 1 ml PBS, then 1 ml of MEM with 2% FBS was added into each 
well. 0 hour post-infection (hpi) samples were harvested immediately after the fresh 
medium was added. Other samples were collected by scraping using cell lifters 
(Corning) and harvested into existing medium at 2, 6, 12 and 24 hpi. These samples 
were frozen, and thawed three times and then titrated as described in Section 2.2.21. 
 
2.2.22.2 Multiple step growth curves 
 
Confluent monolayers of HFF, MRC5, male or female cells in six-well plates were 
infected with the virus at an MOI of 0.01 in 500 μl of MEM without FBS for one hour 
at 37oC with 5% CO2. After adsorption for one hour, the infectious medium was 
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removed and the cell monolayers were washed with 1 ml PBS. Next, 1 ml of MEM 
with 2% FBS was added into each well. 0 hpi samples were harvested immediately after 
the fresh medium was added. At 0, 2, 4, 6, 12 and 24 hpi, the samples were harvested 
as described for the single step growth curve in Section 2.2.22.1. For very low MOI 
infections with HSV-1 in male and female cells, MOIs of 0.001, 0.0003 and 0.0001 
were used for infection and samples were collected at 24, 48, 72 and 96 hpi. 
Determination of viral titres was performed using plaque assays (Section 2.2.21).    
 
2.2.23 Serial passage of viruses 
 
HSV-1 pICP47 recombinant virus or VACV strain WR was blindly passaged in mouse 
skin fibroblasts acquired from male or female C57BL/6 mice. Male passage virus 
means that the virus was blindly passaged only in male cells and female passage virus 
means that the virus was continuously grown in female cells. Cross passage virus was 
first propagated in male cells and then cultured in female cells for the next round.  
 
2.2.23.1 Serial passage of HSV-1 
 
For passaging of HSV-1, mouse skin fibroblasts were obtained from three individual 
three-day-old male or female C57BL/6 mice. Next, 1 x 106 of male or female cells were 
seeded into each well of a six-well plate. Cells were infected with HSV-1 pICP47 
recombinant virus at an MOI of 0.01 for the first passage. After incubation for 48 hours 
at 37oC with 5% CO2, the cells were scraped from the surface of the well with cell lifters 
(Corning), and were submitted to three freezing/thawing cycles. Then, 2 μl of the 
harvested virus was used to infect a new well of the six-well plate seeded with male or 
female cells in 10 ml 2% FBS DMEM. This process was repeated up to 30 times.  
 
2.2.23.2 Serial passage of VACV 
 
For passaging of VACV, mouse skin fibroblasts were obtained from three individual 
three-day-old male or female C57BL/6 mice. Next, 1 x 106 male or female cells were 
seeded into each well of the six-well plate. Cells were then infected with VACV strain 
WR virus at an MOI of 0.01 for the first passage. The following steps were the same as 
described for the serial passage of HSV-1 in Section 2.2.23.1. 
 
2.2.24 Western blotting (WB) 
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The cells were harvested by scraping using cell lifters (Corning) and were then 
centrifuged at 800 rpm (rmax: 207.8 mm) for 10 minutes at room temperature. The cell 
pellet was resuspended in appropriate 5x Western blot loading buffer (Section 2.1.4) 
and incubated at 95oC in the heat block for 15 minutes. Samples were then stored at -
20oC until required.  
 
2.2.24.1 Protein gel electrophoresis 
 
A Mini-PROTEAN Tetra Cell chamber (Biorad), a vertical mini gel electrophoresis 
system was used to perform protein electrophoresis and transfer. The Mini-PROTEAN 
Tetra Cell chamber was first assembled by casting with Tris-glycine SDS-PAGE gels 
and then filling the wells with an appropriate volume of 1x Laemmli buffer (Section 
2.1.4). Boiled samples were then loaded into the wells of Tris-glycine SDS-PAGE gels 
(Table 2-1 and Table 2-2). Appropriate protein ladders (Section 2.1.4) were used to 
indicate molecular size and estimate mass. Gels were run at 100 V for 20 minutes, 
followed by 120 V for 80 minutes to separate the proteins.  
 
2.2.24.2 Transfer 
 
The Mini-PROTEAN Tetra Cell chamber was set with Mini Trans-Blot Module 
(Biorad) and filled with an appropriate volume of transfer buffer (Section 2.1.4). Before 
inserting the assembled gel holder cassette into the electrode module, the correct 
direction for arranging the protein gels, NC membranes, filter papers (Biorad) and fibre 
(Biorad) was checked. The transferring procedure ran at 250 mA for two hours at 4oC. 
 
2.2.24.3 Immunoblotting 
 
After transfer (Section 2.2.24.2), the membrane was blocked with 10 ml of 5% skim 
milk or 3% BSA in PBS-T on the shaker at 37oC for two hours. Following this, immune 
staining was performed with diluted antibodies (Table 2-17). Primary antibodies were 
diluted with 5% skim milk in PBS-T and then incubated with the membrane overnight 
at 4oC. Appropriate secondary antibodies were applied and incubated with the 
membrane for two hours at room temperature. Washing with PBS-T was performed 
three times between each step. An ECL substrate (Biorad; GE Healthcare) was used to 
treat the NC membranes. The signal was detected using an ImageQuant LAS 4000 
system (GE Healthcare).  
 
Table 2-17. Dilution factors for antibodies used in this study. 
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Name Dilution Primary/Secondary 
Anti-rabbit IgG-HRP 1:10000 Secondary 
Anti-mouse IgG-HRP 1:10000 Secondary 
Anti-mouse-MB21D1 
(cGAS) 
1:5000 Primary 
Anti-mouse-IFIH1 
(MDA5) 
1:1000 Primary 
Anti-mouse-DDX58 
(RIG-I) 
1:1000 Primary 
Anti-mouse-TBK1 1:5000 Primary 
Anti-mouse-TBK1p 1:1000 Primary 
Anti-mouse-IRF1 1:500 Primary 
Anti-mouse-IRF3 1:500 Primary 
Anti-mouse-IRF7 1:500 Primary 
Anti-mouse-RSAD2 
(Viperin) 
1:500 Primary 
Anti-mouse-β-CATENIN 1:2000 Primary 
Anti-mouse-TLR3 1:500 Primary 
Anti-mouse-TLR4 1:500 Primary 
Anti-mouse-ZBTB33 1:500 Primary 
Anti-human/mouse-JAK1 1:1000 Primary 
Anti-human/mouse-
JAK1p 
1:500 Primary 
Anti-FLAG 1:5000 Primary 
Anti-GAPDH 1:5000 Primary 
 
2.2.25 Fluorescence microscopy 
 
For this assay, 1 x 106 male or female cells were transfected with 2 µg of p3xFLAG-
viperin or empty p3xFLAG vectors using a Nucleofector transfection kit (Section 
2.2.19.2). Cells were then seeded on the coverslips in the 12-well plate. After 24 hours 
-transfection, cells were infected with HSV-1 pICP47 recombinant virus at an MOI of 
1 for eight hours. Cells were then fixed with 4% PFA for 20 minutes and then washed 
with PBS three times. To visualise the nucleus, cells were stained with 4,6-diamidino-
2-phenylindole (DAPI) for 10 minutes and mounted onto slides and they were then 
observed with confocal microscopy. 
 
2.2.26 Quantification of fluorescent protein expression by flow cytometry 
 
Flow cytometry was used to measure the expression of fluorescent proteins in cells 
being transfected or infected with a plasmid or virus that can express GFP or mCherry. 
Cells were harvested by trypsinisation as described in Section 2.2.17. Approximately 8 
x 105 cells were transferred to an 1.5 ml microcentrifuge tube and were collected by 
centrifugation at 800 rpm (rmax: 207.8 mm) for 10 minutes. After washing with FACS-
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PBS, the cells were fixed by 1% PFA for 20 minutes at room temperature. The cells 
were centrifuged at 800 rpm (rmax: 207.8 mm) for 10 minutes, washed once with FACS-
PBS and resuspended in 100 μl of FACS-PBS. In general, at least 10,000 events were 
collected. An LSR-II (BD Biosciences) or an Accuri C6 (BD Biosciences) flow 
cytometer was used to acquire data in this study. The data acquired by the flow 
cytometer was analysed using FlowJo 10.1 software (Tree Star). Appropriate gates were 
applied to individual experiments when analysing the data (Figure 2-1). 
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Figure 2-1. Gating strategy to identify GFP+ cells after HSV-1 infection. Mouse 
skin fibroblasts were infected with HSV-1 pICP47 recombinant virus at an MOI of 
0.0001 for 72 hours. Cells were harvested, fixed with 4% paraformaldehyde and 
analysed by flow cytometry. To identify GFP+ cells, events were first selected based on 
the forward scatter (FSC) and side scatter (SSC) parameters. Next, singlets were gated 
according to height (H) and area (A) parameters of FSC and then SSC. Lastly, GFP+ 
events were gated on a GFP x SSC-H plot.  
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2.2.27 Sorting cells 
 
A FACS Aria II cell sorter (BD Biosciences) was used to collect GFP-positive cells that 
were infected with HSV-1 pICP47 recombinant virus. Cells were harvested by 
typsinisation as described in Section 2.2.17. Approximately 2 x 106 cells were 
transferred to a 15 ml Falcon tube and were centrifuged at 800 rpm (rmax: 207.8 mm) 
for 10 minutes. Cells were washed once with FACS-PBS and then resuspended in 500 
μl of appropriate culture medium. The samples were filtered using a cell strainer 
(Falcon) to obtain a single-cell suspension, before being subjected to cell sorting. The 
purity of the sorted cells was remeasured immediately after the sorting procedure by a 
FACS Aria II cell sorter (BD Biosciences). 
 
2.2.28 Infection of mice with HSV-1 
 
Six-week-old male or female C57BL/6 mice were obtained from the Australian 
Phenomics Facility (Canberra, Australia) and were kept until eight-week old before 
they were used. Mice were infected with 1 x 108 PFU of HSV-1 by tattooing on the 
flank. Avertin, an injectable anaesthetic agent, was used in this study to anesthetise 
mice through intraperitoneal injection using a 1 ml syringe (BD Biosciences) and a 26G 
x 1/2” needle (BD Biosciences). Under anaesthesia, the hair on the left flank was 
trimmed from the dorsal to ventral midline using clippers and then depilated with Veet 
(Reckitt Benckiser) to remove all hair. A 5 x 5 mm area of skin of the left flank, located 
above the tip of the spleen, was marked. After a tattoo needle was dipped in virus 
solution (1 x 108 PFU/ml) in DMEM without FBS, mice were then tattooed for 20 
seconds using a Swiss rotary tattoo machine (Pullman Tools). Tissue was wrapped 
around the body of each mouse to maintain adequate body temperature until the mouse 
had regained consciousness. The development of lesions was also monitored from day 
one post-infection until an endpoint in each experiment.   
 
2.2.29 Collection and titration of organs from HSV-1-infected mice 
 
Mice were euthanised by asphyxiation with CO2 and all samples were collected on day 
two post-infection. A 1 cm2 region of skin was collected from mice infected by tattoo 
(Section 2.2.27) and was harvested into 500 μl of MEM with 2% FBS. The dorsal root 
ganglions (DRGs) located at the ipsilateral side, referring to spinal levels T8 to T12, 
were isolated using curved forceps and then pooled into 500 μl of MEM with 2% FBS. 
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Organs in MEM with 2% FBS were homogenised by using tissue grinders (Wheaton) 
and were subjected to three freezing/thawing cycles before titration (Section 2.2.21).  
 
2.2.30 Statistical analyses 
 
Statistical analyses were performed using GraphPad Prism 7 software. The difference 
between tested groups was considered to be statistically significant when p-value <0.05. 
In all figures, single, double and triple asterisks indicate p-values <0.05, <0.01 and 
<0.001, respectively. When two groups of samples were compared, the unpaired 
Student’s t-test was used to compare the difference between the two means. If more 
than two sample groups were to be compared, one-way analysis of variance (ANOVA) 
was used and then Tukey’s post-tests were performed for multiple pairwise 
comparisons. Two-way ANOVA was performed to compare growth kinetics of 
multiple viruses across different infection times or passages, followed by Tukey’s post-
tests for pairwise comparisons. If more than two factors were involved in the 
experiment, a linear model was employed to determine significant differences using the 
lm() function in R, a free software program for statistical computing and graphics 
(https://www.r-project.org/). 
 
2.2.31 Bioinformatics analysis 
 
2.2.31.1 Viral genome assembly pipeline 
 
The quality of the resulting reads from Section 2.2.16 were first checked by FastQC 
(version 0.11.4), a quality control tool for high-throughput sequence data. Illumina 
adapters generated by the library preparation protocol, and reads that were shorter than 
50 bp or with a quality lower than 20, were removed using the BBMap tools 
(https://sourceforge.net/projects/bbmap/?source=navbar). The remaining reads were 
uploaded to the VirAmp server via a Galaxy interface (http://viramp.com/) (Wan et al., 
2015). To remove reads from the host genome, Burrows-Wheeler Aligner (BWA) (Li 
and Durbin, 2009) was used to map reads against the mouse genome (mm10). 
Unmapped reads were then performed with pair-end de novo assembly pipeline via 
VirAMP. In general, each sample, including parent virus (i.e., HSV-1 pICP47 
recombinant virus) and three biological replicates from p10 and p30 of the male, female 
or cross passage virus (Section 2.2.23), was assembled into large and continuous 
contigs based on different k-mers and then combined into a dataset using the Velvet 
package (Zerbino and Birney, 2008). After the de novo assembly step, AMOScmp was 
used to orient the resulting contigs by aligning to a reference genome (HSV-1 strain 
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KOS; Gene Bank accession number: JQ673480) and then a new draft genome was 
created by connecting every contig from multiple alignments (Treangen et al., 2011). 
Next, SSPACE was applied for assembly correction and expansion by aligning paired-
ends back to the contigs assembled by AMOScmp (Boetzer et al., 2011; Boetzer and 
Pirovano, 2014). SSPACE then searched for unmapped reads located near the edge of 
the gap and estimated the placement of these reads into the gap regions. Further, the 
spacing between reads was utilised to scaffold contigs to form an intact sequence for 
the final genome assembly. This rescues the information loss in the digital 
normalisation and coverage reduction at the beginning of the VirAmp pipeline. A final 
single linear sequence was created from a set of contigs generated by SSPACE via 
alignment to the reference genome and then production of a linear genome. Finally, 
variation analysis was performed using the MUMmer package to identify 
SNPs/INDELs between the parent virus and serial passage viruses (Delcher et al., 2003; 
Marcais et al., 2018). 
 
2.2.31.2 Differentially regulated transcripts between sexes 
 
The raw reads of male and female cells from three individual mice produced in Section 
2.2.15 were sorted by barcodes and then trimmed for adapters and low quality reads 
using Trimmomatic (Bolger et al., 2014). The reads were then mapped against the 
mouse genome (mm10) using the TopHat2 aligner which uses Bowtie2 as its core read-
alignment engine and has an algorithm to assign reads that span introns in the presence 
of alternative splicing events and isoforms (Kim et al., 2013). The number of reads 
generated from a transcript was calculated by Cufflinks using reads per kilobase of 
transcript per million mapped reads (RPKM) (Trapnell et al., 2012). Differentially 
regulated genes were then identified using the Cuffdiff package which quantifies 
expression of each transcript in the triplicates of male and female cells. Variation in 
each transcript across the replicates was used to test the statistical significance of 
observed changes in expression between HSV-1-infected and uninfected samples 
(Garber et al., 2011; Trapnell et al., 2012). A false discovery rate (FDR) smaller than 
0.05 and a p-value smaller than 0.05 were defined as a significant difference based on 
the Cuffdiff outputs (Trapnell et al., 2010; Trapnell et al., 2013). The log2 fold change 
was measured by comparing the average expression of infected triplicates at 4 or 8 hpi 
to uninfected counterparts in male and female cells, respectively. 
 
Significantly upregulated or downregulated transcripts at 4 or 8 hpi in male and female 
cells were compiled into different lists for biological process gene ontology (GO) 
enrichment classification and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
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pathways analysis via the DAVID online database (https://david.ncifcrf.gov/) (Huang 
et al., 2007; Huang da et al., 2009). An FDR smaller than 0.05 and a p-value smaller 
than 0.05 was classified as differential regulation. Upregulated or downregulated GO 
terms in male or female cells at one and/or more time points were combined into other 
lists and further visualised using REVIGO (http://revigo.irb.hr/) (Supek et al., 2011).  
 
2.2.31.3 Cross-species analysis of RNA-seq data 
 
The raw reads of triplicates of HFF, MRC5 and male cells from three individual mice 
generated in Section 2.2.15 were first allocated by barcodes to separate libraries, then 
Illumina adapters were trimmed and reads with low quality scores were discarded via 
Trimmomatic as described in Section 2.2.31.2 (Bolger et al., 2014). The remaining 
reads were further mapped to the human (hg38) or mouse (mm10) genome, depending 
on the species of cells, using the TopHat2 mapper (Trapnell et al., 2012; Kim et al., 
2013). Raw counts of each gene were calculated by the featureCounts package and were 
then transferred into counts per million (CPM) (Liao et al., 2014). Genes with low raw 
counts (<3) were removed and the TMM method was used to normalise libraries 
through the edgeR package (Robinson et al., 2010). After generating raw counts and 
normalisation, initial Ensembl gene IDs were converted into gene symbols in both 
human and mouse samples. Only shared human and mouse orthologous genes were 
kept for further analysis. The cross-species difference at the gene level was analysed by 
the limma and edgeR packages (Smyth, 2004; Robinson et al., 2010; Ritchie et al., 
2015; Law et al., 2016). In brief, the voom method, a linear modelling strategy, was 
applied to estimate the mean-variance relationship of counts, produce a precision 
weight for each sample and introduce these into the limma empirical Bayes analysis 
procedure to identify significant differences (Law et al., 2014). A log2 fold change more 
than 1 and a p-value smaller than 0.05 between infected samples and mock samples 
were the designated criteria to acquire differentially regulated genes. Differentially 
regulated genes at 4 or 8 hpi in HFF, MRC5 and male cells were combined into lists as 
inputs for GO enrichment analysis via g:Profiler 
(http://biit.cs.ut.ee/gprofiler/index.cgi). Specific regulated GO terms between HFF and 
MRC5 or male cells at 4 and/or 8 hpi were compiled and were further visualised by 
REVIGO (http://revigo.irb.hr/) (Supek et al., 2011). 
 
At the pathway level, rotation gene sets analysis (ROAST) was performed based on the 
expression levels of each gene in human or mouse samples between infection time 
points of 4 or 8 hpi and mock groups (Wu et al., 2010). Differentially regulated 
pathways were defined by those pathways that had both a p-value and an FDR smaller 
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than 0.05 in the REACTOME database (Wu et al., 2010). Reference gene lists were 
based on the human or mouse C2 curated gene sets in the Molecular Signatures 
Database v6.0 (http://software.broadinstitute.org/gsea/msigdb/index.jsp).  
 
2.2.31.4 HSV-1 gene expression analysis 
 
Unmapped reads in Section 2.2.31.2 and Section 2.2.31.3 were mapped against the 
modified HSV-1 genome (Gene Bank accession number: JQ673480) with only one 
copy of the terminal repeats (TRL and TRS) preserved. Raw counts of each viral gene 
were calculated by the featureCounts package and were transferred into CPM and 
normalised by the TMM method in each library, as described in Section 2.2.31.3 (Liao 
et al., 2014). Differential viral gene expression was analysed by a generalised linear 
model built in edgeR. The cutoff of differential expression was set to a p-value smaller 
than 0.05 and a log2 fold change more than 1.5. Finally, for visualisation, an HSV-1 
genome coverage plot was constructed via the Gviz package in R, following the users 
guide (Hahne and Ivanek, 2016).  
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3.1 Introduction 
 
Sex differences in the prevalence and intensity of viral infections are illustrated by a 
growing body of literature (Fischer et al., 2015; Klein and Flanagan, 2016). Males and 
females deploy distinct responses to diverse viruses, including influenza virus, HIV and 
herpesviruses (Klein, 2012). However, the mechanisms that underlie differences 
between the sexes are complicated and can involve genetic, hormonal and behavioural 
factors (Roved et al., 2017). The immune system has evolved to provide a balance 
between proinflammatory and anti-inflammatory reactions, and thereby, determines the 
outcome of viral infection (Rouse and Sehrawat, 2010). Generally, females generate 
higher innate and higher adaptive immune responses compared with males, which 
accelerates virus clearance but may be detrimental through the development of 
immunopathology (de Jong et al., 2006). For example, during influenza virus infection, 
females induce greater proinflammatory responses, such as TNF-α, IL-6 and activation 
of NF-κB signalling, which sometimes correlates with elevated morality in females 
(Walsh et al., 2011). Conversely, in males, multiple depressive effects on the immune 
system during microbial infections have been discovered (Ghosh and Klein, 2017). 
Nonetheless, it is clear that specific differences in immune responses between the sexes 
are dependent on the microbe, as not every infection leads to increased overall 
susceptibility in one sex over the other. Thus, including sex as a criteria in studies is 
critical for improving our knowledge base on immunity to infections in general. 
 
To date, the available evidence on whether a particular sex is more susceptible to HSV-
1 infection in animal models is inconsistent. The best controlled studies of the role of 
sex on HSV-1 infection have been done in mouse models. Male mice show less limb 
paralysis than female mice following intravenous inoculation with HSV-1, despite 
female mice consistently generating more antibodies (Knoblich et al., 1983; Yirrell et 
al., 1987). Likewise, greater mortality is observed in female mice during systemic viral 
infection, such as with intraperitoneal injection (Han et al., 2001; Geurs et al., 2012). 
By contrast, mortality is higher in male 129/SvEv wild-type, IFN-γ knockout and IFN-
γ receptor knockout strains when inoculated with HSV-1 via the corneal route. It also 
varies according to infection routes and strains of mice. Therefore, although several 
studies suggest that sex can influence HSV-1 pathogenesis, sex-based differences in 
HSV-1 infection remain ill-defined. 
 
In this chapter, we addressed whether there is a sex difference during HSV-1 infection 
from various perspectives focusing on cell-intrinsic effects in culture. First of all, we 
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examined growth kinetics of HSV-1 in male and female primary mouse skin fibroblasts 
(referred to hereafter as male and female cells), in a single- or multi-step growth 
experiment. We then tested if HSV-1 can adapt to sex using a serial passage method in 
a cell-based system. Furthermore, whole genome sequencing (WGS) was employed to 
identify SNPs/INDELs in these sex-adapted HSV-1 genomes. Next, we investigated 
whether sex-adapted HSV-1 generates different pathogenesis in the flank zosteriform 
mouse model. Finally, in order to identify potential mechanisms driving the sex 
difference in HSV-1 infection, RNA-seq was applied to comprehensively investigate 
transcriptional differences between HSV-1-infected male and female cells. 
 
3.2 Results 
 
3.2.1 Single- and multi-step growth curves of HSV-1 pICP47 recombinant virus in 
male and female mouse skin fibroblasts 
 
In order to understand whether sex affects general virus replication, both single- and 
multi-step growth curves were constructed. Primary skin fibroblasts were considered 
suitable host cells as skin is the major location where HSV-1 invades and initiates 
infection. Likewise, primary cells with few mutations are considered to be closer to the 
cells infected in vivo, compared with cell lines. The use of primary cells also allows 
replicates to be cultures from individual mice and not simply replicate infection of the 
same batches of cells. HSV-1 pICP47 recombinant virus was selected to conduct this 
experiment as it can express the GFP protein, which is a marker for downstream cell 
sorting enabling collection of the infected cell population post-infection (Section 
2.2.27). It has also been recently plaque purified in the lab. HSV-1 pICP47 contains a 
GFP/Cre cassette driven by an ICP47 promoter, inserted into the UL3 and UL4 
intergenic region of HSV-1 strain KOS (Russell and Tscharke, 2016). Male and female 
cells were infected with HSV-1 pICP47 virus at an MOI of 10 for generating one-step 
growth curves or at an MOI of 0.01, 0.001, 0.0003 and 0.0001 for producing multi-step 
growth curves. Viral titres were determined at indicated time points and are shown in 
Figure 3-1. Male and female cells produced similar viral yields when infected with 
HSV-1 pICP47 recombinant virus during one-cycle replication (Figure 3-1A). 
However, when the cells were exposed to very low amounts of virus, HSV-1 replicated 
more efficiently in male cells compared to female cells. There were significant 
differences in growth between male and female cells during HSV-1 infection at an MOI 
of 0.0003 and 0.0001 (Figure 3-1D and Figure 3-E), which was consistent with a larger 
infected population detected by flow cytometry in male cells compared to female cells 
(Figure 3-2). There was no significant difference in the size of plaques on male and 
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female cells at 96 hpi (Figure 3-3), indicating different viral yields between male and 
female cells is not dependent on the cell-to-cell spread. 
 
3.2.2 HSV-1 but not VACV strain WR can adapt to sex 
 
As shown in Section 3.2.1, HSV-1 replicates differently in male and female cells after 
very low multiplicity infections where virus can continue to spread throughout the 
culture period. Thus, we speculated that the cells of male and female mice might exert 
different selective pressure on virus replication over multiple rounds of growth. To date, 
most studies examining the experimental evolution of viruses have focused on RNA 
viruses with high mutation rates (Montville et al., 2005; Vignuzzi et al., 2006). Less is 
known about the adaptive strategies of large dsDNA viruses, such as herpesviruses and 
poxviruses, but adaptation is possible (Lynch, 2010; Elde et al., 2012). In this section, 
an experimental evolution method was applied to investigate whether HSV-1 can adapt 
to sex using serial infections at relatively small population sizes. Essentially, male or 
female cells were infected with HSV-1 pICP47 recombinant virus at a low MOI (0.01 
PFU/cell) in three independent cultures. Forty-eight hours post-infection, the virus was 
collected and then repeatedly propagated in male cells (male passage virus), female 
cells (female passage virus) or between these two types of cells (cross passage virus) 
for 30 rounds (Section 2.2.23 and Figure 3-4).  
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Figure 3-1. Different growth phenotypes of HSV-1 pICP47 recombinant virus in 
male and female primary mouse fibroblasts (male and female cells). Confluent 
monolayers of male and female cells were infected with HSV-1 pICP47 recombinant 
virus at an MOI of (A) 10, (B) 0.01, (C) 0.001, (D) 0.0003 or (E) 0.0001. After an hour 
of absorption, the inoculum was replaced with 2 ml MEM with 2% FBS. A 0 hpi sample 
was harvested immediately after the addition of fresh media. The samples were 
collected at indicated time points and viral titres were determined by plaque assays. The 
data are expressed as mean ± SEM of cultures from three individual mice. Two-way 
ANOVA with Tukey's post-tests was performed to test differences between means in 
titres over time between male and female cells, where significance is denoted by * (p-
value <0.05). ns, no significant difference. 
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Figure 3-2. A higher percentage of infected cells (GFP-positive) in male than in 
female cultures during low MOI infection with HSV-1 pICP47 recombinant virus. 
Monolayers of male or female cells were infected with HSV-1 pICP47 recombinant 
virus at an MOI of 0.0001 or mock infected with PBS. At 48, 72 and 96 hpi, cells were 
harvested, fixed with 4% paraformaldehyde at room temperature for 20 minutes and 
resuspended in the FACS-PBS for flow cytometry analysis. (A) Representative flow 
cytometry plots from one of three independent experiments showing the percentage of 
GFP expression. (B) The data are presented as mean ± SEM of cultures from three 
individual mice. Two-way ANOVA with Tukey's post-tests was used to test differences 
between means in GFP percentage over time between male and female cells. *** p-
value <0.001.  
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Figure 3-3. Size of plaques formed by HSV-1 in male and female cells at 96 hpi. 
Monolayers of male or female cells from three individual mice were infected with HSV-
1 pICP47 recombinant virus at an MOI of 0.0001 for 96 hr. Plaques were crystal violet 
stained and the area of plaques produced on male and female cells were measured using 
ImageJ (n=40). Statistical significance was determined using Student’s t-test. ns, not 
significant difference. 
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Figure 3-4. Flow chart of experimental evolution of HSV-1 in mouse skin 
fibroblasts. Male or female cells from three individual mice were infected with HSV-
1 pICP47 recombinant virus at an MOI of 0.01 for the first passage. After 48 hours, the 
cell pellet was resuspended in 200 μl of DMEM without FBS, followed by three 
freeze/thaw cycles. Next, 2 μl of this harvested virus was used to infect fresh 
monolayers of male or female cells in 2 ml of DMEM with 2% FBS. Male passage 
virus indicates that the virus was passaged only in male cells and female passage virus 
indicates that the virus was continuously grown in female cells. Cross passage virus 
indicates that the virus was first propagated in male cells and then cultured in female 
cells in the next round. The serial passage was repeated 30 rounds for each male, female 
and cross passage virus. Blue and red dots reflect male and female cells, respectively. 
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After serial passage of HSV-1 pICP47 recombinant virus to obtain male passage virus, 
female passage virus and cross passage virus, the indicated passage number of each 
virus was used to infect fresh male and female cells from another three individual mice 
at an MOI of 0.01 for another 48 hours. Then viral yields were measured to examine 
the replication properties of these viruses (Figure 3-5). Vero cells were used here to  
 
Male passage viruses consistently produced higher viral titres in male cells than in 
female cells after 10 serial passages (Figure 3-6A). Female passage viruses initially 
seemed to produce greater viral titres in male cells, although there was no significant 
difference due to large variation among each replicate. This phenomenon was reversed 
after approximately 10 rounds of passages that female passage viruses began to grow 
more efficiently in female cells compared with male cells (Figure 3-6B). By contrast, 
cross passage viruses generated similar viral yields in male and female cells, indicating 
that inconsistent evolution pressure from the different sexes cannot lead to a virus 
lineage specifically adapted to male or female cells (Figure 3-6C). Finally, increased 
viral titres were observed in all cultures over time, suggesting that HSV-1 also adapted 
to mouse skin fibroblasts during the experiment (Figure 3-6).  
 
As each mouse strain is unique and different from other strains in many respects 
(Casellas, 2011; Hunter, 2012; Walkin et al., 2013), it is necessary to understand 
whether HSV-1 male and female passage viruses harbour similar replication properties 
in other mouse strains. Therefore, instead of using male and female cells derived from 
C57BL/6, which have been utilised for most experiments in this study, mouse skin 
fibroblasts prepared from three individual male and female BALB/c were infected with 
male passage viruses or female passage viruses from 30 passages at an MOI of 0.01 for 
48 hours. Viral titres were then determined by plaque assays. In line with what was 
found in C57BL/6 cells, male passage viruses exhibited titres about 5-10-fold higher in 
male BALB/c skin fibroblasts than in female skin fibroblasts (Figure 3-7). HSV-1 
female passage viruses produced more infectious viruses in female than in male 
BALB/c skin fibroblasts. However, there was no difference in growth phenotype 
between male and female BALB/c skin fibroblasts when the cells were inoculated with 
cross passage viruses. Collectively, the data in BALB/c skin fibroblasts (Figure 3-7) 
are in agreement with the finding in C57BL/6 skin fibroblasts (Figure 3-6).  
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Figure 3-5. A method to determine the growth phenotypes of male, female and 
cross passage viruses in male and female skin fibroblasts. First, to determine the 
viral titres from serial passage viruses, male, female and cross passage viruses from 
each passage were titrated using plaque assays on Vero cells. Then male and female 
cells from three individual mice (independent of the initial cultures) were then infected 
with male, female and cross passage virus at an MOI of 0.01 for 48 hours. The progeny 
were then titrated on Vero cells to investigate whether HSV-1 gains or loses fitness in 
cells of a particular sex after serial passages, because the parental HSV-1 was made and 
titrated on Vero cells. Blue and red dots indicate male and female cells, respectively. 
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Figure 3-6. HSV-1 can adapt to sex. (A) Male, (B) female or (C) cross passage viruses 
at indicated passages were used to infect monolayers of male and female cells from 
three individual mice at an MOI of 0.01. After 48 hours of infection, cell lysates were 
collected and the viral titres were determined on Vero cells. Error bars are mean ± SEM. 
Two-way ANOVA with Tukey's post-tests was performed to test differences between 
means in titres over time between male and female cells, where significance is indicated 
by ** and *** (p-value <0.01 and p-value <0.001). ns, no significant difference. 
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Figure 3-7. Growth phenotypes of sex-adapted HSV-1 in male and female cells 
derived from BALB/c mice. Male and female cells were derived from three individual 
BALB/c mice and then infected with passage 30 male passage virus, female passage 
virus and cross passage virus at an MOI of 0.01 for 48 hours. Cell lysates were collected 
and viral titres were determined by plaque assays. Error bars are mean ± SEM. The data 
were compared using one-way ANOVA with Tukey's post-tests (*** p-value <0.001; 
ns, no significant difference).  
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In order to investigate whether the sex adaptation is specific for HSV-1, or whether it 
can be applied to other large dsDNA viruses, VACV strain WR was selected as another 
candidate to perform serial passages in male and female cells based on the same 
experimental evolution protocol for HSV-1 (Section 2.2.23 and Figure 3-4). After 30 
blind passages, VACV appeared to adapt to mouse cells since viral yields reached a 
peak at 20 passages after rising with increasing passage times (Figure 3-8). However, 
unlike HSV-1, each biological replicate of VACV from 30 passages showed a similar 
growth phenotype in male and female cells.  
 
Taken together, it appears that HSV-1 can adapt to the sex of host cells, and thereby, 
generate different replication abilities in male and female mouse skin fibroblasts 
prepared from both C57BL/6 and BALB/c mice. Although HSV-1 and VACV are large 
dsDNA viruses and both can adapt to mouse cells, only HSV-1 adapted to the sex of 
cells in our experiments. 
 
3.2.3 Replication of sex-adapted HSV-1 in vivo 
 
Next, to understand whether in vitro growth phenotypes observed in the sex-adapted 
HSV-1 (Section 3.2.2) also occurs in live animals, mouse flank skin infection model 
was applied to investigate the replication of sex-adapted HSV-1 in vivo (Robinson and 
Dover 1972; Blyth et al., 1984). Briefly, eight-week-old male and female C57BL/6 
mice were anesthetised and then infected by tattoo infection with male, female or cross 
passage viruses (Russell et al., 2015). The mice were culled at two days post-infection 
and their skin and DRGs were collected and processed as described in Section 2.2.29. 
Viral titres were then measured by plaque assays. In skin, male passage viruses 
produced more infectious virus in male mice than in female mice (Figure 3-9A). In line 
with this, female passage viruses replicated more efficiently in the skin of female mice. 
These results are correlated with what was illustrated in Section 3.2.2. However, 
although there was a similar trend discovered in the DRGs, it was not statistically 
significant (Figure 3-9B). With respect to cross passage viruses, these replicated 
comparably between male and female mice in both skin and DRGs. Taken together, it 
shows that the sex-adapted HSV-1 generated by serial passages in male or female cells 
also shows different replication phenotypes in the skin of male and female mice infected 
via tattoo infection. 
 
3.2.4 Genetic changes in sex-adapted HSV-1 
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To determine the genetic basis of HSV-1 sex adaptation, paired-end deep sequencing 
of parental HSV-1 and each replicate of virus from 10 and 30 passages (p10 and p30), 
including parental HSV-1 pICP47 virus, male, female and cross passage viruses, was 
performed to acquire approximately 2,000-fold genome coverage. Herpesviruses are 
difficult to sequence due to their high GC-content (60-70%) and palindromic sequences 
which result in the formation of a stable hairpin structures (Brown, 2007; Ouyang et 
al., 2012; Lee et al., 2015). For the purpose of resolving uncertainties associated with 
these limitations, several computational and statistical methods have been developed 
for studying the genetic heterogeneity of the herpesviral population (Renner and 
Szpara, 2018). Szpara and colleagues, a research team specialising in evolution and 
diversity of herpesviral genomes, have developed a viral de novo assembly workflow 
specifically for herpesviruses both in a web-based and Unix command-line interface 
(Parsons et al., 2015; Wan et al., 2015). Herein, this multi-step herpesviral genome 
assembly pipeline established by Szpara’s group, VirAmp, was applied to analyse the 
genetic differences between the parental and sex-adapted HSV-1 (Section 3.2.2) (Wan 
et al., 2015). 
 
In brief, HSV-1 genomic DNA was isolated as described in Section 2.2.2.3 and 
elsewhere (Russell and Tscharke, 2016). An Illumina Nextera XT library kit was then 
employed to construct WGS libraries using 10 ng of input HSV-1 DNA. Next, a 300-
bp paired-end run was carried out on the Illumina Miseq platform. After removing 
adaptors and reads with low quality scores, the entire VirAmp pipeline was operated. 
HSV-1 genomes were assembled de novo by Velvet; these assemblers used the de 
Bruijn graph algorithm and then variation analysis was conducted using the MUMmer 
package to identify SNPs and INDELs between the parental HSV-1 recombinant virus 
and each sex-adapted virus (Kurtz et al., 2004; Zerbino and Birney, 2008). The details 
of the genome assembly pipeline are shown in Section 2.2.31.1. The number of 
SNPs/INDELs in each biological replicate of HSV-1 male passage virus, female 
passage virus or cross passage virus from 30 passages was combined accordingly and 
is shown in a boxplot (Figure 3-10A). Slightly more SNPs/INDELs were found in the 
female passage viruses compared with the male passage viruses and cross passage 
viruses, although there was no statistically significant difference. SNPs/INDELs 
identified at least two times in triplicates of male passage viruses, female passage 
viruses or cross passage viruses were defined as mutations derived from the selective 
pressure during serial passages. These mutations from male passage viruses, female 
passage viruses or cross passage viruses were calculated and are presented in a Venn 
diagram (Figure 3-10B). As expected, cross passage viruses rarely produced unique 
mutations and most of the mutations were also found in male or female passage viruses. 
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On the contrary, the populations of male and female passage viruses contained 
relatively more unique mutations, which indicates that consistent pressure from each 
specific sex introduces the potential for fitness advantages for HSV-1. 
 
HSV-1 US3 may contain hot spots for mutations during serial passages in mouse skin 
fibroblasts, as all male, female and cross passage viruses had SNPs in the US3 gene. 
HSV-1 US3 is a multifunctional protein that regulates various cellular and viral 
functions by phosphorylating a number of protein substrates, blocking apoptosis and 
modulating host immune systems (Leopardi et al., 1997; Cartier et al., 2003; Wang et 
al., 2013b). In both p10 and p30, male and cross passage populations shared the same 
mutation C456Y in the US3 region. Female passage viruses specifically gained a 341 
G-to-R AA substitution, which had already been modified since p10 and was 
maintained until p30. These data indicate that US3 is a prime target for HSV-1 
adaptation in experimental evolution and can be quickly modified after only 10 serial 
passages. Likewise, female passage viruses also had a second unique mutation that 
emerged by p10, namely US8 (S477L).  
 
Unique genetic changes (identified at least two times in triplicates and not shared with 
other conditions) associated with male (blue), female (red) and cross (yellow) passage 
viruses resulting after 10 and 30 passages are shown in Figure 3-11. Additionally, 
details of the nucleotide (NT) and deduced amino acid (AA) changes in these sex-
adapted HSV-1 viruses (identified at least two times in triplicates), relative to the 
parental virus, are listed in Table 3-1 and Table 3-2. In 30 passages, both male and 
female passage viruses exhibited NT changes in the UL48 gene that encodes VP16. 
VP16 is a key transcriptional activator of HSV-1 lytic infection to initiate immediate 
early gene expression via the assembly of a transcriptional regulatory complex (Ace et 
al., 1988; Ace et al., 1989; Arnosti et al., 1993). Correspondingly, the identified AA 
sequences revealed that these NT changes led to a 67 D-to-N and a 344 L-to-F AA 
substitution in male and female passage viruses, respectively. Furthermore, selective 
pressure from both male and female sexes caused NT changes in HSV-1 glycoproteins. 
Male passage viruses contained an INDEL (T132H) that may disrupt the structure of 
UL22 (glycoprotein H; gH) due to this mutation leads to a predicted frameshift and may 
generate truncated gH protein. Based on our preliminary alignment result, this predicted 
frameshift caused an early termination at 143 AA and may use another reading frame 
to make the other truncated form of gH protein (from 271 to 839 AA) (data not shown). 
UL22 is an essential component for the cell-to-cell spread of virions and for the 
penetration of virions into cells (Westra et al., 1997). Another mutation (S477L) was 
found in female passage viruses in US8 (glycoprotein E; gE). This is involved in the 
95 
 
promotion of cell-to-cell spread at basolateral surfaces of epithelial cells and functions 
as an Fc receptor (Baucke and Spear, 1979; Dingwell et al., 1994).  
 
Lastly, few SNPs and INDELs were identified across all triplicates in male, female and 
cross passage viruses at intergenic regions in the HSV-1 genome, such as RL2/RL1 
(124544 A to AA) and UL25/UL26 (50732 T to nT) (Table 3-1 and Table 3-2). This 
suggests that these INDELs may be involved in the adaptation of HSV-1 to mouse skin 
fibroblasts, although they did not directly affect coding regions of these genes and did 
not influence potential transcriptional regulatory factors, such as the TATA-box 
sequence. The mechanism behind this is not clear and needs more invstigation to see 
whether there are unidentified cis-acting signals regulating transcription termination, 
and reinitiation at a downstream gene. All mutations mentioned in Section 3.2.4 need 
to be confirmed by Sanger sequencing using a set of sequencing additives for high GC 
rich and repeated regions in HSV-1 genome in the future (Kieleczawa and Mazaika, 
2010; Riet et al., 2017). 
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Figure 3-8. Vaccinia viruses do not adapt to the sex of cells in culture. (A) Male 
and (B) female passage vaccinia viruses at indicated passages were used to infect fresh 
monolayers of male and female cells from three individual mice at an MOI of 0.01. 
After 48 hours of infection, cell lysates from male and female cells were collected and 
the viral titres were determined on BSC-1 cells. Error bars are mean ± SEM. Two-way 
ANOVA with Tukey’s tests was performed to test differences between means in titres 
over time between male and female cells. ns, no significant difference. 
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Figure 3-9. Different growth phenotypes of the sex-adapted HSV-1 pICP47 
recombinant viruses after flank infection. C57BL/6 mice were infected by tattoo 
with 1 × 108 PFU/mL male passage virus (n=10 in male mice; n=10 in female mice), 
female passage virus (n=10 in male mice; n=10 in female mice) or cross passage virus 
(n=4 in male mice; n=4 in female mice). Two days post-infection, mice were culled and 
then skin and DRG (from spinal levels L1 to T5) were harvested for determining viral 
yields on Vero cells. Data are pooled from two independent experiments. Each dot 
represents one mouse and the black bar represents the mean  ± SEM. Statistical 
significance was determined by one-way ANOVA with Tukey's post-tests for pairwise 
comparisons. * p-value <0.05 and ns, no significant difference. 
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Figure 3-10. Number of mutations in the sex-adapted HSV-1 pICP47 recombinant 
virus. (A) Number of SNPs and INDELs from each of the three biological replicates of 
male, female and cross passage viruses were counted and mean ± SEM are shown in 
the bar chart. One-way ANOVA with Tukey’s tests was used to test differences 
between means. (B) Identical SNPs or INDELs (identified at least two times in 
triplicates) between each sex-adapted HSV-1 pICP47 recombinant virus were 
calculated and are shown in the three-way Venn diagram. Blue, male passage virus; 
pink, female passage virus; yellow, cross passage virus. 
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Figure 3-11. Location of SNPs and INDELs to the culture condition in the sex-
adapted HSV-1 pICP47 recombinant viruses. The position of SNPs or INDELs in 
passage 10 (p10) and 30 (p30) is shown relative to a map of HSV-1 genes. The HSV-1 
modified genome is annotated with each HSV-1 gene and shown without the long and 
short terminal repeats, as sequences in these two regions are represented in the internal 
repeats. Black and green lines indicate mutations found in a single virus and identical 
mutations across all viruses, respectively. Blue, red and yellow lines show culture-
specific mutations in male, female or cross passage viruses (identified at least two times 
in triplicates and not shared with other conditions), respectively. M1, M2, M3, 
biological replicates 1-3 of male passage virus; F1, F2, F3, biological replicates 1-3 of 
female passage virus; C1, C2, C3, biological replicates 1-3 of cross passage virus. 
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Table 3-1. Details of mutations (identified at least two times in three isolates) in 
the sex-adpated HSV-1 in passage 10. 
 
 
1: nucleotide 
2: amino acid 
3: mutations identified at least two times in three isolates and unique in the culture  
4: multiple T 
 
Viruses SNP/INDEL Gene name NT1 change AA2 change Unique mutation3
Male passage virus
INDEL RL2/RL1 124544 A -> AA NA No
SNP US3 136446 G -> A C456Y No
Female passage virus
INDEL UL25/UL26 50732 T -> nT
4
NA No
INDEL RL2/RL1 124544 A -> AA NA No
SNP US3 136100 G -> A G341R Yes
SNP US8 142514 C -> T S477L Yes
Cross passage virus
INDEL UL25/UL26 50732 T -> nT NA No
INDEL RL2/RL1 124544 A -> AA NA No
SNP US3 136446 G -> A C456Y No
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Table 3-2. Details of mutations (identified at least two times in three isolates) in 
the sex-adpated HSV-1 in passage 30. 
 
 
1: nucleotide 
2: amino acid 
3: mutations identified at least two times in three isolates and unique in the culture  
4: multiple T 
*: predicted frameshift 
 
Viruses SNP/INDEL Gene name NT1 change AA2 change Unique mutation3
Male passage virus
SNP UL20/21 41598 G -> A NA Yes
INDEL UL22 45930 T -> TG T132H* Yes
INDEL UL25/UL26 50732 T -> nT
4
NA No
SNP UL48 104801 C -> T D67N Yes
INDEL UL56/RL2 120203 CCC -> C NA Yes
INDEL RL2/RL1 124544 A -> AA NA No
INDEL RS1/US1 131692 CC -> C NA Yes
SNP US3 136446 G -> A C456Y No
Female passage virus
INDEL UL25/UL26 50732 T -> nT NA No
SNP UL48 103968 C -> A L344F Yes
SNP RL2 123396 A -> C V204R No
SNP RL2 123397 C -> G C203S No
SNP RL2 123400 A -> T R202R No
INDEL RL2/RL1 124544 A -> AA NA No
SNP RS1/US1 131693 C -> . NA Yes
SNP US3 136100 G -> A G341R Yes
INDEL US7/US8 140910 CC -> C NA No
SNP US8 142514 C -> T S477L Yes
Cross passage virus
INDEL UL3/UL4 11725 GG -> G NA Yes
INDEL UL25/UL26 50732 T -> nT NA No
SNP RL2 123396 A -> C V204R No
SNP RL2 123397 C -> G C203S No
SNP RL2 123400 A -> T R202R No
INDEL RL2/RL1 124544 A -> AA NA No
SNP US3 136446 G -> A C456Y No
INDEL US7/US8 140910 CC -> C NA No
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3.2.5 Investigation of mechanisms driving the different growth of HSV-1 in male 
and female cells  
 
Based on the previous data in Sections 3.2.1-3.2.3, HSV-1 gained different mutations 
in the HSV-1 genome after serial passage on male and female cells and these viruses 
have sex-specific growth phenotypes in vitro and in vivo. In addition, HSV-1 replicates 
more efficiently in male cells compared to female cells after very low inoculum of 
HSV-1 (Figure 3-1). These observations suggested that male and female cells respond 
distinctively to HSV-1 infection. However, the mechanism that counteracts HSV-1 
infection or drives the evolution of HSV-1 in each specific sex is unknown. Herein, 
RNA-seq was employed to comprehensively understand transcriptomic regulation, 
which may provide further information about how male and female cells respond 
differentially to HSV-1. 
 
3.2.5.1 Infection rate of HSV-1 pICP47 recombinant virus in male and female 
cells 
 
Before performing RNA-seq analysis, a suitable MOI and suitable infection time points 
needed to be selected. The use of a high MOI to ensure all cells are infected, may also 
overwhelm cells with excessive viral particles and risks destroying the cells before 
adequate evidence of host gene modulation has accumulated. Thus, the use of a low 
MOI was preferred in this study. The other factor in our experimental design was to 
ensure we could observe expression of all HSV-1 genes, including IE, early and late 
genes of HSV-1. Late genes of HSV-1 are predominantly expressed at least 4 hpi, with 
most transcription occurring between 6 and 12 hours post-infection (Stingley et al., 
2000; Harkness et al., 2014). Hence, 4 and 8 hpi were selected as time points in the 
experiments. To test these conditions, we examined the percentage of infected cells in 
male and female cells at 4 and 8 hpi after infection with an MOI of 0.5 with HSV-1 
pICP47 by flow cytometry. Four hours post-infection with HSV-1 pICP47 recombinant 
virus at an MOI of 0.5, around 75% of cells were GFP-positive in male and female cells 
(Figure 3-12). On the other hand, at 8 hpi, the percentage of GFP-positive cells 
increased to about 85-90% in both male and female cells (Figure 3-12). There was no 
significant difference in infection rate between male and female cells during an MOI of 
0.5 infection with HSV-1 pICP47 virus at 4 and 8 hpi.  
 
3.2.5.2 Design of the RNA-seq experiment to investigate transcription in the 
HSV-1 infected male and female cells 
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We considered using the same MOI that we showed a growth difference for HSV-1 
between male and female cells (MOI <0.0003), but too few cells would be infected and 
this was not practical for use in the RNA-seq methods available at the time. Further, in 
the virus adaptation experiment (Section3.2.2), we used a higher MOI (starting with 
0.01) and the male and female cells drove selection of virus variants. Therefore, it is 
reasonable to suggest that as long as the MOI is not too high (MOI <1) it should be 
possible to probe gene expression differences between male and female cells. An MOI 
of 0.5 was chosen as we reasoned that it would not be so high that any subtle cellular 
responses would be rapidly overwhelmed. In addition, at this MOI, HSV-1 replicated 
similarly between male and female cells (Figure 3-12), which means that differences in 
host response would not be simply due to the infection proceeding more quickly in cells 
of one sex, compared with the other. However, this infection condition left around 10-
15% of uninfected cells and thus we decided to use a GFP-expressing virus and cell 
sorting to exclude uninfected cells in the design of our RNA-seq experiment. In order 
to collect HSV-1-infected cell populations, triplicates of male and female cells derived 
from different individual mice were separately infected with HSV-1 pICP47 
recombinant virus at an MOI of 0.5 for four and eight hours. Following this, GFP-
positive cells were sorted using flow cytometry. Representative plots showing the 
gating strategy for separation of infected and non-infected cells can be found in Figure 
3-13. GFP-positive cells indicated HSV-1-infected populations and the signal detected 
in the phycoerythrin (PE) channel was used as a proxy for autofluorescence. The purity 
of sorted cells was re-analysed by flow cytometry and GFP percentage was around 95-
98%. Total RNA was then extracted from sorted cells at indicated time points for library 
preparation. And RNA-seq was performed using the Illumina platform as described in 
Section 2.2.15. 
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Figure 3-12. The infectivity of HSV-1 in male and female cells. Male and female 
cells from three individual mice were infected with HSV-1 pICP47 recombinant virus 
at an MOI of 0.5 for four or eight hours. Representative flow cytometric histograms 
from three independent experiments show the levels and percentage of GFP expression. 
Blue lines represent cells infected with HSV-1 pICP47 recombinant virus . Red lines 
represent mock infection.  
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Figure 3-13. Strategy for separation of HSV-1-infected and non-infected cells. 
Representative flow cytometric plots show the gating strategy and the purity of cells 
post-sorting. The GFP-positive population was sorted from infected samples at 4 and 8 
hpi. The PE channel was applied as a proxy for cellular autofluorescence. The 
proportions of GFP-positive (GPF +) and negative cells (GPF -) are indicated by 
percentages. Pre-sort represents cells before sorting and re-analysis represents cells 
after sorting. 
Mock
4 hpi
8 hpi
pre-sort                     re-analysis
GFP 
P
E
 (
a
u
to
-f
lu
o
re
s
c
e
n
c
e
)
%
%
%
%
%
%
%
%
%
%
%
%
106 
 
 
 
Figure 3-14. Percentage of raw reads mapped to the HSV-1 genome. Male and 
female cells from three individual mice were infected with HSV1 pICP47 recombinant 
virus at an MOI of 0.5. At 4 and 8 hpi, total RNA was extracted from sorted GFP-
positive cells and then transcribed into cDNA libraries following the manufacturer’s 
guide. Samples were subjected to an Illumina sequencing platform and the conditions 
are described in Section 2.2.15. After filtering reads with low quality scores and 
removing adapters, the resulting reads were mapped to a modified HSV-1 genome 
having only one long and short repeat, using the TopHat2 aligner. Percentage of viral 
reads relative to the total number of reads is shown. One-way ANOVA with Tukey’s 
tests was used to test differences between means. Error bars are mean ± SEM. ns, no 
significant difference. 
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3.2.5.3 Comparison of HSV-1 transcription between male and female cells 
 
Reads resulting from the RNA-seq experiment described in Section 3.2.5.2 were first 
processed and mapped to the mouse genome. The unmapped reads were then aligned 
to the modified sequences of the HSV-1 KOS strain. Details of the analysis of HSV-1 
gene expression are provided in Section 2.2.31.4. The percentage of total reads aligned 
to the viral genome is shown in Figure 3-14. At 4 hpi, around 15% of total reads were 
viral reads in HSV-1-infected male and female cells. Viral reads accounted for about 
20% of all reads at 8 hpi in these two cell types. There was no significant difference in 
the percentage of reads aligned to the virus between male and female cells at either 4 
or 8 hpi. The expression of each HSV-1 gene at four and eight hpi was plotted in a heat 
map (Figure 3-15). Individual replicates of male or female cells were grouped together 
and then clustered based on infection time, indicating that each replicate acts 
comparably and time point post-infection was more important than the sex of cells in 
classifying expression of HSV-1 transcripts. Investigation of differential expression of 
HSV-1 genes between the two sexes revealed that none were statistically significant 
(data not shown). This is consistent with the finding that HSV-1 replication was similar 
for male and female cells at MOIs from 0.001 to 10 (Figure 3-1). 
 
3.2.5.4 Differentially regulated host transcription between male and female cells 
during HSV-1 infection 
 
In addition to investigating viral gene expression during HSV-1 infection in male and 
female cells, overall transcriptional regulation in the host was examined to determine 
whether males and females respond differently to HSV-1 infection. Reads that had been 
mapped against the mouse genome in Section 3.2.5.3 were further analysed for 
differential transcript expression between male and female cells using the Cufflinks 
package, as described in Section 2.2.31.2 (Trapnell et al., 2012). To visualise the 
transcriptional relatedness and reproducibility of each RNA-seq sample, principal 
coordinate analysis (PCA) was used. Each infection condition, including mock, 4 hpi 
and 8 hpi, was grouped into a defined cluster within the PCA plot (Figure 3-16). 
Infected samples were broadly mapped into the 4 hpi or 8 hpi clusters. Major 
transcriptional differences were observed between mock and 8 hpi, for cells of both sex. 
In the PCA plot, more male samples can be differentiated from female ones at 8 hpi, 
compared to 4 hpi or mock, indicating there were more differences between male and 
female cells at eight hours post-infection (Figure 3-16).  
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Next, the correlation of baseline mRNA expression between male and female cells (i.e. 
from the mock infection) was examined. The Pearson’s correlation coefficient of 0.98 
indicates that these two cells had very similar baseline mRNA expression prior to HSV-
1 infection for most genes, although there were several outliers (Figure 3-17). Gene 
expression of 34,618 transcripts are shown in a heatmap (Figure 3-18) and they were 
further analysed for differential regulation compared to mock in male and female cells 
in HSV-1 infection (Figure 3-19 and Figure 3-20). Each replicate was clustered together 
first and then grouped by infection condition based on the Pearson’s correlations and 
unsupervised hierarchical clustering. The results indicate that every replicate subjected 
to RNA-seq showed reproducible characteristics and there were more significant 
differences between individual infection times than the sex of cells (Figure 3-18). This 
was similar to viral transcription observed in Figure 3-15.  
 
Although most genes had similar expression levels before infection between male and 
female cells (Figure 3-17), there were some sex-specific transcripts. Therefore, to 
investigate regulation due to HSV-1 infection, we used log2 fold changes (4 hpi or 8 
hpi relative to mock) to normalize the original differences between male and female 
cells. The correlation of host transcriptional regulation by infection between the sexes 
was relatively high at 4 hpi (0.87) (Figure 3-19A), but it dropped to 0.72 at 8 hpi, 
suggesting that RNA regulation by infection diverged more between male and female 
cells at this time point as infection progressed (Figure 3-19B). 
 
Differentially regulated transcripts at 4 and 8 hpi were evaluated as pairwise 
comparisons relative to mock (log2 fold change >1 or <1 and false discovery rate <0.05) 
in male and female cells. When comparing up- and downregulated differential gene 
regulation by infection between male and female cells at 4 and 8 hpi, the overall 
response to early HSV-1 infection was quite similar between the two sexes and more 
distinctively regulated transcripts were found at 8 hpi (Figure 3-20). In HSV-1-infected 
male or female cells, there were around 4,500 to 5,000 upregulated or downregulated 
transcripts at 4 and 8 hpi, respectively. Although HSV-1 infection induced comparable 
numbers of differentially regulated transcripts between male and female cells, these 
genes were not all shared. The two sexes shared 85.0-91.4% and 87.1-92.0% 
similarities in up- and downregulated transcripts, respectively, at 4 hpi and this 
decreased to 77.2-81.4% and 81.8-84.8%, respectively, at 8 hpi.  
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Figure 3-15. Expression of HSV-1 genes in male and female cells at 4 and 8 hpi. 
Reads that mapped to the HSV-1 genome were converted to counts per million (CPM) 
using the featureCounts package. Log2 CPM of each HSV-1 gene at 4 and 8 hpi, in 
male and female cells from three individual mice, is plotted and grouped by hierarchical 
average linkage clustering and Euclidean distances. Density of individual samples are 
colour-coded: red=high density, blue=low density.
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Figure 3-16. Principal coordinate analysis (PCA) of transcriptional expression in 
male and female cells during HSV-1 infection. PCA was performed based on the 
transcriptional levels in host genes (n=500) in mock (circle), and at 4 (square) or 8 
(triangle) hpi, over dimensions 1 and 2, in male (blue) and female (red) cells from three 
individual mice.  
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Figure 3-17. Baseline transcription levels in male and female cells. This scatterplot 
illustrates the relationship of baseline mRNA expression (mock) between male cells 
and female cells according to the log2 normalised reads per kilobase of transcript per 
million mapped reads (RPKM) (n=34,618). Pearson’s correlation coefficient is 
indicated in the bottom right corner. Significantly differentially expressed transcripts 
are those with p-value <0.05 and FDR <0.05 (n=1890). A simple linear regression 
model was fitted (red line) and dashed lines are confidence intervals for thresholds 
calling differentially expressed transcripts between the two sexes.   
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3.2.5.5 GO and KEGG pathway analysis of up- and downregulated transcripts in 
male and female cells  
 
In an attempt to identify molecular functions regulated by HSV-1 infection that differed 
between male and female cells, transcripts that were up- or downregulated at 4 or 8 hpi 
in male and female cells were compiled into lists for biological process enrichment 
classification in the GO database via the DAVID analysis tool (Harris et al., 2004; 
Huang et al., 2007; Huang da et al., 2009). Representative subsets of the GO terms in 
the upregulated or downregulated transcripts at 4 and 8 hpi were combined and 
displayed using REVIGO, a clustering algorithm that is dependent on semantic 
similarity measures, in order to remove redundant GO terms and visualise them in 
scatterplots (Supek et al., 2011) (Figure 3-21). Specifically, upregulated transcripts in 
male cells at 4 and/or 8 hpi were widely involved in regulation of binding 
[GO:0051098], protein folding [GO:0006457], positive regulation of organelle 
organisation [GO:0010638], RNA modification [GO:0009451] and interphase 
[GO:0051325] (Figure 3-21A). Male cells downregulated several cellular functions, 
such as flagellum organisation [GO:0043064], amino sugar metabolic process 
[GO:0006040] and tRNA processing [GO:0008033] (Figure 3-21B). In female cells, 
protein modification by small protein removal [GO:0070646], regulation of DNA 
repair [GO:0006282], biological regulation [GO:0065007] and vesicle docking 
[GO:0048278] were the classes upregulated at 4 and/or 8 hpi (Figure 3-21C). 
Furthermore, the downregulated subsets included endocytosis [GO:0006897], cellular 
amine metabolic process [GO:0044106], protein homooligomerisation [GO:0051260] 
and regulation of endothelial cell proliferation [GO:0001936] (Figure 3-21D). The 
biological meaning of these GO terms for HSV-1 infection was broad and not obvious 
so they were not pursued further. 
 
In addition to the GO database, differentially regulated transcripts in male and female 
cells were analysed by KEGG pathways through the DAVID online tool to reveal 
differentially regulated pathways (Huang et al., 2007; Huang da et al., 2009). Male cells 
specifically upregulated one carbon pool by folate [mmu00670], alanine, aspartate and 
glutamate metabolism [mmu00250] and colorectal cancer pathways [mmu05210] at 4 
hpi, and the dorso-ventral axis formation pathway [mmu04320] at both 4 and 8 hpi. For 
female cells, the small cell lung cancer pathway [mmu05222] was induced at 4 hpi and 
the non-small cell lung cancer [mmu05223] and cytosolic DNA-sensing pathways 
[mmu04623] were stimulated at 8 hpi. Details of differentially regulated pathways 
between male and female cells are shown in Table 3-3 and each pathway is also plotted 
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in a heatmap (Figure 3-22 and Figure 3-23). Collectively, male and female cells 
regulated several pathways differentially during HSV-1 infection including these 
associated with metabolism, cancer and of particular interest innate immune responses.  
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Figure 3-18. Comparison of host transcriptomes in male and female cells infected 
with HSV-1. A heatmap with hierarchical clustering of each transcript in male and 
female cells (n=34,618) at 4 hpi, 8 hpi and mock is depicted. The vertical dendrogram 
represents the clustering of infection condition and sex of cells based on the similarities 
in transcriptional expression. Reads per kilobase of transcript per million mapped reads 
(RPKM) were normalised to the maximum RPKM across all samples in each transcript, 
resulting in Z-scores (values between 0 and 1). Red indicates relatively high expression 
and blue refers to relatively low expression.  
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Figure 3-19. Relationships of transcriptional regulation by HSV-1 infection 
between male and female cells. Scatterplots show correlations between transcriptional 
changes due to HSV-1 infection in male and female cells at (A) 4 hpi (n=17150) and 
(B) 8 hpi (n=16068). Genes having fold changes equal to 0 were excluded. Pearson’s 
correlation coefficients are shown in the bottom right corners. Simple linear regression 
models were fitted and are illustrated as red lines through each scatterplot.  
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Figure 3-20. Transcripts differentially regulated by HSV-1 infection between male 
and female cells. Transcripts differentially regulated by HSV-1 infection at 4 and 8 hpi 
in male or female cells were determined as pairwise comparisons relative to mock 
infection. Two-way proportional Venn diagrams were drawn according to the number 
and overlap of significantly differentially regulated transcripts (p-value <0.05 and FDR 
<0.05).  
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Figure 3-21. Gene ontology (GO) analysis of differentially regulated transcripts in 
male and female cells during HSV-1 infection. GO terms enriched in the upregulated 
or downregulated transcripts in male or female cells at 4 or 8 hpi were analysed. The 
results of up- or downregulated GO terms at 4 and 8 hpi were combined in (A-B) male 
and (C-D) female cells and further visualised by REVIGO, where GO terms that were 
identical and redundant were removed. The uncorrected log10 p-value for each parent 
GO term is represented by the circle colour. The size of the circle indicates the number 
of enriched child GO populations contributing to the parent term. Semantic space is the 
outcome of multi-dimensional scaling where similar GO populations cluster together.  
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Table 3-3. Differentially regulated KEGG pathways between male and female 
cells during HSV-1 infection. 
 
Cell KEGG pathway p-value Adjusted p-value hpi hpi
Female mmu04623 Cytosolic DNA-sensing pathway 0.0046 0.042 8 upregulated
mmu05222 Small cell lung cancer 0.01 0.049 4 upregulated
mmu05223 Non-small cell lung cancer 0.001 0.0177 8 upregulated
Male mmu00250 Alanine, aspartate and glutamate metabolism 0.0023 0.0263 8 upregulated
mmu00670 One carbon pool by folate 1.88E-04 0.0043 8 upregulated
mmu04320 Dorso-ventral axis formation 0.0026 0.0146 4 upregulated
mmu04320 Dorso-ventral axis formation 0.0012 0.017 8 upregulated
mmu05210 Colorectal cancer 0.0025 0.0271 8 upregulated
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Figure 3-22. Differentially regulated pathways in male cells during HSV-1 
infection. Upregulated genes at 4 or 8 hpi in male cells were subject to the KEGG 
pathway analysis. Pathways regulated by HSV-1 infection uniquely in male cells at 4 
or 8 hpi are illustrated in heatmaps, including the (A) dorso-ventral axis formation 
pathway, (B) one carbon pool by folate pathway, (C) alanine, aspartate and glutamate 
metabolism pathway and (D) colorectal cancer pathway. 
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Figure 3-23. Differentially regulated pathways in female cells during HSV-1 
infection. Upregulated genes at 4 or 8 hpi in female cells were analysed by the KEGG 
database. Pathways regulated by HSV-1 infection uniquely in female cells at 4 or 8 hpi 
are shown in heatmaps, including the (A) small cell lung cancer pathway, (B) non-small 
cell lung cancer pathway and (C) cytosolic DNA-sensing pathway. 
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3.2.5.6 Validation of RNA-seq data in the cytosolic DNA-sensing pathway by 
qPCR and Western Blotting 
 
Previously in Section 3.2.5.5, several pathways differentially regulated by HSV-1 
infection between male and female cells were identified. These included pathways 
involving cellular metabolism, cancer and strikingly, a cytosolic DNA-sensing pathway 
(Table 3-3). As the detection of intracellular nucleic acids has emerged to be an 
essential event in the innate immune response to viruses (Rathinam and Fitzgerald, 
2011; Orzalli and Knipe, 2014), this pathway may be a potential mechanism to explain 
the different HSV-1 growth phenotypes between the two sexes (Figure 3-1). HSV-1 
infection induced higher expression of many genes in the nucleic acid-sensing pathway 
in female cells than in male cells after infection with HSV-1, and this phenomenon was 
more obvious at 8 hpi (Figure 3-24). In order to validate the RNA-seq results, we used 
the same RNA sent for RNA-seq to confirm RNA regulation in HSV-1-infected male 
and female cells and to ensure that the changes were only happening in infected cells.. 
A subset of transcripts involved in this pathway, including Mb21d1 (cGAS), Ddx58 
(Rig-I), Ifih1 (Mda5), Tbk1, Irf1 and Irf7, were chosen for quantitative real-time 
polymerase chain reaction (qPCR) analysis. In all cases, differential regulation by HSV-
1 was confirmed between male and female cells at both times, except for cGAS at 4 hpi 
(Figure 3-25). 
 
In addition to regulation of mRNA, protein expression was examined by WB. Male and 
female cells were infected with HSV-1 pICP47 recombinant virus at an MOI of 0.5 for 
four and eight hours. Protein samples were prepared and analysed by WB as described 
in Section 2.2.24. Each band was then quantitated by densitometry using ImageJ 
software (Version 1.50). There was no statistically significant difference in the levels 
of any proteins at 4 hpi between the sexes. However, at 8 hpi, amounts of protein were 
significantly higher in female cells than in male cells for all tested genes (Figure 3-25A 
and Figure 3-25B).  
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Figure 3-24. Cytosolic sensing pathway is upregulated to a greater extent in female 
cells. Regulation by HSV-1 infection of significantly regulated genes in the cytosolic 
DNA sensing pathway at 4 and 8 hpi illustrated as a heatmap. Blue represents lower 
regulation and red indicates higher regulation.  
Log2 Fold change
Irf1
Ifih1
Ikbkb
Nfkbib
Irf7
Trex1
Adar
Polr3f
Polr1c
Polr3g
Polr3a
Mb21d1
Ccl5
RipK3
Pycard
Cxcl10
Tbk1
Chuk
Ddx58
Polr3d
Polr3b
Polr3c
Rela
Nfkbia
Nfkb1
Ripk1
Mavs
Polr3k
Ikbke
Il18
Irf3
Zbp1
Il6
Male     Female Male     Female
4 hpi 8 hpi
-2  0     2     4
Color Key
123 
 
 
 
Figure 3-25. Validation of RNA-seq data for selected genes in the cytosolic sensing 
pathway by qPCR. Differential regulation was confirmed by qPCR for Mb21d1 
(cGAS), Ddx58 (Rig-I), Ifih1 (Mda5), Tbk1, Irf1 and Irf7 in HSV-1-infected male and 
female cells. Differential regulation was assessed by the 2 -ΔΔCT method based on the 
expression relative to mock and normalised to 18S rRNA. The results are from at least 
six biological replicates and shown as mean ± SEM. One-way ANOVA with Tukey's 
post-tests was used to examine differences between means. ** and *** indicate p-value 
<0.01 and <0.001, respectively. ns, no significant difference. 
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Figure 3-26. Protein expression of differentially regulated genes in the cytosolic 
sensing pathway. (A) Protein expression of genes of interest, including Mb21d1 
(cGAS), Ddx58 (Rig-I), Ifih1 (Mda5), Tbk1, Irf1 and Irf7, was measured by Western 
blotting (WB). β-CATENIN was applied as the loading control. WB blots are 
representative of three independent experiments. The intensity of each band was 
quantified by ImageJ and the ratio of the individual protein to β-CATNEIN is shown 
as mean ± SEM in (B). A linear model was used to evaluate significant differences for 
each protein between the two sexes. A p-value less than 0.05 indicates a statistically 
significant difference. * and ** indicate p-value <0.05 and <0.01. ns, no significant 
difference. 
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3.3 Discussion 
 
This chapter began with the investigation of the growth kinetics of HSV-1 in male and 
female cells at a series of MOIs. Primary skin fibroblasts were chosen as host cells 
given that skin is the major organ where HSV-1 initiates infection (Curry, 1980; Mindel 
et al., 1990). HSV-1 replicated more efficiently at low MOI (0.0003 and 0.0001) in 
male cells than female cells (Figure 3-1D and Figure 3-1E), indicating that distinct 
responses against HSV-1 infection can arise between the sexes and these differences 
can impact virus replication. Infections often begin with a very small number of 
initiating viral particles. Therefore, the outcome of an infection is likely to be influenced 
by the initial molecular interactions between the virus and host cells. Using low MOI 
also allows many rounds of replication in a single culture and this means that subtle 
differences can be seen. It has been reported that different MOIs induce distinct patterns 
of IFN subtypes and ISGs (Zaritsky et al., 2015). For example, JAK/STAT signalling 
via IFNAR occurs to a greater extent in human cells infected with lower virus 
concentrations, which mirrors both the classical model of the IFN pathway and natural 
infection (Devasthanam, 2014; Garcia-Sastre, 2017). Accordingly, a low MOI (<1) was 
applied for most of the experiments in the present study to avoid a biased disruption in 
specific signalling in the cultures infected with high amounts of virus and to prevent 
premature cell death which may mask any evidence of gene modulation by host cells. 
 
As HSV-1 yields were different between male and female cells during low MOI 
exposure, we then asked whether the different selective pressure from each sex could 
drive distinct mutations in the HSV-1 genome. An experimental evolution modified 
from a protocol for VACV was performed to characterise the evolutionary pressures 
and adaptive ability of HSV-1 replication in primary mouse skin cells from each sex 
(Elde et al., 2012). HSV-1 was passaged 30 times starting at a low MOI in three 
biological replicates of male cells (male passage virus), female cells (female passage 
virus) or by alternating between male and female cells (cross passage virus) (Figure 3-
4). The replication activity of these serial passage viruses in male or female cells was 
then evaluated by inoculating a new batch of male or female cells with each adapted 
virus at multiple passages (Figure 3-5). The viral titres in the male or female cells were 
then determined by plaque assays on Vero cells. Surprisingly, HSV-1 was found to 
adapt to each sex and gain replication fitness after as fewer as 10 rounds of serial 
passage. Specifically, male passage virus was found to replicate more efficiently in 
male cells and female passage virus produced more infectious particles in female cells 
(Figure 3-6). In addition, our data support a concept that HSV-1 is capable of adapting 
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to mouse skin cells as the viral yields in both male and female cells positively correlated 
with the serial passage number (Figure 3-6). The subsequent experiments both in 
Section 4.2 and 5.2 suggested that the effect we saw was cell-intrinsic, although we 
cannot not formally exclude a role for secreted factors that might act in a dominant 
fashion. Thus, performing an evaluation on a 50:50 mixture of male and female cells 
may be employed in the future to find whether there is another undiscovered mechanism 
from factors released into the medium. The specific adaptation of a virus to a given 
host, cell or other factors, such as antiviral drugs, usually results in fitness gains in the 
selective condition, but fitness declines in other host environments (Parrish et al., 2008; 
McWhite et al., 2016). The use of cell culture to produce adapted virus strains has been 
well documented for the alphaviruses and flaviviruses (Halstead and Marchette, 2003; 
Greene et al., 2005). For example, gains in fitness for Sindbis virus (SINV), a mosquito-
borne alphavirus, were found after serial passage in mosquito cell culture and fitness 
declines were observed in baby hamster kidney cells (Greene et al., 2005). An 
increasing number of studies report that there is cell-specific adaptation when cell 
culture models are used to characterise viral adaptation (Weaver et al., 1999; Ciota et 
al., 2007a; Ciota et al., 2007b). Arboviruses, naturally maintained by transmission 
cycles between susceptible vertebrate hosts and arthropod vectors, increase their 
efficiency of infection for insect cells after only 10 selective passages, but the lineages 
adapted to growth in avian cells remain relatively non-infectious in avian cells (Cooper 
and Scott, 2001).  
 
Compared to DNA viruses, RNA viruses are capable of rapid evolution owing to their 
high mutation rates, large population sizes and short replication times (Drake and 
Holland, 1999; Smith, 2017). Moreover, genome size appears to negatively correlate 
with mutation rate (Sanjuan and Domingo-Calap, 2016). Several studies have shown 
that some DNA viruses evolve at rates close to those of RNA viruses, including 
emerging canine parvovirus strains, human parvovirus B19, the circovirus SEN-V and 
the plant geminivirus (Shackelton et al., 2005; Shackelton and Holmes, 2006; Duffy 
and Holmes, 2008). These findings suggest that viral evolution may rely on multiple 
factors. In some cases, mutation rates for herpesviruses approach those observed in 
RNA viruses. A novel model of time-structured data demonstrated that high 
substitution rates can occur in the thymidine kinase gene of HSV-1 and the genome-
wide evolution rate of HCMV is higher than previously thought for large dsDNA 
viruses (Firth et al., 2010; Renzette et al., 2015). Selection of HSV-1 variants by hosts 
that have evolved defensive mechanisms against virus infection have contributed to a 
greater substitution rate and more rapid adaptive evolution than previously believed 
(Drake and Hwang, 2005; Firth et al., 2010; Parsons et al., 2015; Renner and Szpara, 
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2018). Whole genome analysis of mutations in the sex-adapted viruses revealed that 
there were slightly more mutations in female passage viruses than their male 
counterparts (Figure 3-10A). These observations suggest that higher anti-HSV-1 
responses may be produced by female cells and the mechanism behind this will be 
investigated in Chapter 5. Furthermore, single-sex passage series underwent more 
specific nucleotide and amino acid changes compared to viruses forced to replicate 
alternately in each sex (Figure 3-10B). This result is similar to what has been discovered 
in alphaviruses, such as SINV and equine encephalitis virus (EEEV), whereby single-
host adaptation leads to more mutations than alternating cell passages (Weaver et al., 
1999; Cooper and Scott, 2001; Greene et al., 2005).  
 
Our SNP/INDEL analysis suggests that selective pressures from male and female cells 
induce mutations in the coding sequence of gH and gE, respectively. The envelope of 
herpesviruses contains at least five viral membrane proteins that have functions in viral 
entry. A gH/gL heterodimer binds integrins on the host cells as a regulator for fusion, 
and therefore, defines the tropism for the virus into epithelial and endothelial cells 
(Sinzger et al., 2008; Chesnokova et al., 2009). This heterodimeric complex is also a 
main target for HSV neutralising antibodies, which underscores its importance for virus 
infection (Peng et al., 1998; Macagno et al., 2010). Interestingly, mutation of gE gene 
was found as early as after 10 serial cultures and was maintained until passage 30 in 
female passage viruses (Table 3-1 and Table 3-2). HSV-1 gE is a key factor in cell-to-
cell spread and virus-induced cell fusion. Mutations in the external domain of gE have 
been shown to block cell-to-cell spread (Wisner et al., 2000; Polcicova et al., 2005). 
Furthermore, gE is important for virus spread from epithelial cells to neurons and a 
coordinated complex of gE with tegument proteins, contributes to virus assembly and 
egress (Wang et al., 2010a; Han et al., 2011; Han et al., 2012). Perhaps there are 
differences in the cell membrane content between male and female cells, which could 
be further tested by electrospray ionisation and high-performance liquid 
chromatography mass spectrometry (Nealon et al., 2008; Russell et al., 2018). Lastly, 
based on our current data, we do not know whether these changes in glycoproteins, 
particularly the predicted frameshift in male passage viruses, may alter viral entry until 
we confirm these mutations by Sanger sequencing and then make recombinant viruses 
accordingly to investigate the importance of these mutations in virus replication. 
 
In addition to glycoproteins, mutations in the UL48 gene (VP16) at different locations 
were separately identified in male and female passage viruses (Figure 3-11). VP16 is a 
multifunctional and conserved tegument protein in the herpesviruses (Liu et al., 1999). 
VP16 directly delivered by the infecting virions plays an essential role at the earliest 
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stage of infection and it induces IE gene expression via the recruitment of host 
transcription factors and RNA polymerase II to the IE promoters (Triezenberg et al., 
1988a; Triezenberg et al., 1988b). Moreover, the interaction of VP16 with a number of 
virion tegument proteins and gH has been shown to promote viral assembly (Gross et 
al., 2003). Recent reports suggest that VP16 abrogates IFN signalling by various 
strategies, including suppressing the expression of immediate-early ISGs downstream 
of MAVS, inhibiting NF-κB activation and blocking the association between IRF3 and 
its coactivator (Xing et al., 2013; Zheng and Su, 2017). A single substitution in the 
VP16 sequence is lethal to HSV-1 due to blockage of virus assembly and virion 
maturation, suggesting that VP16 is important for these steps in HSV-1 replication (Ace 
et al., 1989; Weinheimer et al., 1992). Coincidently, the mutation site (amino acid 
residue 344) of VP16 identified in the female passage viruses (Table 3-2) has been 
found to be critical for binding to the virion host shutoff protein (vhs) and for productive 
infection (Knez et al., 2003). In the study published by Knez et al. (Knez et al., 2003), 
an L-to-F substitution at residue 344 of VP16 was found to act like wild-type VP16 and 
did not affect the interaction with host cell factor-1 (HCF-1). However, whether this 
circumstance is similar to our case requires further investigation to reveal the 
underlying molecular mechanisms.  
 
Several regions in the HSV-1 genome were found to be prone to mutations that due to 
selective pressure from serial passage in mouse skin fibroblasts. For example, US3 is a 
multifunctional protein that mediates numerous cellular and viral functions. HSV-1 
US3 has been reported to block apoptosis (Leopardi et al., 1997; Ogg et al., 2004), 
regulate intracellular transport and trafficking (Mou et al., 2009; Kato et al., 2011) and 
modulate host responses in innate and adaptive immune systems (Sloan et al., 2003; 
Wang et al., 2013b; Kalamvoki and Roizman, 2014). Mutation in the US3 gene was 
observed across male, female and cross passage viruses (Table 3-1 and Table 3-2), 
although it occurred at different locations. Notably, a G341R substitution in US3 was 
identified at passage 10 and maintained at passage 30 in female passage viruses, 
highlighting the importance of US3 in responding to the selective pressure from female 
cells. Insertions in two intergenic regions, UL25/UL26 and RL2/RL1, were also 
identified across male, female and cross passage viruses, suggesting that these 
mutations are acquired from the selective pressure of mouse skin fibroblasts. How these 
mutations might influence HSV-1 infection is unknown.  
 
Given that different growth phenotypes were found between male and female cells 
during low MOI HSV-1 infection (Figure 3-1), and differential selective pressure in 
experimental evolution against HSV-1 was observed between the two sexes (Figure 3-
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10 and Figure 3-11), we then employed RNA-seq to comprehensively investigate 
differences in the transcriptional program of these cells in responses to HSV-1. RNA-
seq has been developed to reduce, and in some cases eliminate, the limitations 
associated with microarray-based analysis of a transcriptome, such as a limited dynamic 
range, high background noise and applicability only to detect known messages (Wang 
et al., 2009; Fang et al., 2012). In order to compare differential regulation by HSV-1 at 
the transcript level, the Tuxedo suite pipeline for RNA-seq data, a fragments per 
kilobase per million reads (FPKM)-based method, was performed as quantifying 
expression at the gene level may occasionally mask alterations if two or more isoforms 
have different expression patterns (Trapnell et al., 2012; Kim et al., 2013). In addition, 
we only focused on the HSV-1-infected cells by sorting the infected cell population. 
This method was chosen for several reasons. First, the difference in transcriptional 
modulation between the two sexes was expected to be very subtle. Inoculation of very 
low amounts of virus revealed a difference in HSV-1 replication between male and 
female cells (Figure 3-1), but a low MOI of HSV-1 infection may leave a large 
uninfected population that could mask genuine transcriptional regulation. Second, 
Schmidt et al. showed that HSV-1 triggers host DNA synthesis in uninfected cells via 
a virus-induced paracrine effector during infection. This was initiated by a single viral 
particle with progressive cell-cell transmission (Schmidt et al., 2015). This mechanism 
supports the notion that the inclusion of all cell populations in measurements may mask 
crucial properties of the signalling networks (Korobkova et al., 2004). Using an MOI 
of 0.5 lead to around 85-89% infection rate at 8 hpi (Figure 3-11), indicating most of 
the cells were infected and only a small proportion of cells left uninfected. This MOI 
and time point were always used in investigating RNA regulation between male and 
female cells to make it comparable with our RNA-seq experiments (MOI=0.5, 8 hpi). 
Whilst differences in HSV-1 replication were only observed at very low MOI 
(<0.0003), we were able to observe different host responses at a higher MOI (0.5). It is 
most likely that these antiviral effects were relatively subtle, but have a cumulative 
effect that is only seen after several rounds of infection.   
 
Although our RNA-seq analysis revealed no significant difference in viral gene 
expression between the two sexes at both 4 and 8 hpi, cells still clustered by sex within 
each time point, indicating sex does play some roles during the infection. However, the 
host gene regulation by HSV-1 infection gradually diverged and this finding was 
supported by our PCA (Figure 3-16) and Pearson’s correlations (Figure 3-18). In order 
to organise differentially expressed transcripts into a more meaningful framework, two 
well-established databases (GO and KEGG) were utilised to identify differentially 
regulated pathways between the two sexes. The results of the GO analysis (Figure 3-
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21) revealed that most of the biological process terms were too broad and not obviously 
related to virus infection to obviously inform further investigation. According to the 
KEGG pathways analysis, various cellular functions were regulated differentially 
between male and female cells, including several cancer, metabolic and innate immune 
pathways. Cancer-related pathways are of interest in herpesvirus infections because at 
least two members in the human herpesviruses have been identified to be oncogenic 
viruses. Human herpesvirus 8 (HHV-8) is the oncogenic virus related to Kaposi’s 
sarcoma and Epstein–Barr virus (EBV), the first virus found to cause cancer in humans, 
is associated with a wide spectrum of human cancers originating from epithelial cells, 
lymphocytes and mesenchymal cells (Sunil et al., 2010; Chen et al., 2015b; Naseem et 
al., 2018). There is less evidence that HSV-1 might be related to cancer. Two studies 
used serological analyses to investigate the relationship between HSV infections and 
primary central nervous system malignancy, showing a high percentage of 
seropositivity (76-86%) in glioblastoma, glioma and meningioma (Poltermann et al., 
2006; Saddawi-Konefka and Crawford, 2010). There seems to be a trend towards a 
positive correlation of anti-HSV antibodies with glioma (Poltermann et al., 2006). 
However, the statistical analysis showed no significant difference between 
seroprevalences in brain tumor patients and the general population (Poltermann et al., 
2006). Therefore, more clinical samples are required to support the hypothesis of an 
association of herpesviruses with the development of primary brain tumors. Vastag et 
al., found that HCMV and HSV-1 trigger different metabolic changes in their cellular 
hosts, such as human skin and lung fibroblats (Vastag et al., 2011). HCMV largely 
affects the production of substrates for lipid metabolism, whereas HSV-1 greatly 
impacts carbon metabolism toward the synthesis of pyrimidine nucleotides. 
Particularly,  carbamoyl-aspartate levels are significantly induced  both in HCMV and 
HSV-1 infections. In addition to the regulation of amino acids, a cohort of 50 patitents 
with recurrent HSV eye diseases showed that recurrence rate of herpetic keratitis was 
lower in patients with higher blood level of folic acid (Savic et al., 2019). The data 
suggest that folic acid might play an role in HSV keratitis reactivation. However, more 
experiments are needed to understand how these metabolic pathways might be involved 
in the sex-specific difference in our cultures. Lastly, there is no literature relevant to 
genes in developmental pathways, such as dorso-ventral axis formation in HSV 
infection, so the reason why this was found in the pathway analysis of genes 
upregualted by HSV-1 infection remains to be investigated. 
 
Importantly, our results revealed that HSV-1 induced greater upregulation of multiple 
genes in a cytosolic DNA sensing pathway in female cells (Table 3-3), which was 
confirmed by qPCR and WB for selected genes (Figure 3-25 and Figure 3-26). As the 
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first line of host defence, the innate immune system has evolved a multi-faceted 
surveillance network to prevent virus infection (Bhat and Fitzgerald, 2014; Ma and He, 
2014; Chow et al., 2018). Accumulating evidence suggests that cytosolic sensors 
recognise HSV-1 to induce IFN secretion and expression of ISGs. Herein, three nucleic 
acid sensors, including cGAS, Rig-I and Mda5, and three signalling transducers, Tbk1, 
Irf1 and Irf7, were found to be upregulated to a higher degree in female cells than male 
cells. All of the genes mentioned above have been shown to play a role in the induction 
of antiviral immunity against HSV-1. cGAS deficiency renders mice susceptible to 
herpes simplex encephalitis and correlates with impaired type I IFN expression in 
microglia (Li et al., 2013; Reinert et al., 2016). Two other sensors, Rig-I and Mda5, 
primarily recognise virus-derived RNA and are responsible for HSV-induced cytokine 
and chemokine expression in early innate recognition (Melchjorsen et al., 2010; Xing 
et al., 2012b). Signalling transduced from recognition of foreign nucleic acids leads to 
a conformational change by STING, allowing recruitment of TBK1 and IRFs. This 
process then activates IRFs in a TBK1-dependent manner to regulate ISGs expression.  
An innate antiviral pathway can be activated in an IFN-independent manner, which is 
consistent with our observation that there were no IFNs detected in both male and 
female cells based on our RNA-seq analysis (data not shown) (Paladino et al., 2006; 
Tanaka and Chen, 2012; Iversen et al., 2016). Therefore, upregulation of these genes in 
the cytosolic sensing pathway in female cells may be a key factor that influences the 
difference in growth of HSV-1 between male and female cells (Figure 3-1).  
 
While there were genes in the nucleic acid-sensing pathway upregulated in female cells 
and also some ISGs, there was a surprising absence of type I IFN. This gave rise to two 
questions: 
 
1. In the absence of IFNs, what are the anti-viral effectors downstream of the nucleic 
acid-sensing pathway? 
 
2. What is the mechanism that underlies the greater upregulation of genes in the nucleic 
acid-sensing pathway in response to HSV-1 in female cells? 
 
For the first question, a potential anti-HSV-1 effector expressing in an IFN-independent 
manner will be discussed in Chapter 4. The regulation of nucleic acid-sensing pathway 
by HSV-1 infection will be further investigated and discussed at a mechanistic level in 
Chapter 5. 
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Chapter 4. Is viperin an anti-HSV-1 
effector and an important factor for 
the sex-specific difference? 
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4.1 Introduction 
 
Virus recognition by cellular sensors typically leads to production of an antiviral state, 
which is established by the activity of various ISGs (Schneider et al., 2014; Schoggins 
2014). These downstream effectors have a range of functions, such as induction of 
programmed cell death, inhibition of virus replication and recruitment of immune cells 
to infected sites (Wang et al., 2017). As nucleic acid sensing pathways were upregulated 
by HSV-1 infection (Section 3.2.5.5), downstream antiviral proteins, many of which 
are also ISGs, are expected to be upregulated (Junt and Barchet, 2015; Ahlers and 
Goodman, 2016). Indeed, there were several potential antiviral ISGs upregulated in 
HSV-1-infected cultures, including the OAS family, the GBP family, viperin and 
Cxcl10 (data not shown). Of these, we found that viperin was upregulated to a very high 
level and ranked at the top of lists of upregulated ISGs in male and female cells based 
on our RNA-seq analysis. However, viperin induction was higher in female compared 
with male cells after HSV-1 infection. This was intriguing because the only publication 
on viperin and HSV suggests that viperin is not induced by HSV infection, which 
contradicts our observations (Shen et al., 2014). Shen et al., have shown that HSV-1 
was found to induce a trace amount of viperin in a female human cell line (HEK293 
cells) and ectopically expressed viperin had no effect on the replication of HSV-1 (Shen 
et al., 2014). For this reason, we wanted to explore viperin further. 
 
The first aim of this chapter is to investigate whether or not viperin can be upregulated 
by HSV-1 infection and play an antiviral role in a variety of cell types. In addition, 
which domain of viperin contributes to the antiviral function against HSV-1 was 
investigated. Lastly, we investigated whether viperin is an essential factor responsible 
for the increased resistance to HSV-1 in female cells. 
 
4.2 Results 
 
4.2.1 Validation of viperin upregulation during HSV-1 infection  
 
4.2.1.1 Confirmation of viperin upregulation by qPCR and WB in male and 
female cells from mice 
 
Our RNA-seq analysis (Section 3.2.5.3) indicated that viperin was upregulated at 4 and 
8 hpi in both male and female cells during HSV-1 infection (Figure 4-1A). To confirm 
this, qPCR using primer sets specific for mouse viperin was performed to confirm 
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upregulation of viperin in male and female cells (Figure 4-1B). For normalisation, 
mouse 18S rRNA was used as an internal control since it cannot be degraded by HSV-
1 vhs (Zenner et al., 2013). Consistent with the RNA-seq data, an increased amount of 
viperin was detected with approximately 3 and 9-fold induction at 4 hpi and 10 and 40-
fold changes at 8 hpi, in male and female cells, respectively. This analysis also 
confirmed that female cells upregulated viperin expression more in response to HSV-1 
infection as compared with male cells at 8 hpi (Figure 4-1B).  
 
In addition to RNA level, expression of viperin protein during HSV-1 infection was 
determined. Male and female cells were infected with HSV-1 pICP47 recombinant 
virus at an MOI of 0.5 for four or eight hours. Cells were then harvested and subjected 
to WB analysis with antibodies against mouse viperin. In line with mRNA upregulation, 
viperin protein levels were higher in male and female cells four and eight hours post-
infection (Figure 4-2A). Moreover, female cells produced a significantly greater 
amount of viperin protein than male cells at 8 hpi (Figure 4-2B).   
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Figure 4-1. Regulation of viperin by HSV-1 infection in male and female cells from 
mice at 4 and 8 hpi. (A) Log2 fold changes of viperin in male and female cells at 4 and 
8 hpi, compared to mock from RNA-seq analysis. (B) Male and female cells from three 
individual mice were infected with HSV-1 pICP47 recombinant virus at an MOI of 0.5 
for four and eight hours. Total RNA was then extracted, followed by cDNA synthesis 
and qPCR analysis for viperin expression. Differential regulation of viperin mRNA was 
assessed by the 2 -ΔΔCT method based on expression relative to mock infected cells and 
normalised to 18S rRNA. The results are shown as mean ± SEM. One-way ANOVAs 
with Tukey’s tests were used to examine differences between means. *, ** and *** 
indicate p-value <0.05, <0.01 and <0.001, respectively. 
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Figure 4-2. Protein expression of viperin in male and female cells at 4 and 8 hpi. 
Male and female cells from three individual mice were mock infected or infected with 
HSV-1 pICP47 recombinant virus at an MOI of 0.5 for four and eight hours. Cell lysates 
were harvested for Western blotting analysis (WB). β-CATENIN acted as the loading 
control. (A) Representative WB shown for one pair of male and female cultures. (B) 
Quantification of WBs by densitometry using ImageJ. The ratio of viperin to β-
CATNEIN pooled from three replicates is shown. A linear model was used to evaluate 
significant differences between the two sexes. * indicates p-value <0.05. ns, no 
significant difference. 
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4.2.1.2 A time course study of viperin regulation by HSV-1 infection in RNA and 
protein levels 
 
In order to understand the dynamics of viperin expression in mouse cells, a time course 
study of viperin levels in male and female cells during HSV-1 infection was performed 
using qPCR for absolute quantification. Male and female cells were infected with HSV-
1 pICP47 recombinant virus at an MOI of 1 and then total RNA was isolated at indicated 
time points (4, 8, 12 and 24 hpi) for cDNA synthesis and qPCR reaction. To provide a 
copy number control, plasmid DNA containing the coding sequence of full-length 
mouse viperin was used. The concentration of this plasmid was determined by 
Nanodrop spectroscopy and 10-fold dilutions were prepared from 101 to 108 copies/µl 
to construct a standard curve. The standard curve had an R2 value of 0.99 and the linear 
regression equation shown was used to calculate viperin copy number (Figure 4-3A). 
In male and female cells, viperin expression gradually increased from 4 to 12 hpi and 
was decreased at 24 hpi. The decrease at the latest time most likely represents the 
reduced viability of cells at this time. Furthermore, significant differences in viperin 
levels in male and female cells were found at 8, 12 and 24 hpi (Figure 4-3B).  
 
Next, a time course of viperin protein expression during HSV-1 infection was 
investigated in female cells, as HEK293 cells used in the previous report were derived 
from female human embryonic kidney (Shen et al., 2014). Female mouse cells were 
infected with HSV-1 pICP47 recombinant virus at an MOI of 2 for 0, 4, 8, 12 and 24 
hours. Following this, WB analysis was performed with antibodies detecting viperin. 
Quantification of individual bands was carried out by densitometry using ImageJ 
software (version 1.50). In female mouse cells, the protein level of viperin started to 
increase from 4 hpi, plateaued at 12 hpi and began to decrease after 24 hours of infection 
(Figure 4-3C and Figure 4-3D).  
 
4.2.1.3 Regulation of viperin in a variety of human cell types by HSV-1 infection 
 
Upregulation of viperin by HSV-1 infection has been found in mouse skin fibroblasts 
in the previous sections. However, Shen et al. showed that viperin is not induced during 
HSV-1 infection in a human cell line (HEK293). Therefore, we wanted to explore 
whether upregulation of viperin by infection is strictly species- and/or cell-type-specific. 
To further explore the role of viperin in other human cell types, four human cell types, 
two of each sex were included in the experiment: HFF (male), MRC5 (male), HEK293 
(female) and HeLa (female). HEK293 cells were used to confirm Shen et al.’s 
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observation. In the four tested human cell types, except for HeLa cells at 8 hpi, viperin 
was not induced compared to mock infected cells at 4 and 8 hpi (Figure 4-4). Viperin 
was however significantly induced by infection in HeLa cells compared with other 
human cell types. This upregulation of viperin in HeLa cells was clear, but was around 
a tenth of what we observed with mouse cells being a five-fold increase, compared with 
a 50-fold increase in the mouse cultures (Figure 4-1).  
 
In addition to regulation of viperin mRNA by HSV-1, we extended the analysis to the 
protein level. A time course of viperin protein expression during HSV-1 infection was 
investigated in two human cell types (HEK293 and HeLa cells). HEK293 cells were 
used for comparison with the data from Shen et al and HeLa cells were utilized as HSV-
1 induced significantly more viperin mRNA in HeLa compared with other tested human 
cell types (Figure 4-4). There was no significant increase of viperin protein in HEK293 
cells during HSV-1 infection (Figure 4-5A and Figure 4-5B), which is consistent with 
previous findings (Shen et al., 2014). In HeLa cells, viperin protein started to increase 
from 8 hpi and then decreased after 12 hours of infection (Figure 4-5C and Figure 4-
5D) such that level and duration of viperin induction were lower and shorter compare 
with female mouse fibroblasts (Figure 4-3C). Taken together, regulation of viperin by 
HSV-1 infection is dependent on different species and cell types. 
 
4.2.1.4 HSV-1 can stimulate viperin expression in an IFN-independent manner 
 
According to the RNA-seq result in Section 3.2.5.3, there was no difference in IFN 
regulation by HSV-1 infection between male and female cells (data not shown), 
indicating that IFN may not be involved in the differential regulation of viperin between 
the sexes during early HSV-1 infection. There is a precedent for IFN-independent 
regulation of viperin transcripts (Fitzgerald, 2011; Duschene and Broderick, 2012), but 
it remained to be shown formally whether viperin upregulation in our culture was 
independent on type I IFN. To investigate this, two approaches were used to identify 
whether soluble factors and specifically IFNs, are important for induction of viperin in 
our cultures. First, conditioned medium was collected from the supernatant of male or 
female cells that had been infected with HSV-1 for eight hours at an MOI of 1. This 
was then centrifuged to remove virus particles and cell debris. The supernatant was then 
used to treat a fresh monolayer of male or female cells for 24 hours. Following this, 
RNA extraction, cDNA synthesis and qPCR analysis for viperin expression was 
performed. No induction of viperin was observed in either male or female cells, 
suggesting that soluble factors released by HSV-1-infected cells are not sufficient to 
stimulate viperin expression (Figure4-6). 
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Next, to rule out a role for type I IFNs in particular, viperin induction by HSV-1 
infection was investigated using IFNAR knockout cells (IFNAR-/-). Male and female 
cells derived from three-day-old WT or IFNAR knockout C57BL/6 mice (Section 
2.1.10) were infected with HSV-1 KOS strain at an MOI of 0.5 for 24 hours. Total RNA 
was isolated and reverse transcribed into cDNA for further qPCR analysis. Both in WT 
and IFNAR-/- cells, female cells consistently induced higher viperin expression than 
male cells (Figure 4-7). Further, viperin levels were lower in the absence of IFNAR 
compared to WT cells, but the difference was not statistically significant. The data 
suggest that type I IFNs play a minor role in viperin induction after HSV-1 infection in 
primary mouse skin fibroblasts and do not contribute to the difference in viperin 
upregulation between cells from male and female mice.  
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Figure 4-3. Absolute quantification of viperin expression during HSV-1 infection. 
(A) A standard curve was generated by plotting the mean cycle threshold (Ct) values 
versus the concentration of p3xFLAG-viperin plasmid from a dilution series (100 to 109 
copies/µl). (B) Male and female cells were infected with HSV-1 pICP47 recombinant 
virus at an MOI of 0.5. Total RNA was isolated at indicated time points and then 
subjected to cDNA synthesis and qPCR for determining viperin expression. Ct values 
were changed into copy numbers by the equation shown in (A). The data were from 
three individual mice and shown as mean ± SEM. A linear model was used to evaluate 
significant differences between the two sexes in (B). Female mouse cells from three 
individual mice were infected with HSV-1 pICP47 recombinant virus at an MOI of 2. 
Cell lysates were collected at indicated time points and then protein levels of viperin 
were measured by Western blotting. (C) Representative blots of one culture of female 
cells. (D) Quantification of each band was performed using ImageJ and the ratio of 
viperin normalised to β-CATNEIN are shown as mean ± SEM. One-way ANOVA with 
Tukey’s post-tests was used to examine differences between means. * and *** indicate 
p-value <0.05 and <0.001, respectively. ns, no -significant difference. 
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Figure 4-4. Regulation of viperin by HSV-1 infection in different human cell types. 
Triplicates of HEK293, HFF, MRC5 and HeLa cells were infected with HSV-1 pICP47 
recombinant virus at an MOI of 0.5 for four and eight hours. Total RNA was isolated, 
followed by cDNA synthesis and qPCR analysis for viperin expression. Differential 
regulation of viperin mRNA was assessed by the 2 -ΔΔCT method based on expression 
relative to mock infected cells and normalised to 18S rRNA. The results are shown as 
mean ± SEM. One-way ANOVA with Tukey’s post-tests was used to examine 
differences between means. * and ** indicate p-value <0.05 and <0.01, respectively. 
ns, no -significant difference. 
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Figure 4-5. Viperin protein expression in HEK293 and HeLa cells during HSV-1 
infection. Triplicates of (A-B) HEK293 and (C-D) HeLa cells were infected with HSV-
1 pICP47 recombinant virus at an MOI of 2. (A, C) Cell lysates were collected at 
indicated time points and then protein levels of viperin were measured by Western 
blotting. (B, D) Quantification of each band was performed using ImageJ and the ratio 
of viperin normalised to β-CATNEIN are shown as mean ± SEM. One-way ANOVA 
with Tukey’s post-tests was used to examine differences between means. * indicates p-
value <0.05. ns, no -significant difference. 
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Figure 4-6. Soluble factors are not sufficient to induce viperin expression. Male 
and female cells from three individual mice were infected with HSV-1 for eight hours 
at an MOI of 1. Medium from infected cells was collected and centrifuged at 25,000 
for 60 minutes. The supernatant of the conditioned medium was applied to treat new 
batches of male or female cells for 24 hours. Total RNA was extracted from the 
medium-treated cells and detection of viperin expression was performed using qPCR. 
Differential regulation was assessed by the 2 -ΔΔCT method based on expression relative 
to mock and normalised to 18S rRNA. The results are expressed as mean ± SEM. One-
way ANOVA was used to examine differences between means. ns, no significant 
difference. 
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Figure 4-7. Viperin can be induced in an IFN-independent manner. Male or female 
cells from three individual mice were generated from three-day-old wild-type (WT) or 
IFNAR knockout (IFNAR-/-) C57BL/6 mice. The cells were infected with HSV-1 strain 
KOS at an MOI of 0.5 for 24 hours. The cell lysate was harvested for qPCR analysis of 
viperin expression, which was normalised to 18S rRNA and compared with mock. The 
results are expressed as mean ± SEM. One-way ANOVA with Tukey's post-tests was 
used to evaluate differences between means. ***p-value <0.001. 
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4.2.2 Identification of viperin as an anti-HSV-1 protein 
 
4.2.2.1 Ectopic expression of viperin suppresses the replication of HSV-1 
 
The data in Section 4.2.1 showed that viperin is upregulated in male and female mouse 
cells. Next, we investigated whether viperin has an anti-HSV-1 function. Viperin has 
been identified to inhibit virus replication in a broad range of viruses, including 
influenza virus, flaviviruses and human cytomegalovirus (Chin and Cresswell, 2001; 
Tan et al., 2012; Helbig et al., 2013; Panayiotou et al., 2018). However, whether viperin 
can play a role to counter HSV-1 infection is not well- explored. First, ectopic 
expression of viperin was used to examine any inhibitory effect on HSV-1 replication. 
Male and female cells were transfected with a plasmid expressing full-length mouse 
viperin (wild-type viperin; WT viperin) for 24 hours. Following this, inoculation of 
HSV-1 strain KOS was performed at an MOI of 1. Cell lysates were harvested for 
titration to determine viral titres. Transient expression of WT viperin both in male and 
in female cells significantly inhibited HSV-1 replication (Figure 4-8A and Figure 4-
8B). Figure 4-8C and Figure 4-8D show the transfection efficiency of WT viperin in 
male and female cells, respectively. To show this in another way, we examined the 
ability of viperin to reduce fluorescence in cells infected with HSV-1 pICP47 by 
microscopy. After transfection of male and female cells with WT viperin and infection 
with HSV-1 pICP47 virus, GFP expression was obviously reduced compared with 
control transfected cells (Figure 4-9 and Figure 4-9B). 
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Figure 4-8. Ectopic expression of viperin inhibits HSV-1 replication in male and 
female cells. (A, C) Male and (B, D) female cells from three individual mice were 
transfected with 2 μg of p3xFLAG-viperin. After 24 hours, cells were (A-B) infected 
with HSV-1 strain KOS at an MOI of 1 and viral yields were then measured or (C-D) 
harvested for determination of transfection efficiency of p3xFLAG-viperin by Western 
blotting with representative blots shown. (A-B) The viral titres are presented as mean 
± SEM and unpaired Student’s t-tests were used to evaluate differences between means. 
* and ** indicate p-value <0.05 and <0.01, respectively. 
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Figure 4-9. Overexpression of viperin suppresses HSV-1 replication in male and 
female cells. Male and female cells were transfected with 2 μg of p3xFLAG-viperin, 
followed by inoculation of HSV-1 pICP47 recombinant virus expressing GFP at an 
MOI of 1. After eight hours of infection, cells were then fixed, stained with DAPI to 
localise the nucleus and examined by confocal microscopy. The data are representative 
of three independent experiments.  
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4.2.2.2 A dose-dependent effect of viperin against HSV-1 infection and the region 
of viperin involved in the inhibitory effect 
 
Our experiments so far showed that viperin can suppress HSV-1, but this may have 
been due to overexpression from the plasmid. For this reason, we examined a range of 
viperin levels. Male or female cells were transfected with 0, 0.5, 1, 2, 4 or 8 µg of WT 
viperin plasmid and were then infected with HSV-1 strain KOS for 24 hours. 
Quantitation of viral titres in cell lysates by plaque assays revealed a dose-dependent 
inhibition of HSV-1 infection in these cultures (Figure 4-10A and Figure 4-10B). A 
significant inhibitory effect was observed in cells transfected with 1 µg or more of WT 
viperin plasmid and the effect reached its peak level with transfection of 4 µg plasmid. 
Expression of the indicated concentration of WT viperin in both male and female cells 
was confirmed by WB analysis (Figure 4-10C and Figure 4-10D). Collectively, the 
results described above indicate the anti-HSV-1 activity of viperin is dose-dependent 
and can be observed when half the amount of plasmid is used than in our original 
experiments. We note that there will be endogenous viperin expressed and this might 
mask the effect of small amounts of additional viperin.  
 
Different domains of viperin are responsible for different functions and this protein 
works in a virus-specific manner (Seo et al., 2011a; Helbig and Beard, 2014). 
Therefore, the residues or domains required for the antiviral ability against HSV-1 are 
of interest. To address this issue, a panel of viperin mutants, including deletions of the 
amphipathic helix domain (N-terminal domain; Δ9-42), the radical SAM domain 
(central domain; Δ71-182) and the C-terminal domain (Δ218-361), were constructed 
and transfected into male or female cells. Stability of the viperin variants was 
determined by WB (Figure 4-11A and Figure 4-11B). After transfection for 24 hours, 
cells were infected with HSV-1 strain KOS at an MOI of 1 for another 24 hours and 
viral titres in the cell lysate of each sample were then measured. Transient 
overexpression of WT viperin in both male and female cells significantly reduced HSV-
1 replication by around 10-fold, which was comparable to the effect of Δ71-182 and 
Δ218-361 groups, indicating that the radical SAM domain and C-terminal domain of 
viperin are dispensable for the anti-HSV-1 activity (Figure 4-11C and Figure 4-11D). 
By contrast, removal of the N-terminal domain, which was the smallest deletion 
examined, abolished the anti-HSV-1 activity of viperin. These data emphasise the 
importance of the N-terminal domain of viperin in the antiviral activity against HSV-1.  
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4.2.2.3 Induction of viperin expression cannot fully explain the sex difference in 
HSV-1 replication between male and female cells 
 
As viperin was upregulated more in female cells (Section 4.2.1) and was confirmed as 
an anti-HSV-1 effector (Section 4.2.2), we then investigated whether differential 
regulation of viperin by HSV-1 between the sexes is a key factor that explains the sex 
difference in HSV-1 replication in our cultures (Figure 3-1). First of all, the necessity 
of induction of viperin in restricting HSV-1 replication was assessed by transient 
expression of lentiCRISPR plasmid containing the coding sequence of Cas9 and a 
gRNA targeting the viperin gene (Sanjana et al., 2014). In brief, male and female cells 
were transfected with lentiCRISPRmCherry-Rsad2 (Viperin) (Table 2-5) for 24 hours, 
and then infected with HSV-1 at an MOI of 0.1. HSV-1 infection in the viperin 
knockout cells resulted in a significant, approximately 10-fold enhancement of 
infectious HSV-1 release at 24 hpi compared with control cells, in male and female 
cells (Figure 4-12A and Figure 4-12B). In addition to mouse skin fibroblasts, we also 
examined whether viperin is necessary for inhibiting HSV-1 replication in HeLa cells, 
a human cell line that has been found to upregulate viperin during HSV-1 infection 
(Section 4.2.1.3). HSV-1 yields in the viperin knockdown HeLa cells were significantly 
higher than in control cells (Figure 4-12C). Knockout efficiency of viperin in male, 
female and HeLa cells was evaluated by WB after 24 hours transfection and found to 
be similar (Figure 4-12D, Figure 4-12E and Figure 4-12F). Collectively, these data 
suggest that viperin was required to restrict HSV-1 replication in male and female 
mouse cells and in HeLa cells. 
 
Next, male and female cells were transfected with siRNA specific for viperin for 24 
hours and the cells were then infected with HSV-1 pICP47 recombinant virus at a very 
low level (0.0003 PFU/cell). These were the conditions used to reveal a difference in 
HSV-1 replication between male and female cells. Knockdown of viperin led to 
significant more replication of HSV-1 both in male and female cells (Figure 4-13A and 
Figure 4-13B). However, the knockdown had a significantly greater impact on female 
cells, increasing titres by around 15-fold, compared to approximately 3-fold in male 
cells (Figure 4-13C and Figure 4-13D). Likewise, the effect of viperin knockdown on 
spread of virus in cultures was also significantly greater in female than in male cells. 
Despite this, viral titres (Figure 4-13A) and infected cell populations (Figure 4-13B) 
remained significant higher in male cells compared with female cells irrespective of 
viperin knockdown cells. These data show that while the sex difference in HSV-1 
infection is narrowed in viperin knockdown cells if is not eliminated. Thus, viperin 
alone cannot explain the sex difference in HSV-1 replication. 
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Figure 4-10. A dose-dependent effect of viperin against HSV-1. Male and female 
cells from three individual mice were transfected with p3xFLAG-viperin at indicated 
concentrations and were then infected with HSV-1 strain KOS at an MOI of 1. After 
24 hours infection, viral titres in (A) male and (B) female cells were determined by 
plaque assays. Overexpression of viperin at various concentrations in (C) male and (D) 
female cells was measured by Western blotting. The data are shown as mean ± SEM. 
One-way ANOVA with Tukey’s post-tests was used to evaluate differences between 
means. *, ** and *** indicate p-value <0.05, <0.01 and <0.001, respectively. ns, no 
significant difference. 
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Figure 4-11. The N-terminal domain of viperin is required for the anti-HSV-1 
activity of viperin. Plasmids expressing FLAG-tagged full-length viperin (WT) and 
Δ9-42, Δ71-182 and Δ218-361 mutants of viperin, or empty vectors (2 μg), were 
transfected into male or female cells from three individual mice. After 24 hours, cells 
were then (A-B) harvested for Western blotting analysis using anti-FLAG or anti-β-
CATNEIN antibodies or (C-D) infected with HSV-1 strain KOS at an MOI of 1. HSV-
1 titres in (C) male or (D) female cells were then measured by plaque assays. The results 
are shown as mean ± SEM and analysed using One-way ANOVA with Tukey’s post-
tests. ** and *** indicate p-value <0.01 and <0.001, respectively. ns, no significant 
difference. 
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Figure 4-12. Viperin is required to restrict HSV-1 replication. (A-B, D-E) 
LentiCRISPR vectors (2 μg) or (C, F) 50 nM of siRNA targeting the viperin gene were 
transfected into male and female cells from three individual mice or HeLa cells. These 
cells were then infected with HSV-1 strain KOS at MOI of 0.1 for 24 hours. (A-C) Viral 
titres were determined by plaque assays. (D-F) Knockout or knockdown efficiency 
prior to infection was evaluated by Western blotting using an anti-viperin antibody. The 
results are shown as mean ± SEM. Unpaired Student’s t-tests were used to test 
differences between means. * and *** indicate p-value <0.05 and <0.001, respectively. 
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Figure 4-13. Viperin alone cannot explain the replication difference between male 
and female cells. Male or female cells were transfected with 50 nM of control siRNA 
(siControl) or siRNA specific for viperin for 24 hours and were then infected with HSV-
1 pICP47 recombinant virus at an MOI of 0.0003. (A) Viral titres in the cell lysates 
from three individual mice were determined by plaque assays and (B) GFP percentage 
was measured at 72 hpi by flow cytometry. Fold changes of (C) viral titres or (D) GFP 
percentage between knockdown and control cells were calculated in male and female 
cells. The results are expressed as mean ± SEM. One-way ANOVA with Tukey’s tests 
and unpaired Student’s t-tests were used to test differences between means in (A-B) 
and (C-D), respectively. *p-value <0.05; **p-value <0.01; ***p-value <0.001. 
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4.3 Discussion 
 
Viperin has a broad spectrum of antiviral functions and inhibits virus replication by 
various mechanisms (Duschene and Broderick, 2012; Helbig and Beard, 2014). 
However, most of the current literature is aimed at RNA viruses, and whether viperin 
functions efficiently against DNA viruses is controversial (Chin and Cresswell, 2001; 
Seo et al., 2011b; Shen et al., 2014). Taking HSV-1 as an example, although Shen et al. 
found that HSV-1 only induces a trace amount of viperin and overexpression of viperin 
cannot suppress HSV-1 replication, they did not mention which HSV-1 strain they used 
and the species origin of viperin was not specified (Shen et al., 2014). By contrast, 
Zheng and Su concluded that HSV-1 can trigger the MAVS-dependent induction of 
viperin using identical cells (HEK293) and a similar MOI (0.1-0.2). Therefore, the role 
of viperin against HSV-1 infection is not clear (Zheng and Su, 2017).  
 
At the beginning of this chapter, we confirmed that viperin, a potential downstream 
effector of nucleic acid-sensing signalling, was upregulated in mouse skin fibroblasts 
during HSV-1 infection. Female cells induced greater expression of viperin than male 
cells, as determined by qPCR and WB (Figure 4-1 and Figure 4-2). Therefore, in our 
culture system we found strong evidence of viperin induction by HSV-1 infection and 
this varied between the sexes. 
 
We then investigated whether the induction of viperin during HSV-1 requires type I 
IFNs or not. Viperin has been found to be induced in a variety of cell types by IFN, 
LPS, dsDNA, dsRNA analogue poly I:C and by infection with a diverse range of 
viruses. The IFN-dependent and IFN-independent signalling pathways are not mutually 
exclusive in the mediation of the upregulation of viperin. In IFN-dependent signalling, 
treatment with specific ligands, such as LPS, poly I:C and  multiple RNA viruses, 
stimulates RLRs, TLR3 and TLR4, leading to activation of IRF3 and IRF7 to produce 
type I IFN. The interaction between IFN and IFNAR further facilitates a signalling 
cascade in the formation of ISGF3 to bind to the viperin promoter, and therefore, induce 
its expression (Severa et al., 2006; Xu et al., 2009). However, viperin can be induced 
in an IFN-independent manner by some viruses (Boudinot et al., 2000; Severa et al., 
2006). The transcriptional factor IRF1 has been found to act as a critical mediator of 
viperin induction via the overexpression of RLRs. For example, RIG-I and MDA5 
directly activate viperin promoter regulation via the TBK1/IRF3 axis through an IFN-
independent pathway (Severa et al., 2006; Stirnweiss et al., 2010). Similarly, a recent 
study has revealed an innate antiviral pathway acting before the IFN pathway in HSV-
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infected epithelial surfaces, which indicates that host cells can rapidly employ ISGs as 
the first line of defence against viruses in an IFN-independent manner at the beginning 
of virus infection (Iversen et al., 2016). HCMV can induce viperin expression by the 
binding of the gB component of the viral envelope to an unknown cell surface receptor 
in human fibroblasts independent of IFNs (Chin and Cresswell, 2001)(Rossini et al., 
2012). Additionally, IFN-independent pathways of viperin regulation have been found 
to be directly regulated by IRF1 or IRF3 in VSV and JEV infection (Chan et al., 2008). 
Our data add to these host-virus models where upregulation of viperin can be detected 
during the initial infection in the absence of IFNs and other soluble factors (Figure 4-6 
and Figure 4-7).  
 
In addition to the upregulation of viperin in both male and female cells, ectopically 
expressed mouse viperin was found to inhibit HSV-1 infection and endogenous viperin 
was shown to restrict HSV-1 replication (Figure 4-8 and Figure 4-12). These findings 
demonstrate that in our cultures viperin is able to counteract HSV-1 infection unlike 
those reported by Shen et al (Shen et al., 2014). This allowed us to dissect the roles of 
the various domains of viperin with respect to their anti-HSV-1 function. Since viperin 
is composed of different functional domains, mutants with deletions of each individual 
domain, namely, N-terminal domain (Δ9-42), radical SAM domain (Δ71-182) and C-
terminal domain (Δ218-361), were generated and tested for their anti-HSV-1 abilities. 
An in vitro study indicated that viperin inhibits the release of influenza particles from 
plasma membrane by disrupting the formation of the lipid raft where influenza virus 
buds (Wang et al., 2007). In addition, viperin also restricts human immunodeficiency 
virus (HIV) egress from the cell, which is dependent on the SAM domain of viperin 
(Nasr et al., 2012). Viperin uses different mechanisms to restrict flavivirus infections, 
including DENV and ZIKV. DENV infection was found to significantly induce viperin 
expression, thus inhibiting DENV RNA synthesis and infectious virus release (Helbig 
et al., 2013). This anti-DENV activity was mediated by residues within the C-terminal 
domain of viperin, but not the N-terminal helix domain and SAM motifs (Helbig et al., 
2013). Viperin has been documented to control ZIKV infection by the C-terminal 
region and viperin knockout mouse embryonic fibroblasts were found to have increased 
ZIKV infection compared with wild-type cells (Van der Hoek et al., 2017). 
Furthermore, viperin can directly interact with the non-structural (NS) protein of ZIKV 
and further reduce the expression of NS3 by inducing proteasome-dependent 
degradation. ZIKV replication was rescued when NS3 was overexpressed in the 
presence of viperin, indicating that ZIKV NS3 is the specific target of viperin 
(Panayiotou et al., 2018). Our data in Figure 4-11 show that the N-terminal domain of 
viperin is essential for its anti-HSV-1 function. This domain has been found to be 
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crucial for the association between the endoplasmic reticulum and lipid droplets 
whereby viperin interacts with HCV non-structural protein 5A to inhibit virus 
replication (Hinson and Cresswell, 2009a; Hinson and Cresswell, 2009b; Helbig et al., 
2011). Likewise, the amphipathic helix in the N terminus of viperin is necessary for its 
antiviral activity against the release of chikungunya virus (CHIKV) and equine 
infectious anaemia virus (EIAV) (Teng et al., 2012; Tang et al., 2014). Thus, viperin 
might use a similar strategy by residing in the endoplasmic reticulum to suppress HSV-
1 release, although this hypothesis requires further investigation.  
 
An obvious difference between our experiments and those published previously for 
HSV-1 was the use of mouse cells. Therefore, it was important to extend our study to 
human cells. We examined a variety of human cells and found that viperin was 
significantly induced in HeLa cells compared with other tested human cell types (Figure 
4-4). Our conclusion about the role of viperin in HSV-1 infection is that it has cell-type-
specific actions and may be important in mouse and human cells. In line with this, 
viperin levels induced by rabies virus (RABV) seems to be cell-type-specific. 
Replication of RABV was found to be restricted by both transient overexpression and 
stable expression of viperin through a TLR4- and IRF3-dependent pathway (Tang et 
al., 2016). Viperin was apparently upregulated in macrophage RAW264.7 cells, but 
there was only weak upregulation detected in NA, BHK-21 and BSR cells (Tang et al., 
2016). In another cell-type-specific case, Szretter et al. (Szretter et al., 2011) showed 
that there was an  increase in the viral load of West Nile virus (WNV) when primary 
viperin-/- macrophages and dendritic cells were infected with WNV. However, no 
significant differences were found in viperin deficient mouse embryonic cortical 
neurons and fibroblasts, compared with wild-type cells, during WNV infection (Szretter 
et al., 2011). 
 
In summary, viperin can be an important antiviral function against HSV-1, although it 
only partially explained the sex difference in HSV-1 replication (Figure 4-13). Several 
other genes with antiviral functions were also upregulated more in female than in male 
cells and it is likely that these also play roles in the sex-related difference in HSV-1 
replication. It is possible that many or all of these antiviral effectors are under the 
control of the same pathway, which our RNA-seq data suggests is linked to detection 
of viral DNA. So, the next obvious direction is to examine this upstream pathway. The 
upregulation of viperin in female cells provides an ideal marker to probe such a pathway 
for mechanistic leads. Therefore, viperin will be used as a readout in the next chapter 
(Chapter 5) to investigate the regulation of the cytosolic DNA-sensing pathway by 
HSV-1 infection in male and female cells. 
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Chapter 5. Regulation of the 
cytosolic sensing pathway by HSV-1 
infection in male and female cells. 
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5.1 Introduction 
 
The detection of viral components involves numerous PRRs, leading to signal 
transduction, and ultimately, the production of type I IFNs and/or antiviral proteins 
(Akira and Hemmi, 2003; Reikine et al., 2014). A broad variety of viral products can 
serve as triggers for the molecular recognition of HSV-1 infection, including viral 
genomic DNA, virion components and replication intermediates (Chew et al., 2009; 
Rathinam and Fitzgerald, 2011). The major stimuli for cellular recognition of viral 
infection are viral nucleic acids, because they can be identified at many cellular 
locations (Whittaker and Helenius, 1998; Chew et al., 2009). Nucleic acid sensors are 
classified into different categories based on the structure of the nucleic acid detected 
and the cellular localisation. These comprise the TLRs, the Nod-like receptors (NLRs), 
the RLRs and cytosolic DNA sensors such as DAIs and cGAS.  
 
A number of these nucleic acid sensors have been shown to play an important role 
during HSV-1 infection (Sharma and Fitzgerald, 2011; Paludan and Bowie, 2013). In 
the endosomal compartment, the recognition of dsDNA containing CpG motifs by 
TLR9 is required for early type I IFN expression in response to HSV-1 infection 
through a cell-type-specific mechanism (Hochrein et al., 2004; Rasmussen et al., 2007). 
In addition, TLR3 exerts protective immunity to HSV-1 in the central nervous system 
and notably, HSV-1 replicates more efficiently in TLR3-deficient astrocytes and 
dendritic cells, which have impaired production of type I IFNs (Davey et al., 2010; 
Lafaille et al., 2012). In the cytoplasmic compartment, recognition of intracellular 
HSV-1 DNA by cytosolic DNA sensors leads to a TLR-independent mechanism that 
activates IRFs via TBK1 (Ishii et al., 2006). Among these sensors, DAI, cGAS and 
IFI16 induce innate antiviral signalling through the STING-TBK1 axis in response to 
HSV infection (Takaoka et al., 2007; Unterholzner et al., 2010; Sun et al., 2013). 
Moreover, RLRs such as RIG-I and MDA5 can sense viral dsRNA in the cytoplasm 
and then elicit antiviral responses (Dixit and Kagan, 2013; Chan and Gack, 2016). 
HSV-1 viral dsRNAs are detectable in infected cells, which may arise as a result of 
highly structured single-stranded RNA or from overlapping transcription. Thus, these 
serve as the ligands for RLRs (Weber et al., 2006). RLRs further transmit signals to the 
MAVS protein, leading to the activation of IRFs and NF-κB. This process results in 
upregulation of IFNs, inflammatory cytokines and ISGs (Loo and Gale, 2011; Reikine 
et al., 2014). 
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As multiple players in cytosolic nucleic acid-sensing pathways were differentially 
regulated between mouse cells of the two sexes in the initial stage of HSV-1 infection 
(Section 3.2.5.4), we focused next on dissecting the mechanism behind these 
differences. In Chapter 4, we found that viperin cannot fully explain the sex-difference 
in HSV-1 replication, although it has anti-HSV-1 activity. To understand upstream 
events that lead to the sex-specific difference, we relied on the use of CRISPR knockout 
and siRNA knockdown systems to reveal the crucial cellular sensors that regulate the 
sex difference using viperin as a readout. Lastly, differentially regulated transcription 
factors on the sex chromosomes were screened for their abilities to regulate the sex-
specific differences. A potential candidate was then examined to determine whether it 
has a critical role in mediating the sex difference in the cytosolic sensing pathway, and 
the different growth phenotypes of HSV-1 in mouse male and female cells. 
 
5.2 Results 
 
5.2.1 Determining which components from nucleic acids-sensing pathways 
contribute to differential antiviral responses in male and female cells 
 
5.2.1.1 cGAS and Tbk1 are essential for the sex difference in antiviral responses 
 
The results in Section 3.2.5.5 showed that female cells induced higher expression of 
several genes in the nucleic acid-sensing pathways than male cells. These genes 
included nucleic acid sensors such as cGAS, Rig-I and Mda5, and a signalling adaptor, 
Tbk1. In addition to the genes mentioned above, Tlr3 and Tlr4, two key nucleic acid 
sensors that also signal via TBK1, leading to viperin upregulation, were also 
investigated (Figure 5-1). These were included as negative controls because we had no 
evidence for their involvement from our initial RNA-seq experiment. 
 
The lentiCRISPR system was applied to knockout each indicated gene in male and 
female cells. An empty lentiCRISPR plasmid or one that contained guide a RNA 
targeting cGAS, Rig-I, Mda5, Tbk1, Tlr3 or Tlr4 (Table 2-5), was transfected into male 
and female cells. After 24 hours, cells were infected with HSV-1 strain KOS at an MOI 
of 0.5 for eight hours. Cell lysates were harvested for RNA isolation, cDNA synthesis 
and qPCR detection of viperin expression. When Tlr3 and Tlr4 were deficient, viperin 
upregulation due to infection was similar to the appropriate control both in male and in 
female cells. This suggests that as we expected Tlr3 and Tlr4 are not involved in the 
regulation of viperin due to HSV-1 infection (Figure 5-1). On the contrary, cGAS, Rig-
I, Mda5 and Tbk1 were all required for full induction of viperin in male and female 
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cells. However, of these, cGAS and Tbk1 were the only genes required to maintain the 
difference in viperin upregulation between male and female cells. When cGAS and Tbk1 
were knocked out, viperin upregulation was decreased such that it reached a comparable 
level in male and female cells (Figure 5-1). Importantly, similar knockout efficiency 
for each gene was found by comparing cells transfected with lentiCRISPR empty 
vectors to those having gene-specific guide RNA by using qPCR analysis (Figure 5-2). 
These data suggest that while Rig-I and Mda5 may play some roles in viperin induction 
by HSV-1 in our cultures, only cGAS and Tbk1 are necessary for the difference 
observed between male and female cells. 
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Figure 5-1. Nucleic acids sensors contributing to viperin regulation by HSV-1 
infection. (A) Male or female cells from three individual mice were transfected with 2 
μg of empty lentiCRISPR vectors or those containing gRNA specific for cGAS, Mda5, 
Rig-I, Tbk1, Tlr3 or Tlr4. Cells were then infected with HSV-1 strain KOS at an MOI 
of 0.5. RNA level of viperin was measured at 8 hpi. Differential regulation was assessed 
by the 2 -ΔΔCT method based on expression relative to mock infected cells and 
normalised to 18S rRNA. The data are expressed as mean ± SEM. (B) One-way 
ANOVA with Tukey’s tests was used to evaluate differences between means. Blue and 
red indicate male and female cells respectively. *p-value <0.05; ***p-value <0.001. ns, 
no significant difference. 
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Figure 5-2. Knockout efficiency of lentiCRISPR targeting cGAS, Mda5, Rig-I, 
Tbk1, Tlr3 or Tlr4. RNA from the experiment in Figure 5-1, cell lysates were 
harvested for RNA isolation, cDNA synthesis and qPCR reaction using primers for the 
genes being knocked out. The results are expressed as mean ± SEM. No statistically 
significant differences (ns) were found by one-way ANOVA with Tukey’s tests. 
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5.2.1.2 Involvement of Irf1, Irf3 and Irf7 in viperin induction during HSV-1 
infection  
 
A growing number of studies have shown that the initial entry of the enveloped virus 
into cells, especially epithelial cells and fibroblasts, can elicit an antiviral defence that 
is independent of IFNs and sometimes the most likely sensors like TLRs and RLRs. 
Nonetheless, this reaction requires the participation of IRFs (Paladino et al., 2006; 
Noyce et al., 2011). IRF3 is the most obvious transcription factor to examine as many 
papers have pointed out it is an important factor for regulation of ISGs during virus 
infection (Hiscott, 2007; Chen et al., 2016). We included IRF1 and IRF7 as well 
because they are associated with other pathogen sensing pathways (Kimura et al., 1994; 
Ning et al., 2005). In particular, the roles of IRF1 and IRF3 in viperin regulation were 
confirmed in an IFN-independent manner during VSV infection (Dixit et al., 2010), but 
whether HSV-1 triggers a similar mechanism is unknown. To address this issue, the 
siRNA knockdown method was employed. In brief, male or female cells were 
transfected with control siRNA (siControl) or siRNA targeting Irf1, Irf3 or Irf7, 
respectively, for 24 hours, followed by inoculation of HSV-1 strain KOS and detection 
of viperin expression after eight hours infection. 
 
In the absence of Irf1, Irf3 or Irf7, the upregulation of viperin relative to mock was 
significantly reduced both in male and in female cells (Figure 5-3). When Irf1 was 
knocked down, upregulation of viperin was almost nil for cells of both sex. This makes 
it difficult to be sure whether this is a critical determinant of the male and female 
difference, or simply required for any signalling through the relevant pathway. Irf3 and 
Irf7 also play roles in the viperin regulation by HSV-1. However, knockdown of these 
two genes did not completely eliminate the sex difference in viperin level (Figure 5-3). 
Moreover, knockdown of Irf7 increased the difference in viperin upregulation by HSV-
1 infection between male and female cells. Knockdown efficiency of each siRNA was 
demonstrated to be equal by qPCR and is shown in Figure 5-4. The results suggest that 
Irf3 and Irf7 are involved in this pathway, but Irf1 was the most critical factor as 
knockdown of Irf1 ablated all viperin expression.  
 
5.2.1.3 Irf1 transduces signals upstream of cGAS, but not Tbk1, Irf3 and Irf7, 
during initial HSV-1 infection 
 
As Irf1 had such an important role in response to HSV-1 infection (Figure 5-3), we 
speculated that Irf1 is required upstream of other sensors and IRFs at the beginning of 
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HSV-1 infection. To test this hypothesis and keep the focus on the canonical pathway, 
two candidates in the nucleic acids-sensing pathway, cGAS and Tbk1, which have been 
shown to participate in viperin regulation by HSV-1 infection and are required for the 
difference between male and female cells, and two IRFs, Irf3 and Irf7, were examined 
in this experiment. Male and female cells were transfected with siRNA to knock down 
the expression of Irf1. After 24 hours, the cells were infected with HSV-1 at an MOI of 
0.5 for eight hours. Gene expression of cGAS, Tbk1, Irf3 and Irf7 was then analysed by 
qPCR in Irf1 knockdown and siControl cells.  
 
When Irf1 was reduced in male and in female cells, the upregulation of Tbk1, Irf3 and 
Irf7 did not differ statistically from siControl cells (Figure 5-5). However, cGAS 
upregulation was significantly decreased in the Irf1 knockdown cells, regardless of sex. 
Moreover, the difference in the cGAS upregulation between the two sexes disappeared 
(Figure 5-5). These data suggest that Irf1 is required for cGAS upregulation by HSV-1 
infection and therefore, for the stronger response by female cells. This notion was 
further investigated by detecting protein expression of cGAS via WB in Irf1, Irf3 or Irf7 
deficient cells. Male and female cells were transfected with siRNA to knockdown Irf1, 
Irf3 and Irf7 for 24 hours. Cells were then infected with HSV-1 strain KOS. The results 
indicated that the cGAS protein level was reduced to a comparable level between male 
and female cells when Irf1 was knocked down (Figure 5-6). This is consistent with the 
regulation of mRNA shown in Figure 5-5. There was no significant decrease in cGAS 
protein in the Irf3 or Irf7 knockdown cells and the sex difference in cGAS expression 
remained in these cultures (Figure 5-6). 
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Figure 5-3. Involvement of IRFs in the regulation of viperin by HSV-1 infection. 
Male or female cells from three individual mice were transfected with 50 nM of control 
siRNA (siControl) or siRNA specific for Irf1, Irf3 or Irf7 for 24 hours. Cells were then 
infected with HSV-1 strain KOS at an MOI of 0.5. Total RNA was isolated at 8 hpi and 
then viperin expression was determined by qPCR. Differential regulation was assessed 
by the 2 -ΔΔCT method based on expression relative to mock and normalised to 18S 
rRNA. The results are expressed as mean ± SEM. One-way ANOVA with Tukey’s tests 
was used to evaluate differences between means. *p-value <0.05. ns, no significant 
difference. 
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Figure 5-4. Knockdown efficiency of siRNA targeting Irf1, Irf3 and Irf7. RNA from 
the experiment in Figure 5-3 were used to determine the level of knockdown by siRNA, 
using qPCR with primers for the relevant genes. The results are shown relative to the 
control siRNA treatment and expressed as mean ± SEM. No significant difference (ns) 
were seen between any pair of male and female cells by one-way ANOVA with Tukey’s 
tests. 
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Figure 5-5. Irf1 regulates cGAS upregulation during HSV-1 infection. Male or 
female cells from three individual mice were transfected with 50 nM of siRNA specific 
for Irf1 or control siRNA, and were then infected with HSV-1 strain KOS at an MOI of 
0.5. RNA expression of (A) cGAS, (B) Tbk1, (C) Irf3 and (D) Irf7 was measured at 24 
hpi. The data are normalised to 18S rRNA and are presented as the relative fold change 
over normalised RNA from mock. The data are expressed as mean ± SEM. One-way 
ANOVA with Tukey’s tests was used to evaluate differences between means. Asterisks 
indicate values that are statistically significant (*p-value <0.05; **p-value <0.01; ***p-
value <0.001). ns, no significant difference. 
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Figure 5-6. Irf1 is important for cGAS protein expression during HSV-1 infection. 
Male or female cells from three individual mice were transfected with 50 nM of control 
siRNA (siControl) or siRNA specific for Irf1, Irf3 or Irf7 and were then infected with 
HSV-1 strain KOS at an MOI of 0.5. Cell lysates were harvested at 24 hpi. Protein 
levels of cGAS were examined by Western blotting using an anti-cGAS antibody. (A) 
Representative WB images. (B) Each band was quantified by densitometry and 
normalised to β-CATENIN. The results are expressed as mean ± SEM. A linear model 
was employed to determine differences between the sexes. Asterisks indicate values 
that are statistically significant (*p-value <0.05; **p-value <0.01). ns, no statistically 
significant difference; nd, not detectable. 
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5.2.2 Regulation of viperin expression by transcription factors on the sex 
chromosomes 
 
5.2.2.1 Potential transcription factors to mediate viperin expression on the sex 
chromosomes 
 
Irf1 explains the cGAS difference in Section 5.2.1.3, but there is no obvious link from 
Irf1 or any of the other genes of interest to the sex chromosomes or other possible 
explaination of the sex-specific difference. In order to understand the mechanism 
underlying the difference in the nucleic acid-sensing pathway between male and female 
cells, we turned our attention to transcription factors on the sex chromosomes. 
Differential expression of immune regulated genes on sex chromosomes have 
previously been suggested to lead to differences in immune responses between males 
and females, so we reasoned that this might extend to transcriptional regulators. Firstly, 
transcripts from the X or Y chromosome that were differentially regulated between 
mock and 4 or 8 hpi, in male or female cells, were collected. A further filtering 
parameter was set to acquire those predicted to have the ability to interact with enhancer 
binding sites in the differentially regulated genes in the cytosolic sensing pathway, such 
as cGAS, Mda5, Rig-I, Tbk1, Irf1 or Irf7, based on the GeneCards® database 
(http://www.genecards.org/). Eight transcripts from seven genes, including Taf1, 
Zbtb33, Phf8, Hdac8, Elk1 and Hcfc1, on the X chromosome met the filtering criteria 
(Figure 5-7), but none were found on the Y chromosome (data not shown). Fold 
changes between mock and 4 or 8 hpi of these transcripts in male and female cells, were 
plotted in a heatmap (Figure 5-7). Detailed description of these regulators is provided 
in Table 5-1, including gene symbol, full gene name and list of genes for which each 
one has binding sites upstream. Most of the genes were regulated similarly between 
male and female cells. For instance, Taf1, Phf8 and Hcfc1 were upregulated at both 4 
and 8 hpi in male and female cells (Figure 5-7). Hdac5 was downregulated at the two 
time points and Elk1 was downregulated at 8 hpi. Interestingly, two different transcripts 
of Zbtb33 were both decreased during HSV-1 infection in female cells, but were slightly 
increased at 4 hpi (NM_020256) or were unchanged (NM_007079513) in male cells 
(Figure 5-7).   
 
174 
 
 
 
Figure 5-7. Transcription regulators on the X chromosome with binding sites 
upstream of genes of interest. (A) The heatmap shows log2 fold changes of 
transcription factors on the X chromosome that have a predicted ability to bind within 
the enhancer regions in cGAS, Rig-I, Mda5, Tbk1, Irf1 or Irf7 and that were also 
differentially regulated post HSV-1 infection.  
(NM_020256)
(NM_001079513)
Male Female   Male Female
4 hpi 8 hpi
Taf1
Phf8
Hcfc1
Zbtb33
Zbtb33
Elk1
Hdac8
-1 -0.5 0 0.5 1
Fold change (log2)
Color Key
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Table 5-1. Details of the differential regulated transcriptional regulators on the X 
chromosome. 
 
Gene symbol Gene name Enhancer binding sites
Taf1 TATA-box binding protein associated factor 1 Ifih1 (Mda5), Ddx58 (Rigi), Irf1, Irf7, Mb21d1 (cGAS), Tbk1
Zbtb33 Zinc finger and BTB domain containing 33 Ifih1 (Mda5), Ddx58 (Rigi), Tbk1
Phf8 PHD finger protein 8 Ddx58 (Rigi), Irf1, Irf7, Tbk1
Hdac8 Histone deacetylase 8 Irf1,Irf7, Tbk1
Elk1 Ets family of transcription factors Ddx58 (Rigi), Irf1,Tbk1
Hcfc1 Host cell factor C1 Ddx58 (Rigi),Tbk1
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5.2.2.2 Transcription factors on the X chromosome affect viperin regulation 
during HSV-1 infection 
 
Next, we investigated whether these differentially regulated transcription factors on the 
X chromosome might regulate the cGAS pathway in HSV-1 infection. To do this, 
siRNA targeting Taf1, Phf8, Hdac8, Elk1, Zbtb33 or Hcfc1 were used to knock down 
gene expression in male and female cells. In brief, siRNA were transfected into male 
or female cells for 24 hours, followed by inoculation of the HSV-1 virus at an MOI of 
0.5. Viperin expression was then detected from the total RNA in the infected cells by 
qPCR and the change in level compared to mock cells was determined. 
 
When Taf1, Hdac8 or Elk1 was deficient in male and female cells, viperin regulation 
by HSV-1 infection did not differ greatly for male or female cells (Figure 5-8). 
Although viperin level was reduced in all cells with Phf8 knocked down, the difference 
between the two sexes remained. On the contrary, viperin significantly increased both 
in male and in female cells when Hcfc1 was depleted, as compared to siControl cells, 
but this increased the difference between the sexes (Figure 5-8). Most notably, viperin 
upregulation was detected in male and female cells deficient in Zbtb33, leading to a 
comparable upregulation of viperin between the sexes (Figure 5-8). The knockdown 
efficiency of each siRNA was evaluated by qPCR and is shown in Figure 5-9. Because 
two transcripts of Zbtb33 were differentially regulated between the two sexes during 
HSV-1 infection (Figure 5-7), the lentiCRISPR technique described in Section 5.2.1.1 
was done to knock out Zbtb33 in male and female cells, followed by inoculation with 
HSV-1. When Zbtb33 was knocked out, viperin regulation by HSV-1 infection was at 
a comparable level between male and female cells (Figure 5-10), consistent with the 
data in Figure 5-8A. Together, these results indicate that Zbtb33 is a key gene that is 
required for the sex difference in viperin induction during HSV-1 infection.  
 
5.2.2.3 Zbtb33 negatively regulates the cytosolic sensing pathway via Tbk1 in 
HSV-1 infection 
 
Given that Zbtb33 was negatively correlated with viperin upregulation and removed the 
sex difference in HSV-1 infection (Section 5.2.1.1), it is of interest to understand where 
Zbtb33 intervenes in the cytosolic DNA-sensing pathway. The obvious targets are those 
have been shown to be required for the sex difference in viperin regulation by HSV-1, 
including, cGAS, Tbk1 and Irf1 (Section 5.2.1.1 and Section 5.2.1.2). To investigate 
this, Zbtb33 knockout cells were prepared as described in Section 5.2.2.2 and were 
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infected with HSV-1 strain KOS for eight hours. The regulation by infection of 
candidate genes that may be modified by Zbtb33, including cGAS, Tbk1, Irf1, Irf3 and 
Irf7, was determined by qPCR. When Zbtb33 was knocked out, levels of regulation by 
infection of cGAS, Irf1, Irf3 and Irf7 were similar between knockout and control cells 
in both male and in female cells (Figure 5-11). Moreover, the sex difference in 
regulation of these genes was maintained. By contrast, Tbk1 was induced to a greater 
degree in the Zbtb33-deficient cells than control cells and in these cells there was no 
difference between the sexes in Tbk1 regulation by HSV-1 infection.  
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Figure 5-8. Effect of Zbtb33, Hdac8, Taf1, Elk1, Phf8, and Hcfc1 on viperin 
regulation in HSV-1 infection. Male or female cells from three individual mice were 
transfected with 50 nM of siRNA specific for (A) Zbtb33, (B) Hdac8, (C) Taf1 (D) 
Elk1, (E) Phf8, (F) Hcfc1, or (G) control siRNA (siControl). Cells were then inoculated 
with HSV-1 strain KOS at an MOI of 0.5. After 24 hours of infection, total RNA was 
extracted and viperin expression was measured by qPCR. Differential regulation was 
assessed by the 2 -ΔΔCT method based on expression relative mock and normalised to 
18S rRNA. The data are presented as mean ± SEM. Unpaired Student’s t-tests were 
applied to examine differences between means. Asterisks indicate values that are 
statistically significant (*p-value <0.05; ***p-value <0.001). ns, no statistically 
significant difference 
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Figure 5-9. Knockdown efficiency of siRNA specific for Taf1, Zbtb33, Phf8, Hcfc1, 
Elk1 or Hdac8 in male and female cells. RNA from the experiment in Figure 5-8 were 
used to evaluate the level of knockdown by siRNA, using qPCR with primers for the 
relevant genes. The results are shown relative to the control siRNA treatment and 
expressed as mean ± SEM. No significant difference (ns) were seen between any pair 
of male and female cells by one-way ANOVA with Tukey’s tests. 
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Figure 5-10. Zbtb33 negatively regulates viperin expression during HSV-1 
infection. (A) Male or female cells from three individual mice were transfected with 2 
μg of empty lentiCRISPR vectors or those containing gRNA targeting Zbtb33. These 
cells were infected with HSV-1 strain KOS at an MOI of 0.5 or (B) were harvested for 
Western blotting analysis using indicated antibodies. Viperin expression was measured 
by qPCR at 8 hpi. Differential regulation was assessed by the 2 -ΔΔCT method based on 
expression relative to mock and normalised to 18S rRNA. The data are presented as 
mean ± SEM. One-way ANOVA with Tukey’s tests was used to evaluate differences 
between means. An asterisk indicates values that are statistically significant (*p-value 
<0.05). ns, no significant difference. Graphs are representative of three independent 
experiments.  
A.
B.
Z
B
T
B
3
3
V
e
c
to
r
0
2 0
4 0
6 0
8 0
W T  c e lls -F ig
R
e
la
ti
v
e
 e
x
p
r
e
s
s
io
n
M ale
F e m a le
gRNA-Zbtb33          vector
*
Viperin
ns
lentiZbtb33 vector     lentiZbtb33   vector
100-
100-
ZBTB33
β-CATENIN
(kDA)
Male Female
Mal
Fe l
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 (
to
 m
o
c
k
)
181 
 
 
 
Figure 5-11. Zbtb33 negatively regulates Tbk1 induction in HSV-1 infection. Male 
or female cells from three individual mice were transfected with 2 μg of empty 
lentiCRISPR vectors or those containing gRNA targeting Zbtb33, followed by 
inoculation of HSV-1 strain KOS at an MOI of 0.5. At 8 hpi, (A) cGAS, (B) Tbk1, (C) 
Irf1, (D) Irf3 and (E) Irf7 regulation by infection was measured by qPCR. Differential 
regulation was assessed by the 2 -ΔΔCT method based on expression relative to mock and 
normalised to 18S rRNA. The data are expressed as mean ± SEM. One-way ANOVA 
with Tukey’s tests was used to examine differences between means. Asterisks indicate 
values that are statistically significant (*p-value <0.05 and ** p-value <0.01). ns, no 
significant difference. 
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In Section 3.2.5.6, we found that mRNA regulation by HSV-1 infection and protein 
levels of Tbk1 were higher in female cells than in male cells. Further, Zbtb33 seems 
likely to regulate viperin expression by inhibiting Tbk1 expression (Section 5.2.2.3), 
highlighting the importance of Tbk1 in the observed sex difference. However, a more 
accurate indication of TBK1 activity is its phosphorylation status. Therefore, the 
phosphorylated form of TBK1 was detected by WB analysis using anti-phosphorylated 
TBK1 antibody. In Figure 5-12A, more active TBK1 was produced in female cells 
compared to male cells, likely due to the higher TBK1 expression in female cells. When 
Zbtb33 was knocked out, both the basal and active form of TBK1 were significantly 
elevated and reached a similar level in cells of both sex, which correlated with viperin 
protein expression (Figure 5-12). Quantification of each band was performed by 
densitometry and expression level of basal and activated TBK1 and viperin was 
normalised to β-Catenin (Figure 5-12B). Collectively, the data suggest that Zbtb33 is a 
negative regulator of viperin through suppressing Tbk1 expression, and therefore, also 
limiting amounts of active TBK1. 
 
5.2.2.3 Zbtb33 is a proviral factor during HSV-1 infection leading to male and 
female differences in replication 
 
Lastly, we wanted to test whether the key role of Zbtb33 shown above extended to 
control of HSV-1 replication. To do this the siRNA and lentiCRISPR technique was 
employed to knock down or knock out Zbtb33 in male and female cells, which were 
then infected with HSV-1 at an MOI of 1 for 24 hours. HSV-1 titres were significantly 
lower in the Zbtb33 knockdown and knockout cells than the control (Figure 5-13A and 
Figure 5-13B). This experiment was then repeated using a very low MOI in the Zbtb33 
knockout male and female cells (Figure 5-13C and Figure 5-13D). The difference in 
virus titre and fraction of infected cells seen between male and female cells in the 
control vector cultures was not found in the Zbtb33 knockout cells. Further, in line with 
the experiment in Figure 5-13A, both measures of infection were reduced in the Zbtb33 
knockout cells. These data, along with those from the immediately previous sections, 
suggest that Zbtb33 is an important negative regulator of Tbk1 expression and thus, 
antiviral effectors, such as viperin. As a result, Zbtb33 is an important factor in the sex-
specific difference in HSV-1 replication we observed at the beginning of Chapter 3. 
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Figure 5-12. Zbtb33 negatively regulates the cytosolic sensing pathway via Tbk1 in 
HSV-1 infection. Male or female cells from three individual mice were transfected 
with 2 μg of empty lentiCRISPR vectors or those containing gRNA targeting Zbtb33, 
followed by inoculation of HSV-1 strain KOS at an MOI of 1. At 8 hpi, cell lysates 
were collected for Western blotting analysis using anti-TBK1p, anti-TBK1, anti-viperin 
and anti-β-CATENIN antibodies. (A) Bolts shown are representative of three 
independent experiments. (B) Quantification of blots by densitometry using ImageJ. 
The intensity of bands was normalised to β-CATENIN. The results are expressed as 
mean ± SEM. A linear model was employed to determine the significance of differences 
between the two sexes. Asterisks indicate values that are statistically significant (*p-
value <0.05). ns, not statistically significant; nd, not detectable. 
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Figure 5-13. Zbtb33 is a proviral factor in HSV-1 infection that leads to male and 
female differences in replication. Male or female cells from three individual mice 
were transfected with (A) 50 nM of control siRNA (siControl) or siRNA specific for 
Zbtb33 or (B-C) 2 μg of empty lentiCRISPR vectors or those with gRNA targeting 
Zbtb33, followed by inoculation of (A-B) HSV-1 strain KOS at an MOI of 1 for 24 
hours or (C-D) HSV-1 pICP47 at an MOI of 0.0001 for 72 hours. (A-C) Viral titres or 
(D) GFP percentage were then determined by plaque assays or flow cytometry 
respectively. The results are expressed as mean ± SEM. One-way ANOVAs with 
Tukey’s post-tests was applied to examine differences between means. Asterisks 
indicate values that are statistically significant (*p-value <0.05 and **p-values <0.01). 
ns, not statistically significant. 
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5.2.3 Role of Xist in regulating an antiviral pathway and therefore HSV-1 
replication in female cells 
 
The results in Section 5.2.2 revealed that Zbtb33, a transcription factor on the X 
chromosome, is downregulated in female cells but not in male cells. It then regulates 
Tbk1 expression and influences viperin regulation by HSV-1 infection. This section 
aims to identify a factor upstream of Zbtb33 that only downregulates genes in females, 
not in males. We chose Xist as a reasonable candidate due to both its function and its 
upregulation during HSV-1 infection (Pasieka et al., 2006). One of the two X 
chromosomes in female mammals is transcriptionally silenced during embryogenesis 
to balance the dosage of gene expression between the two sexes. This is called X 
chromosome inactivation (Brockdorff and Duthie, 1998; Kay, 1998). Xist, a long non-
coding RNA, is a main mediator of this process, inducing a series of events leading to 
stable silencing by accumulating repressive marks on the future inactive X chromosome 
(Leung and Panning, 2014; da Rocha and Heard, 2017). However, it has been observed 
that some X-linked genes are subject to regulation beyond dosage compensation by Xist 
(Disteche et al., 2002; Berletch et al., 2011). As noted above, Xist was found to be 
upregulated during HSV-1 infection in mouse embryonic fibroblasts in a previous 
microarray experiment (Pasieka et al., 2006). Further, our RNA-seq results found that 
Xist was induced at 4 and 8 hpi, but only in female cells. So we examined a set of X-
linked genes that have been reported to be regulated by Xist beyond dosage 
compensation. These are illustrated in a heatmap, based on our RNA-seq analysis, in 
Figure 5-14 (Gayen et al., 2016; Lv et al., 2016; da Rocha and Heard, 2017). Many of 
these genes were downregulated by HSV-1 infection in female cells but not male cells 
at 8 hpi, consistent with the idea that increased Xist during HSV-1 infection is able to 
drive changes in gene expression. 
 
5.2.3.1 Xist inhibits Zbtb33 and therefore, regulates Tbk1 and antiviral gene 
expression during HSV-1 infection 
 
Firstly, the upregulation of Xist in HSV-1 infection was confirmed by qPCR. Male and 
female cells were infected with HSV-1 strain KOS at an MOI of 0.5 for four and eight 
hours. The expression of Xist was then analysed by qPCR using a specific primer set 
targeting mouse Xist (Table 2-7). Compared to the mock cells, Xist expression was 
around 10-fold higher at 4 hpi, increasing to 20-fold higher at 8 hpi in female cells 
(Figure 5-15A). However, this was not observed in male cells. Next, to identify whether 
Xist regulates Zbtb33 and genes in the cytosolic DNA-sensing pathway during HSV-1 
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infection, siRNA was utilised to knockdown Xist, and the regulation by HSV-1 of 
Zbtb33, Tbk1 and viperin were detected by qPCR. The knockdown efficiency of Xist in 
these cells was also determined by qPCR and were found that Xist expression was 
reduced by 80-90% in female cells. Conversely, there was no effect on the male cells 
(Figure 5-15B), which was expected because somatic cells in male mice generally do 
not express any Xist (Kay et al., 1993). Strikingly, when Xist was depleted in female 
cells before infection, Zbtb33 regulation by infection was rescued to a similar level as 
that in male cells (Figure 5-15C), suggesting that HSV-1-induced Xist has the ability to 
reduce Zbtb33 expression in female cells. Furthermore, both Tbk1 (Figure 5-15D) and 
viperin (Figure 5-15E) upregulation by HSV-1 infection in female cells were reduced 
to levels comparable with male cells after Xist knockdown. These findings support the 
idea that upregulation of viperin and other antiviral effectors in female cells is due to 
the release of Tbk1 expression from regulation by Zbtb33, via induction of Xist during 
HSV-1 infection.  
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Figure 5-14. Changes in expression of genes known to be negatively regulated by 
Xist during HSV-1 infection. Using our data from RNA-seq experiment, log2 fold 
changes of published target genes of Xist at 4 and 8 hpi are shown in a heatmap. Red 
and blue indicate high and low regulation, respectively.  
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Figure 5-15. Xist is induced by HSV-1 in female cells and controls the regulation 
of Zbtb33, Tbk1 and viperin. (A) Xist expression was measured by qPCR in male and 
female cells from three individual mice infected with HSV-1 pICP47 recombinant virus 
at an MOI of 0.5 for four and eight hours. (B-E) Male and female cells were transfected 
with 50 nM of control siRNA (siControl) or siRNA specific for Xist and then infected 
with HSV-1 at an MOI of 0.5 for eight hours. Following this, (B) Xist, (C) Zbtb33, (D) 
Tbk1, or (E) viperin mRNAs were measured by qPCR. The results are presented as 
mean ± SEM. One-way ANOVAs with Tukey’s tests was applied to examine 
differences between means. Asterisks indicate values that are statistically significant 
(*p-value <0.05; **p-value <0.01; ***p-value <0.001). ns, not statistically significant. 
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5.2.3.2 Silencing Xist eliminates the difference in HSV-1 growth in male and 
female cells 
 
While Xist is important for the sex difference in Zbtb33 regulation by infection (Section 
5.2.3.1), it remained to be shown whether it also altered HSV-1 replication. For this 
reason, we examined the growth phenotypes of HSV-1 in male and female cells lacking 
Xist expression. Cells depleted with Xist or control cells were infected with HSV-1 at 
an MOI of 0.0003, followed by titration using plaque assays at indicated time points. 
In male cells, there was no difference in HSV-1 replication between control and Xist 
knockdown cells (Figure 5-16A). By contrast, HSV-1 replicated significantly more 
efficiently in female cells lacking Xist than in the control female cells. In addition to 
viral titres, the infected cell populations at 72 hpi were measured and these results 
showed that Xist knockdown increased the spread of HSV-1 in female cultures (Figure 
5-16B). These data indicate that induced Xist is required for the difference in HSV-1 
replication between male and female cells.  
 
5.2.3.3 Xist regulates sensing of DNA and HSV-1 replication in a human cell line. 
 
Since HSV-1 is a human pathogen, we further examined whether the regulatory circuit 
described in Section 5.2.2 and Section 5.2.3 occurs in human female cells. To address 
this, we used HeLa cells, because they are commonly used for virology research and 
we found viperin upregulation in these cells after HSV-1 infection (Figure 4-4). HSV-
1 induced Xist expression significantly above mock levels in HeLa cells (Figure 5-17A). 
The induction of Xist reduced Zbtb33 expression (Figure 5-17B) and positively 
correlated with Tbk1 and viperin regulation (Figure 5-17C and Figure 5-17D) as shown 
by an siRNA knockdown experiment. In the same manner observed in mouse cells, 
knockdown of Zbtb33 demonstrated that this gene impacted Tbk1 and viperin 
upregulation by HSV-1 infection in HeLa cells (Figure 5-17E and Figure 5-17F). 
Lastly, a knockdown of Xist in HeLa cells increased HSV-1 yields and the percentage 
of infected cells (Figure 5-17G and Figure 5-17H). Taken together, HeLa cells act 
similarly to female mouse cells during HSV-1 infection. That is, the upregulation of 
Xist reduces Zbtb33 upregulation leading to increased Tbk1 and antiviral effector 
expression, which inhibits HSV-1 replication.  
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Figure 5-16. Xist is required for reduced HSV-1 replication in female cells 
compared with male cells.  Male or female cells from three individual mice were 
transfected with 50 nM of siRNA specific for Xist (siXist) or control siRNA (siControl) 
and were then infected with HSV-1 pICP47 recombinant virus at an MOI of 0.0003. 
(A) Viral yields were evaluated at indicated time points by plaque assays and (B) GFP 
percentage was measured at 72 hpi. The results are presented as mean ± SEM. Two-
way ANOVA and one-way ANOVA with Tukey’s tests were applied to test differences 
between means in (A) and (B) respectively. Asterisks indicate values that are 
statistically significant (**p-value <0.01). ns, not statistically significant. 
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Figure 5-17. Xist is induced in HeLa cells and regulates HSV-1 infection. (A) HeLa 
cells were infected with HSV-1 pICP47 recombinant virus at an MOI of 1 and Xist 
expression was then determined by qPCR at 24 hpi relative to mock. (B-H) HeLa cells 
were transfected with 50nM of control siRNA (siControl) or siRNA specific for  Xist 
(B-D and G-H) or  Zbtb33 (E-F), followed by inoculation of HSV-1 pICP47 
recombinant virus at an MOI of 1. (B) Zbtb33, (C and E) Tbk1, and (D and F) viperin 
expression were then measured by qPCR at 24 hpi relative to mock. (G) Viral titres and 
(H) GFP percentage were determined by plaque assays and evaluated by flow 
cytometry, respectively, at 48 hpi. Unpaired Student’s t-tests were performed to test 
differences between means. Asterisks indicate values that are statistically significant 
(*p-value <0.05; **p-value <0.01; ***p-value <0.001). 
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5.2.4 HSV-1 genes involved in the upregulation of Xist 
 
Based on the results in Section 5.2.3, we found that Xist is required for the sex-specific 
difference in HSV-1 replication. However, how HSV-1 might induce Xist expression 
was not clear. To address this, we first narrowed down the range of possible viral 
functions that might be involved by treating cells with cycloheximide during infection 
to inhibit protein synthesis. In the absence of protein synthesis, Xist upregulation was 
still detected in female cells (Figure 5-18). These data indicate that de novo protein 
expression was not required for Xist upregulation. This also ruled out non-specific 
effects of virus infection on cells. Instead, it suggests that HSV-1 proteins carried into 
cells by the virion may play a role in regulation of Xist. Apart from structural 
components, herpesvirus virions have a store of proteins that are carried into cells to 
carry out functions that prepare the cell for virus replication or that act as transcription 
factors for viral IE genes. These proteins are in the tegument of the virion so that we 
examined the list of HSV-1 tegumant proteins for likely candidates for Xist regulation. 
The first one was VP16, a viral transcription factor that recognizes an octamer motif, 
of which we found two copies upstream of Xist in the promoter region (Figure 5-19). 
The other one was ICP34.5, which is a neurovirulence factor and a regulator of 
TBK1/IRF3 signalling (Wilcox and Longnecker, 2016; Manivanh et al., 2017). Further, 
we found that a HSV-1 lacking this gene is unable to upregulate Xist in a published 
microarray data set (Pasieka et al., 2006). These genes were cloned into expression 
vectors and transfected into male and female cells to see if either or both together might 
induce Xist expression. When we overexpressed VP16 alone, it did not significantly 
increase Xist regulation in female cells compared with male cells (Figure 5-20). 
Expression of ICP34.5 had a modest effect on Xist RNA level, but co-expression of 
these two genes led to substantial Xist upregulation. Collectively, these data show that 
VP16 and ICP34.5, which are carried into cells by the HSV-1 virion, can co-operate to 
induce Xist expression. 
 
5.2.5 Sex differences between male and female cells in other DNA viruses 
 
The mechanism established above suggests that the difference in virus replication 
between male and female cells discovered in this study may be an HSV-1-specific 
phenomemnon. To explore this possibility, given that we discovered sex-related 
differences in a DNA sensing pathway during HSV-1 infection, we selected another 
three large DNA viruses to look for differences in replication between male and female 
cells. These included another herpesvirus, mouse cytomegalovirus (MCMV) and two 
poxviruses, VACV and cowpox virus (CPXV). CPXV, but not MCMV and VACV, 
193 
 
showed a significant difference in replication in male and female cells inoculated with 
very low doses of virus (Figure 5-21). Next, we asked whether Xist might be involved 
in the reduced replication of CPXV using the same siRNA knockdown approach used 
with HSV-1. When Xist was knocked down, this did not alter the difference in CPVX 
replication between male and female cells (Figure 5-22). The results suggest that effect 
of Xist on virus replication may be HSV-1-specific, but implies that there are multiple 
mechanisms that can result in sex-related differences in virus replication in cell cultures.  
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Figure 5-18. Xist regulation by HSV-1 infection in male and female cells treated 
with cycloheximide. Male and female cells from three individual mice were pretreated 
with 100 µg/ml cycloheximide for one hour, followed by inoculation of HSV-1 pICP47 
recombinant virus at an MOI of 0.5 in the media containing 100 µg/ml cycloheximide. 
Xist expression was then measured by qPCR at 8 hpi. Differential regulation was 
assessed by the 2 -ΔΔCT method based on expression relative to mock and normalised to 
18S rRNA. The results are expressed as mean ± SEM. One-way ANOVAs with Tukey’s 
tests was applied to test differences between means. ns, not statistically significant. 
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Figure 5-19. A schematic diagram of sequence near the start codon of Xist (-400~+100). The sequence started from -400 to +100 of Xist is 
shown. Red highlights the start codon of Xist. Yellow shows two predicted octamer motifs for VP16 binding with the consensus sequence 
“TAATGARAT”. Note that the first one is a relatively poor match and exists on the opposite strand. 
-301~-400
-201~-300
-101~-200
-1~-100
+1~+100
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Figure 5-20. Effects of overexpression of VP16 and/or ICP34.5 on Xist regulation. 
Male and female cells from three individual mice were transfected with 2 µg of 
plasmids expressing VP16 or ICP34.5 or were co-transfected with 1 µg of each of these 
plasmids. Xist expression was then determined by qPCR at 24 post transfection. 
Differential regulation was assessed by the 2 -ΔΔCT method based on expression relative 
to control transfectants and normalised to 18S rRNA. The results are shown as mean ± 
SEM. One-way ANOVAs with Tukey’s tests was applied to test differences between 
means. Asterisks indicate values that are statistically significant (**p-value <0.01 and 
***p-values <0.001). ns, not statistically significant. 
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Figure 5-21. VACV, CPXV, MCMV and HSV-1 replication in male and female 
cells. Male and female cells from three individual mice were infected with VAVC (MOI 
0.0001), CPVX (MOI 0.00001), MCMV (MOI 0.00001) and HSV-1 (MOI 0.0001). 
Viral titres were then measured by plaque assays at 72 hpi. The results are expressed as 
mean ± SEM. One-way ANOVAs with Tukey’s tests was applied to test differences 
between means. Asterisks indicate values that are statistically significant (*p-value 
<0.05). ns, not statistically significant.  
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Figure 5-22. Replication of CPXV in Xist-kockdown cells. Male and female cells 
from three individual mice were transfected with 50 nM of control siRNA (siControl) 
or siRNA specific for Xist for 24 hr, followed by inoculation of CPXV at an MOI of 
0.00001. Viral titres were measured by plaque assays at 72 hpi. The results are shown 
as mean ± SEM. One-way ANOVAs with Tukey’s tests was applied to test differences 
between means. Asterisks indicate values that are statistically significant (**p-value 
<0.05).  
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5.3 Discussion 
 
In this chapter, a mechanism that regulates the sex-specific difference in HSV-1 
infection via nucleic acid sensors was dissected. We found that cGAS and Tbk1 in the 
cytosolic sensing pathway are two key players in a nucleic acid-sensing pathway 
required for differential upregulation of viperin between male and female cells (Figure 
5-1). Higher upregulation of Irf1 in female cells led to higher cGAS expression (Figure 
5-6), although current data do not identify a ligand that stimulates Irf1 upregulation. 
Furthermore, we then linked our observations to sex chromosomes by showing that an 
X-linked transcription factor (Zbtb33) is important for regulating Tbk1 and therefore 
downstream antiviral effectors between the sexes (Figure 5-12). Next, a sex-specific 
gene (Xist) was shown to explain the difference in Zbtb33 expression and HSV-1 
replication (Figure 5-16). Finally, two HSV-1 tegument proteins, namely VP16 and 
ICP34.5 were shown to be able to induce Xist expression in female cells. A schematic 
diagram of this mechanism is presented in Figure 5-23. 
 
Mossman’s lab has used many approaches to find support for a model whereby the first 
line of innate antiviral defence in response to enveloped viruses, including HSV-1 and 
HCMV, occurs before virus replication (Mossman et al., 2001; Collins et al., 2004; 
Paladino et al., 2006). This mechanism is characterised by the induction of a subset of 
ISGs independent of TLRs and NF-κB in response to cytoplasmic DNA, following the 
activation of the TBK1/IRFs pathway, during a low MOI infection in fibroblasts and 
epithelial cells (Lin et al., 2004; Paladino et al., 2010; Noyce et al., 2011). Similarly, 
we found that IRFs such as IRF1, IRF3 and IRF7 are essential for viperin induction in 
mouse skin fibroblasts during low MOI infection with HSV-1 (Figure 5-3). Previous 
findings suggesting that IRF1 also controls IFN-independent signalling via peroxisomal 
MAVS for rapid ISG upregulation in a conventional manner at the bottom of a nucleic 
acid-sensing pathway (Dixit et al., 2010). However, we show evidence here for a novel 
mechanism whereby Irf1 acts upstream of nucleic acid sensing by regulating cGAS 
expression and thereby, potentiates an innate immune response in HSV-1 infection 
(Figure 5-6). Presumably, this is the result of sensing some other aspect of infection, 
but this remains unknown. Binding of viral particles to the cell surface is not sufficient 
to elicit IFN-mediated pathways. Therefore, if the signalling cascades upstream of IRFs 
are independent of nucleic acids and viral structural components (Nicholl et al., 2000; 
Mossman et al., 2001; Paladino et al., 2006; Tsitoura et al., 2009), the most reasonable 
explanation may be that membrane fusion triggered by enveloped viruses, such as HSV-
1 and HCMV, results in activation of IRFs through ion transport (Hare et al., 2015). 
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We speculated that this may be the case in our model, where neither RIG-I family 
members, the sensor upstream of MAVS, nor Tlr3 or Tlr4 had as strong an impact on 
virperin expression as cGAS and Irf1. 
 
In addition to cGAS, Tbk1 is another factor that is required for the sex difference in 
viperin regulation by infection (Figure 5-1). As Tbk1 was not regulated by Irf1 in our 
experiments (Figure 5-5), we further searched transcription factors on the sex 
chromosomes that may function upstream of the cytosolic sensing pathway during 
HSV-1 infection. Approximately 1,000 genes are expressed on the X chromosome, 
most of which are distinct from the fewer than 100 genes that are encoded by the Y 
chromosome (Fish, 2008; Klein and Flanagan, 2016; Roved et al., 2017). This 
biological character may contribute to the lack of potential candidates on the Y 
chromosome for transcriptional regulation of cGAS, Mda5, Rig-I, Tbk1, Irf1 or Irf7. 
Therefore, it was considered more likely that a potential candidate would be on the X 
chromosome. Several transcription regulators on the X chromosome were predicted to 
modify expression of the genes mentioned above, and so whether they could affect an 
antiviral pathway in male and female cells was further examined (Figure 5-7 and Figure 
5-8). Of these genes, only the knockdown of Zbtb33 reduced the difference in viperin 
induction and virus replication between male and female cells after infection with HSV-
1. Zbtb33, also known as Kaiso, is a 95-kDa Zinc finger transcription factor that has 
been implicated in regulation of the cell cycle and tumour cell invasion (Pozner et al., 
2016; Wang et al., 2016a; Bassey-Archibong et al., 2017). Zbtb33 is recruited into the 
nucleus where it suppresses gene expression by binding to methylated CpG motifs in 
response to extracellular signals and then forms the repressor complex with the histone 
deacetylase-nuclear receptor (Yoon et al., 2003; Buck-Koehntop et al., 2012).  
 
To date, there is no literature that has found a role for Zbtb33 in the innate immune 
response. However, Zhenilo et al. (Zhenilo et al., 2018) found that ZBTB33 is a 
transcriptional repressor for Trim25 during hyperosmotic stress. TRIM25 is an E3 
ubiquitin ligase enzyme with multiple functions, including regulation of the innate 
immune response against viruses (Gack et al., 2007; Castanier et al., 2012; Martin-
Vicente et al., 2017). TRIM25 has been well-characterised for its role in the regulation 
of RIG-I signalling and therefore, IFN-β production in response to viral infection in 
mouse embryonic fibroblasts (Sanchez et al., 2016; Martin-Vicente et al., 2017). 
Herein, our RNA-seq data found that Trim25 regulation by HSV-1 was inversely related 
to Zbtb33 and was stimulated to a higher degree in female cells (data not shown). This 
pathway should be investigated to determine if it contributes to the effect of Zbtb33 
regulation by HSV-1 infection in female cells. 
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In our model, Zbtb33 was found to negatively regulate Tbk1 expression, and hence, 
levels of activated TBK1. Tbk1 is an essential transducer which receives signals from 
different pathogen-associated molecular patterns, TLRs and cytosolic receptors post-
recognition of foreign pathogens (Weidberg and Elazar, 2011). As TBK1 signalling 
plays a pivotal role in signal transduction, HSV-1 deploys at least two proteins, the IE 
protein ICP27 and the tegument protein UL46 to target this signalling pathway. The 
action of these proteins prevents phosphorylation of IRF3 to evade cellular sensing in 
human macrophages and epithelial cells (Christensen et al., 2016; Deschamps and 
Kalamvoki, 2017). We did not explore the role of these proteins in our model, but they 
add to the complexity of HSV-host interaction and so this should be examined. 
 
Another key finding of this chapter is that Xist is induced by HSV-1 infection in female 
cells. This process increases antiviral responses through restricting Zbtb33 induction 
(Figure 5-15). This also explains the different growth phenotypes whereby HSV-1 was 
found to replicate more efficiently in male cells than female cells after inoculation with 
very low doses of virus (Figure 5-16). This complete pathway starting with Xist 
upregulation and ending in reduced HSV-1 replication was also found in the human 
female cell, HeLa. However, the extent of differences in the regulation of target genes 
and virus replication seen when Xist was knocked down was modest compared with 
female mouse cells. This may be a species difference, or something particular to HeLa 
cells. For example, it has been noted that these cells have high level of Xist expression 
(Sun et al., 2018), but it is unclear what this might mean for our model. 
 
Xist is a non-coding RNA expressed from the X chromosome and it is involved in X-
linked gene silencing by recruiting a protein complex to the future inactive X 
chromosome in female mammals during early embryonic development (Brockdorff and 
Duthie, 1998; Kay, 1998). X-inactivation serves as a compensation mechanism to 
achieve dosage equivalence for X-linked genes between males and females. Currently, 
most studies focus on the relationship between Xist and cancer since Xist is crucial for 
the regulation of different types of cancers (Lopes et al., 2008; Dai et al., 2010; Yildirim 
et al., 2013; Yu et al., 2017). For example, X reactivation leads to genome-wide changes 
driving induction of an aggressive and lethal blood cancer specific to females (Yildirim 
et al., 2013). However, this study is the first to link levels of Xist to control of an 
immune process. X-inactivation does not achieve perfect dosage compensation as 
described for more and more genes (Berletch et al., 2011; Mugford et al., 2014; 
Disteche and Berletch, 2015). While over-expression of X-linked genes in females has 
been examined as a reason for sexually dimorphic immune responses, under-
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expression, such as we described for Zbtb33, has not been suggested previously, neither 
has the role of Xist in this context. However, Xist plays crucial roles in various 
multigenetic human diseases, including cancers, neurological diseases and autoimmune 
diseases (Agrelo and Wutz, 2010; Seton-Rogers, 2013). Moreover, recent studies have 
reported that differentiation of B cells has correlation with Xist expression and the 
inactive X chromosome is predisposed to become partially reactivated particularly in 
female lymphocytes (Wang et al., 2016b; Syrett et al., 2017).  
 
Two HSV-1 genes were found to cooperatively induce Xist expression. VP16 is a 
transcriptional activation of viral immediate early genes and there are two octamer 
binding motifs of VP16 in the promoter region of Xist (Figure 5-19). This background 
supported VP16 as a potential candidate for understanding Xist regulation. However, 
surprisingly, overexpression of VP16 alone did not lead to upregulation of Xist (Figure 
5-20). We then found a published microarray data set showing HSV-1 ICP34.5, but not 
an ICP34.5 deletion mutant of HSV-1, induces Xist expression, though Xist was not 
mentioned in the paper (Pasieka et al., 2006). We found upregulation of Xist in female 
cells expressing ICP34.5 and this became more pronounced if VP16 was co-expressed 
(Figure 5-20). VP16 and ICP34.5 serve multiple functions and both have been shown 
to interfere with TBK1/IRF3 signalling. Of relevance here, while some direct 
interaction have been reported, there are also some indirect effects (Xing et al., 2013; 
Manivanh et al., 2017). However, the relative effects of any direct effect of these 
proteins and the indirect effect we show here via Xist in female cells remains unknown. 
This point reinforces the importance of taking the sex of cells into account when 
dissecting the roles of viral genes.  
 
Finally, we investigated whether the sex-specific difference in virus replication found 
for HSV-1 might occur for other large DNA viruses. We found that in addition to HSV-
1, CPXV replicated more efficiently in male cells than in female cells, but no difference 
was noted for VACV or MCMV (Figure 5-21). We note that for MCMV in particular, 
primary skin fibroblasts are not an especially relevant host cells. So perhaps a sex 
difference might be found in other cell types. In addition, there remains many viruses 
and cell types where sex may play a role. Coming back to CPXV, the difference in viral 
titres was not changed by knockdown of Xist (Figure 5-22). Overall, these data suggest 
that there are multiple mechanisms leading to sex-related differences in virus 
replication in cells. Further, the effect of knocking down Xist on virus replication 
appears to be HSV-1-specific and not a pan-viral effect, or a derangement of these cells 
such that they no longer support virus replication. 
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Figure 5-23. A schematic diagram of HSV-1-triggered cytosolic sensing pathway 
in male and female cells. During HSV-1 infection, female cells induce higher IRF1 
which acts upstream of cGAS to drive viperin upregulation. In addition, upregulation 
of Xist in female cells leads to inhibition of Zbtb33, and therefore, enhancement of Tbk1 
regulation and function, which finally contributes to greater antiviral activity against 
HSV-1 infection in female cells. 
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Chapter 6. Different responses 
between human and mouse cells 
during HSV-1 infection. 
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6.1 Introduction 
 
Humans are the only natural host for HSV-1, but investigating infections in humans is 
difficult for several reasons, including the fact that primary infections are frequently 
asymptomatic (Klysik et al., 2018). Likewise, HSV-1 establishes latency in sensory 
neurons, such as trigeminal ganglia or dorsal root ganglia, which makes investigation 
of the immune mechanism that controls the reactivation of latent infection in humans 
more complicated (Jones, 1998; Preston and Efstathiou, 2007; Grinde, 2013). This is 
because the only access to collect human nervous samples are from post-mortem 
samples (Schmutzhard, 2001; Steiner, 2011). Therefore, animal models have been 
developed to achieve a better understanding of HSV-1 pathogenesis. Mouse models are 
frequently used to study HSV diseases (Mester and Rouse, 1991; Brandt et al., 1992; 
Parr et al., 1994). Different routes of HSV-1 infection, including flank skin, corneal 
epithelium and footpads, have been used to examine various stages and types of HSV 
infection (Kollias et al., 2015). Even though there are many HSV-1 models, the 
translation of murine experimental results to human diseases remains challenging, not 
least because of species-specific differences that may exist in the host responses to the 
virus. 
 
Several lines of evidence have shown that host cells respond in species-specific ways 
to HSV-1 infection. For example, both caspase-8-mediated apoptosis and RIP3-induced 
necroptosis are suppressed in human cells by the large subunit of the HSV-1 
ribonucleotide reductase (Langelier et al., 2002; Yu et al., 2015). By contrast, after 
sensing HSV-1, mouse cells directly induce necroptosis which inhibits virus replication 
(Guo et al., 2015a; Guo et al., 2015b). In another case, ICP47, an IE protein of HSV-1, 
efficiently blocks MHC class I antigen presentation to CD8+ T cells via inhibition of 
the human transporter associated with antigen presentation (TAP) (York et al., 1994; 
Fruh et al., 1995). However, mouse TAP is relatively resistant to inhibition by the HSV-
1 ICP47 protein, and therefore, mouse fibroblasts infected with HSV-1 are effectively 
lysed by anti-HSV CD8+ cytotoxic T lymphocytes (CTL), as compared to human cells 
(Ahn et al., 1996; Jugovic et al., 1998). Our data also show human-mouse differences 
against HSV-1 replication whereby viperin is upregulated in mouse skin fibroblasts but 
not significantly in human cells such as HFF, MRC5 and HEK293 cells and relatively 
poorly in HeLa cells (Section 4.2.1.3). However, to date, there is no global 
understanding and investigation of human-mouse differences in HSV-1 infection. 
Hence, the aim of this chapter was to investigate overall differences between human 
and mouse cells in the regulation of transcription during HSV-1 infection. 
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6.2 Results 
 
Two human cell lines and one mouse cell type were used in this chapter, including 
primary human foreskin fibroblasts (HFF), an immortalised human cell line, MRC5 and 
primary male mouse skin fibroblasts. Both HFF and MRC5 are from males. In order to 
avoid the sex difference, mouse skin fibroblasts (MF) and IFNAR-/- cells were only 
collected from male mice in this chapter. Data from HFF and MRC5 are from replicate 
infections, but for the mouse cells, we generated and infected cultures from individual 
mice, as in the previous chapters. 
 
6.2.1 Different HSV-1 growth phenotypes between human and mouse cells 
 
To investigate whether HSV-1 replication differs between human and mouse cells in 
our fibroblast culture model, single and multi-step growth experiments were done in 
two human cell lines (HFF and MRC5) and in primary male mouse fibroblasts (MF). 
HSV-1 yields were comparable in the three tested cell types in a single round infection, 
indicating all cultures support basic HSV-1 replication (Figure 6-1A). The pattern of 
the multi-step growth curves of HSV-1 in HFF and MRC5 were similar, but differed 
markedly from that generated using mouse cells (Figure 6-1B). The data indicated that 
there was significantly more HSV-1 replication in the human primary and immortalised 
cells than in primary mouse cells. Taken together, these results suggest that human and 
mouse cells may respond differently to HSV-1 in vitro with mouse cells being able to 
limit virus replication compared with human cells. 
 
6.2.2 Infection rate of HSV-1 pICP47 recombinant virus in HFF, MRC5 and MF 
 
In order to set up a suitable MOI and suitable infection time points for investigation of 
transcriptional differences, we then infected human and mouse cells with HSV-1 
pICP47 that expresses GFP to allow infection to be monitored by flow cytometry. 
About 70% of cells were GFP-positive when HFF, MRC5 and MF were infected with 
HSV-1 pICP47 recombinant virus at an MOI of 0.5 for four hours. After eight hours of 
infection, infection rates increased to around 85% among these three cells (Figure 6-2). 
However, there was no significant difference in infection rate across the four cell types 
at either time. 
 
6.2.2.1 Transcriptional analysis by RNA-seq for HSV-1-infected HFF, MRC5 and 
MF  
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The transcriptional analysis presented here was an extension of the RNA-seq 
experiment described in Chapter 3 (Section 3.2.5.2). Given that HFF and MRC5 are 
male human cells, RNA-seq data from male mouse cells (Section 3.2.5) were 
incorporated for downstream analysis. The male mouse cell cultures used here were the 
same that we used for comparison with female mouse cells.  
 
HFF and MRC5 cells were infected at the same time with the same conditions (See 
Section 2.2.15). To reduce any confounding data from uninfected cells, as mentioned 
in Section 3.2.5.1, sorting was employed to collect infected cell populations based on 
the GFP signals in the triplicates of HHF and MRC5 post HSV-1 pICP47 virus 
infection. Total RNA was isolated from sorted cells for library preparation and then 
subjected to RNA-seq using the Illumina platform as described in Section 2.2.15. A 
customised pipeline for cross-species analysis were used to identify comprehensive 
differences between human and mouse cells during HSV-1 infection.  
 
6.2.3 Expression of HSV-1 genes in HFF, MRC5 and MF 
 
The resulting reads from the HFF and MRC5 samples were aligned to the human 
genome and those from MF were mapped against the mouse genome, as described in 
Section 3.2.5.2. The unmapped reads were then aligned to the sequence of the HSV-1 
KOS strain that had been modified to remove repeat regions in the genome. More detail 
on the analysis of HSV-1 transcripts is given in Section 2.2.31.4. Expression of 
individual HSV-1 genes is plotted in a heatmap (Figure 6-3). Each replicate of HFF, 
MRC5 and MF clustered together, indicating that there was no significant difference 
between each replicate. Samples clustered first by infection time. At 4 hpi they clustered 
according to species, but at 8 hpi the two primary cell types (HFF and MF) were 
clustered together and the immortalized MRC5 was the outlier. Despite the fact that 
replicate infections were used for the human cell lines and independently derived cells 
were used for mouse cultures, in each case the clustering by cell type was similarly 
close. 
 
To observe the dynamic change in HSV-1 gene expression between the two time points, 
gene abundance of HSV-1 between the mouse and two human cell types at 4 and 8 hpi 
was plotted in genome coverage figures (Figure 6-4). Changes in the expression of 
individual viral genes between 4 and 8 hpi were observed and these data generally 
reflected the established viral gene expression patterns for HSV-1 infection. Although 
some regions were appeared to be regulated slightly differently across these three cell 
types, such as UL4 in HFF at 8 hpi, there were no statistically significant differences 
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for any HSV-1 gene between human and mouse cells at either time based on the 
selection criteria: p-value <0.05 and log2 fold change >1.   
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Figure 6-1. Growth kinetics of HSV-1 in human and mouse cells. (A) Triplicate 
cultures of HFF and MRC5 or MF from three individual mice were infected with HSV-
1 pICP47 recombinant virus at an MOI of (A) 10 or (B) 0.001 and then cell lysates were 
collected at the indicated time points. Plaque assays were performed to measure viral 
titres. The results are expressed as mean ± SEM. Two-way ANOVA with Tukey's post-
tests was used to test differences between means across the growth curves. ***p <0.001. 
ns, no significant difference. 
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Figure 6-2. Infection rate of HSV-1 in HFF, MRC5 and MF. Triplicate cultures of 
HFF and MRC5 or MF from three individual mice were infected with HSV-1 pICP47 
recombinant virus at an MOI of 0.5 for four or eight hours and then analysed by flow 
cytometry. The percentages of cells that were GFP positive are presented in a bar chart 
and expressed as mean ± SEM. One-way ANOVAs with Tukey’s tests was applied to 
analyse differences between means. ns, no significant difference. 
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Figure 6-3. Expression of HSV-1 genes in HFF, MRC5 and MF at 4 and 8 hpi. 
Reads that mapped to the HSV-1 genome were converted into counts per million (CPM) 
using the featureCounts package. The log2 CPM of each HSV-1 gene at 4 and 8 hpi, in 
three replicates of HFF and MRC5 and MF from three mice were clustered by 
hierarchical average linkage clustering and Euclidean distances. The density of reads 
mapping to each gene is colour-coded according to the color key above (red=high 
density, blue=low density). 
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Figure 6-4. Location and relative coverage of mapped reads across the HSV-1 genome. The position of reads at 4 and 8 hpi between HFF and 
MRC5 or MF are marked relative to a map of HSV-1 genes. In order to compare gene abundance between the different cell types, the scales of the 
plots were normalised to the total reads. The modified genome is shown without the long and short terminal repeats in the HSV-1 genome and 
sequences in these two regions are represented in the internal repeats. 
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6.2.4 Distinct gene regulation by HSV-1 infection between human and mouse cells  
 
Reads that mapped to the human genome in HFF and MRC5 or those mapped to the 
mouse genome in MF were calculated by the featureCounts package and were then 
transferred into CPM (Liao et al., 2014). The trimmed mean of the log expression ratios 
(trimmed mean of M values) was used to normalise each library using edgeR (Robinson 
et al., 2010). Ensembl IDs were then converted into gene symbols and shared gene 
symbols between humans and mice were used for an analysis of differentially regulated 
genes using the limma package (Law et al., 2014; Ritchie et al., 2015). A detailed 
description of the analysis of the cross-species data is provided in Section 2.2.31.3.  
 
Expression of the top 500 genes was analysed by multidimensional scaling (MDS) to 
visualise the similarity between individual samples (Figure 6-5). Each replicate 
clustered together, but all different infection times were separated in human and mouse 
samples. In addition, mouse cell samples were located a substantial distance from the 
two human cell types on a plot of the first two dimensions (Figure 6-5), suggesting 
substantial differences in gene expression between the species at all times.  
 
Next, hierarchical clustering of all host transcript levels in each RNA-seq sample was 
arranged as a heat map. This figure further confirms the high reproducibility of the 
transcriptional signature within each infection condition with replicates clustering 
together. It also shows that human and mouse cells were transcriptionally distinct before 
and during HSV-1 infection, as all mouse samples were clustered together and away 
from the two human samples (Figure 6-6). 
 
Next fold changes in host gene expression at 4 and 8 hpi were calculated by comparison 
with mock infected samples, HFF and MRC5 shared high similarity in RNA regulation 
by HSV-1 infection, with Pearson’s correlations of 0.76 and 0.81 at 4 and 8 hpi (Figure 
6-7A and Figure 6-7C). However, the correlation of regulation of orthologous genes 
between primary human (HFF) and primary mouse cells (MF) was extremely low at 
both times (Figure 6-7B and Figure 6-7D). Taken together, the data show that human 
and mouse cells are transcriptionally distinct and respond to HSV-1 infection with 
different transcriptional changes. 
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Figure 6-5. Multidimensional scaling analysis of transcriptome data from human 
and mouse cell samples during HSV-1 infection. Multidimensional scaling analysis 
was conducted based on the expression of the top 500 genes from the mock, 4 or 8 hpi 
samples of each cell type and their position over dimensions 1 and 2 are shown. Mock, 
4 hpi and 8 hpi samples are presented in black, blue and red with three replicates. □, 
HFF; ○, MRC5; Δ, MF. 
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Figure 6-6. Distinct transcriptional profiles between human and mouse cells 
before and during HSV-1 infection. Hierarchical clustering of expression level of 
each orthologous gene in HFF, MRC5 and MF at 4 hpi, 8hpi and mock is shown. The 
vertical dendrogram shows the clustering of each sample and its infection condition 
according to similarities in transcript expression. Red refers to relatively high 
expression and blue refers to relatively low expression. The expression value for each 
gene is given based on log2 CPM. 
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Figure 6-7. Correlation of fold changes of differentially regulated genes during 
HSV-1 infection between human and mouse cells. Scatterplots of the correlations in 
log2 fold changes in transcripts due to infection between HFF and MRC5 or MF at (A-
B) 4 and (C-D) 8 hpi relative to mock are shown. Pearson’s correlation coefficients are 
given at the bottom right. Linear regression models were fitted and are illustrated as a 
red line in each scatterplot. 
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6.2.5 Differentially regulated cellular functions and pathways between human and 
mouse cells in HSV-1 infection 
 
In order to acquire a functional profile of differentially regulated genes between human 
and mouse cells, GO analysis was performed on the combined list of genes that were 
differentially up- or downregulated by infection, between HFF and MRC5 or MF. 
When investigating the difference between HFF and MRC5, no significant GO terms 
were detected, indicating that gene regulation by infection is very similar in these two 
human cell types. On the contrary, a broad range of GO enrichment results were 
revealed between human and mouse cells. Specifically regulation was observed with 
regard to signal transduction [GO:0009966], the apoptotic process [GO:0006915], ion 
transport [GO:0006811] and protein phosphorylation [GO:0006468] (Figure 6-8). 
These data show that multiple cellular functions are regulated differently between the 
two species in response to HSV-1 infection. 
 
Next, to organise the information from gene lists into pathways, ROAST was applied 
to identify differentially regulated pathways between human and mouse cells by 
utilising a commonly used pathway database, namely REACTOME (Wu et al., 2010). 
When comparing 4 or 8 hpi to mock, about 500 differentially regulated REACTOME 
pathways were discovered across the three tested cell types (Figure 6-9). To compare 
these data for the three cell types, the number of pathways regulated by infection for 
each are shown in three-circle Venn diagrams (Figure 6-9). If the direction of regulation 
by infection for a modified pathway was the same in the comparison of two cell types, 
it was placed into the intersection. Other situations, such as different directions of 
regulation or regulation by only one of the cell types, were considered to be cell-type-
specific. More uniquely regulated pathways were detected in the cross-species 
comparison and these accounted for 60-70% of all differentially regulated pathways 
(Figure 6-9). A relatively smaller number of uniquely regulated pathways were 
identified when comparing the two human cell types. This observation occurred at both 
times after infection. The top 20 pathways upregulated in MF but downregulated in 
both human cell types at 8 hpi are listed in Table 6-1 and ranked by number of genes. 
In summary, by these two analysis methods, the two human cell types were found to 
respond similarly to HSV-1 infection, while mouse cells had a distinct transcriptional 
response.  
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6.2.5.1 Mouse cells upregulate an antiviral pathway characterized by ISG 
expression, but human cell types downregulate this pathway during HSV-1 
infection 
 
According to Section 6.2.5, there were many differentially regulated pathways between 
human and mouse cells, however, we chose to focus on just one for a deeper analysis. 
The results of the ROAST analysis in the REACTOME database in Section 6.2.5 found 
that the pathway called “Antiviral mechanism by IFN stimulated genes” (hereafter 
referred to as the antiviral/ISG pathway) was upregulated in mouse cells but 
downregulated both in HFF and in MRC5. We chose this pathway for further analysis, 
because ISGs have diverse antiviral functions. Therefore, different regulation of this 
pathway between the two species may be a potential mechanism that explains the 
restricted growth in MF compared to the human cell types (Figure 6-1). The expression 
of each gene in the antiviral/ISG pathway was collected and combined into a boxplot 
(Figure 6-10). A significantly upregulated pattern was observed in MF at both times 
after infection. On the contrary, genes in this pathway were both significantly 
downregulated by HSV-1 infection at 8 hpi in the human cells (Figure 6-10).  
 
In addition to viewing the data at the pathway level, genes that were significantly 
differentially regulated by HSV-1 infection at 4 and/or 8 hpi in HFF, MRC5 and MF 
within the antiviral/ISG pathway were extracted and then presented in a heatmap 
(Figure 6-11). As expected, HFF and MRC5 clustered together, while MF diverged 
from the human cells. This phenomenon was observed both at 4 and at 8 hpi. In 
particular, several signalling transducers and downstream effectors were found to be 
highly upregulated in MF at 8 hpi, including Jak1, Stat2, Mapk1, Eif2ak2, Mx1 and 
Mx2 (Figure 6-11B).  
 
In order to validate this cross-species RNA-seq analysis, regulation of these genes by 
HSV-1 infection was further confirmed by qPCR (Figure 6-12). We included the kinase 
JAK1 and the transcription factor STAT2, because they act apically in type I IFN 
signalling pathways. In addition to classical JAK-STAT pathway, MAPK pathways are 
also activated by type I IFNs to induce ISG expression. Therefore, expression of 
MAPK1, a signalling component receiving signals from JAK1, was also tested to 
explore possible cross-talk between components in the antiviral/ISG pathway. We 
chose MX proteins and EIF2AK2, as downstream antiviral effectors, to understand the 
differences at the end of the antiviral/ISG pathway. In particular, MX genes were 
included as a control, because of that they have been found by others to be upregulated 
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in mouse embryonic fibroblasts (MEFs), but downregulated in human primary 
fibroblasts during HSV-1 infection (Pasieka et al., 2006; Peng et al., 2008). 
 
The transcription of genes mentioned above was examined by qPCR and the regulation 
of each by HSV-1 infection showed a significant difference when comparing MF to 
HFF and to MRC5 at 8 hpi. Furthermore, some genes, such as Stat2 and Mx1, were 
significantly upregulated by HSV-1 infection in MF compared with the two human cell 
types at 4 hpi. In summary, the data suggest that HSV-1 infection induces expression 
of genes in the antiviral/ISG pathway in mouse cells but not human cells. 
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Figure 6-8. Gene ontology (GO) analysis visualised by REVIGO. GO terms enriched in the transcriptomes defined by differential regulation 
by HSV-1 infection between HFF and MF at 8 hpi were analysed. The results were visualised by REVIGO, where same and redundant GO terms 
were removed. The log10 p-value for each parent GO term is represented by the circle colour. The size of the circle indicates the number of 
enriched child GO populations contributing to the parent term. Semantic space was the outcome of multi-dimensional scaling, where similar GO 
populations clustered together.  
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Figure 6-9. Pathways differentially regulated by HSV-1 between human and 
mouse cells. Pathways differentially regulated by HSV-1 infection were defined based 
on the pairwise comparison between mock and (A) 4 or (B) 8 hpi in HFF, MRC5 and 
MF with both p-value and FDR <0.05. Analyses were performed by the ROAST 
method using the REACTOME database.  
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Table 6-1. Pathways regulated by HSV-1 infection differentially between human 
and mouse cells. 
 
Pathway name Number of genes p-value FDR
REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2_ 109 0.001 0.001
REACTOME_ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES 64 0.001 0.001
REACTOME_SIGNALING_BY_WNT 54 0.001 0.001
REACTOME_SPHINGOLIPID_METABOLISM 47 0.001 0.001
REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES 44 0.001 0.001
REACTOME_AQUAPORIN_MEDIATED_TRANSPORT 37 0.001 0.001
REACTOME_METABOLISM_OF_STEROID_HORMONES_AND_VITAMINS_A_AND_D 35 0.001 0.001
REACTOME_REGULATION_OF_WATER_BALANCE_BY_RENAL_AQUAPORINS 33 0.001 0.001
REACTOME_MYOGENESIS 31 0.001 0.001
REACTOME_PREFOLDIN_MEDIATED_TRANSFER_OF_SUBSTRATE_TO_CCT_TRIC 27 0.001 0.001
REACTOME_PERK_REGULATED_GENE_EXPRESSION 26 0.001 0.001
REACTOME_DNA_STRAND_ELONGATION 25 0.001 0.001
REACTOME_CA_DEPENDENT_EVENTS 24 0.001 0.001
REACTOME_SULFUR_AMINO_ACID_METABOLISM 22 0.001 0.001
REACTOME_HDL_MEDIATED_LIPID_TRANSPORT 21 0.001 0.001
REACTOME_SIGNALING_BY_BMP 20 0.001 0.001
REACTOME_OTHER_SEMAPHORIN_INTERACTIONS 20 0.001 0.001
REACTOME_GLYCOLYSIS 20 0.001 0.001
REACTOME_NEPHRIN_INTERACTIONS 20 0.001 0.001
REACTOME_HYALURONAN_METABOLISM 18 0.001 0.001
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Figure 6-10. Regulation of gene expression in the antiviral/ISG pathway in HSV-
1-infected HFF, MRC5 and MF. Log2 CPM values of individual genes in the 
antiviral/ISG pathway at each condition were collected and plotted in boxplots. Grey, 
pink and red represent mock, 4 hpi and 8 hpi, respectively. *FDR <0.05, ***FDR 
<0.001 and ns, no significant difference.  
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Figure 6-11. Profile of regulation of genes in the antiviral/ISG pathway by HSV-1 
infection. Genes significantly up- or downregulated regulated by HSV-1 infection at 
(A) 4 and (B) 8 hpi in each cell type are illustrated in heat maps. The log2 fold change 
of each gene relative to mock infected cells is shown. Blue represents lower regulation 
and red indicates higher regulation. 
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Figure 6-12. Validation of the cross-species RNA-seq analysis by qPCR. Selected 
genes from the antiviral/ISG pathway regulated by HSV-1 infection in mouse and 
human cells (n=3) were confirmed by qPCR, including (A) Jak1, (B) Stat2, (C) Mapk1, 
(D) Mx1, (E) Mx2 and (F) Eif2ak2. Differential regulation was determined by the 2 -
ΔΔCT method based on relative expression between mock and infected samples, followed 
by normalisation to 18S rRNA. One-way ANOVA with Tukey’s tests was applied to 
evaluate differences between cell types. The results are expressed as mean ± SEM. *p 
<0.05, **p <0.01, ***p <0.001 and ns, no significant difference.  
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6.2.6 Regulation and importance of Jak1 in human and mouse cells in HSV-1 
infection 
 
6.2.6.1 Jak1 is essential for generating the human-mouse difference in HSV-1 
replication 
 
We then directly investigated whether Jak1 plays a role during HSV-1 infection in 
human and mouse cells, because this protein acts furthest upstream in the IFN signalling 
pathway. HFF, MRC5, C57BL/6 MF and BALB/c MF were transfected with empty 
plasmids or indicated lentiCRISPR vectors with gRNA targeting the human or mouse 
Jak1 gene. Knockout efficiency was evaluated by qPCR and WB (Figure 6-13A and 
Figure 6-13B). Knockout efficiency was at least 80% in each culture based on the qPCR 
analysis (Figure 6-13A) and JAK1 protein was not detected in human and mouse Jak1 
knockout cells (Figure 6-13B). When Jak1 was depleted in the cells, HSV-1 replicated 
equally well among HFF, MRC5 and MF (Figure 6-14A). This observation was then 
extended to MF derived from BALB/c mice, which gave consistent results with those 
observed with C57BL/6 MF cells (Figure 6-14B).  
 
To further confirm the importance of JAK1, we examined whether JAK1 activation 
influences the replication of HSV-1 in human and mouse cells. HFF, MRC5, C57BL/6 
MF and BALB/c MF were treated with Ruxolitinib (100 nM), a selective JAK1/2 
inhibitor and infected with HSV-1 for 24 hours. Treatment with Ruxolitinib led to HSV-
1 replication that was equivalent among the tested cell types (Figure 6-15). However, 
treatment with vehicle did not alter the usual pattern of reduced HSV-1 replication in 
mouse cells compared with human cells. Collectively, the data indicate that 
upregulation and activation of JAK1 are essential factors contributing to the human-
mouse difference in HSV-1 replication. 
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Figure 6-13. Knockout efficiency of lentiCRISPR targeting Jak1. Triplicates of HFF 
and MRC5 or MF from three individual mice were transfected with empty lentiCRISPR 
vectors or lentiCRISPR vectors designed to knockout Jak1 gene. Each transfected cell 
type was harvested for investigation of knockout efficiency by (A) qPCR in Jak1 or (B) 
Western blotting (WB) for JAK1 protein level. One-way ANOVA with Tukey’s tests 
was applied to determine differences between means. The results are expressed as mean 
± SEM. Graphs of WB are representative of three independent experiments. ns, no 
significant difference. 
H
F
F
M
R
C
5
M
F
 (
C
5
7
B
L
/6
)
M
F
 (
B
A
L
B
/c
)
0
2 0
4 0
6 0
8 0
1 0 0
H F F
M R C 5
M F  (C 5 7 B L /6 )
M F  (B A L B /c )
A.
B. 
gRNA:     +      - +        - +       -
HFF              MRC5         MF (C57BL/6)
JAK1
GAPDH
100-
37-
(kDA)
Jak1
E
x
p
re
s
s
io
n
 (
%
)
(r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
ns
230 
 
 
 
 
 
Figure 6-14. Importance of JAK1 in the human-mouse difference during HSV-1 
replication. Triplicates of HFF and MRC5, or (A) C57BL/6 MF and (B) BALB/c MF 
cells from three individual mice were transfected with empty lentiCRISPR vectors or 
lentiCRISPR vectors targeting Jak1, followed by inoculation of HSV-1 pICP47 
recombinant virus at an MOI of 0.5 for 24 hours. Infected cell lysates were then 
collected and prepared for determination of viral titres by plaque assays. One-way 
ANOVA with Tukey’s tests was applied to test differences between means (**p <0.01). 
The results are expressed as mean ± SEM. ns, no significant difference. 
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Figure 6-15. Effect of JAK1 inhibitor on HSV-1 infection. Triplicates of HFF and 
MRC5 or C57BL/6 MF and BALB/c MF from three individual mice were infected with 
wild-type HSV-1 at an MOI of 0.01 for 24 hours in the presence of 100 nM Ruxolitinib 
or DMSO vehicle control. Following this, viral titres were measured using plaque 
assays. One-way ANOVA with Tukey’s tests was used to evaluate differences between 
means. The results are expressed as mean ± SEM. ***p <0.001 and ns, no significant 
difference.  
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6.2.7 HSV-1 virion host shutoff protein vhs, but not ICP27, is an important viral 
gene regulating the human-mouse difference  
 
Host species differences in virus infection can occur if a viral immune evasion strategy 
functions more effectively in one species than another. This can occur if one species is 
the natural host and the other species does not faithfully model an interaction that is the 
result of a co-evolved host response and viral counter-response. HSV-1 has several 
strategies to inhibit the IFN signalling pathway at multiple sites. Of particular interest, 
HSV-1 vhs has been shown to be responsible for the reduction of JAK1 and STAT2 
protein expression (Chee and Roizman, 2004). Further, HSV-1 IE protein ICP27 may 
cooperate with vhs to regulate mRNA stability, but also decreases the phosphorylation 
of STAT1 and inhibits the accumulation of STAT1 in the nucleus (Yokota et al., 2001; 
Johnson et al., 2008). Therefore, we explored whether these viral genes might regulate 
Jak1 differently in human and mouse cells.  
 
6.2.7.1 HSV-1 vhs and ICP27 decrease Jak1 upregulation, but only vhs is required 
for the species-specific difference in Jak1 upregulation 
 
To directly test whether vhs and/or ICP27 might impact Jak1 expression in response to 
HSV-1 differently across species, we used virus strains with these genes ablated. The 
viruses were a truncation mutant of vhs (ΔSma) and a deletion mutant of ICP27 (5dl1.2) 
(McCarthy et al., 1989; Read et al., 1993). Both of these HSV-1 mutants were generated 
from HSV-1 strain KOS (Corcoran et al., 2006). HFF, MRC5 and MF were infected 
with wild-type HSV-1 strain KOS, ΔSma or 5dl1.2 and Jak1 upregulation was 
determined by qPCR.  
 
In the ICP27 deletion mutant, Jak1 upregulation was observed in all cell types, but was 
still significantly higher in MF than in the human cells, suggesting that ICP27 limits 
Jak1 expression during HSV-1 infection, but does so similarly in human and mouse 
cells (Figure 6-16). Conversely, during vhs mutant virus infection, Jak1 upregulation 
was increased in all cell types and strikingly was induced to a comparable degree 
irrespective of host species (Figure 6-16). These data suggest that ICP27 and vhs act to 
limit Jak1 expression in response to HSV-1, but vhs has the stronger effect. More 
importantly here, vhs is necessary for the differential upregulation of Jak1 in mouse 
compared with human cells. 
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6.2.7.2 HSV-1 vhs regulates the protein expression and the activation of JAK1 
during HSV-1 infection 
 
We extended this finding to investigate the protein level and activation of JAK1 during 
HSV-1 infection. HFF, MRC5 and MF derived from C57BL/6 and BALB/c were 
infected with wild-type HSV-1 and the vhs mutant virus and JAK1 protein level and 
phosphorylation status were analysed by WB using anti-JAK1 and anti-phosphorylated 
JAK1 antibodies (Figure 6-17A and Figure 6-17B). Quantification of each band was 
performed by densitometry and levels of basal and activated JAK1 was normalised to 
GAPDH (Figure 6-17C and Figure 6-17D). Wild-type HSV-1 induced significantly 
higher levels of basal and activated JAK1 in MF compared with HFF and MRC5. 
Further, this observation was found consistently in MF collected from C57BL/6 and 
BALB/c strains. By contrast, in the absence of vhs, protein expression and 
phosphorylation of JAK1 was similar among the tested cell types. These data confirm 
the qPCR results above, supporting the conclusion that vhs is required for the species-
specific difference in JAK1 expression and function observed during HSV-1 infection.  
 
6.2.7.3 Growth kinetics of HSV-1 ICP27 and vhs mutants in human and mouse 
cells 
 
Finally, to investigate whether the differential effect of vhs in human and mouse cells 
extends to HSV-1 replication, a multi-step growth analysis was performed using the 
two recombinant HSV-1 viruses. In HHF, MRC5 and MF, attenuated yields were 
detected when HSV-1 was defective for ICP27 (Figure 6-18A). Consistent with 
published results for Vero and 3-3 cells (McCarthy et al., 1989). However, even with 
ICP27 deletion, HSV-1 still replicated more efficiently in human cells than in mouse 
cells from 72 hpi (Figure 6-18A). By contrast, the growth kinetics of the HSV-1 vhs 
mutant virus were the same irrespective of species. The ΔSma viral titres were reduced 
about 1000-fold and 10-fold compared to the wild-type virus in human and mouse cells, 
respectively (Figure 6-18B). Taken together, the data indicate that vhs is required for 
the difference in HSV-1 replication seen between human and mouse cells. This is 
consistent with a model in which vhs antagonises Jak1 expression and/or function more 
effectively in human versus mouse cells.   
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Figure 6-16. Regulation of Jak1 by HSV-1 vhs and ICP27. Triplicates of HFF and 
MRC5 or MF cells from three individual mice were infected with wild-type, ICP27 
deletion mutant (5dl1.2) or vhs mutant virus (ΔSma) at an MOI of 0.5 for eight hours. 
Cell lysates were subjected to RNA extraction, cDNA synthesis and qPCR analysis for 
Jak1 RNA levels, which were shown relative to mock infected cells. One-way ANOVA 
with Tukey’s tests was used to examine differences between means. The results are 
expressed as mean ± SEM. **p <0.01, ***p <0.001 and ns, no significant difference.  
R
e
la
ti
v
e
 e
x
p
r
e
s
s
io
n
H
F
F
M
R
C
5
M
F
H
F
F
M
R
C
5
M
F
H
F
F
M
R
C
5
M
F
0
1
2
3
4
5
W T
5 d l1 .2
S m a
WT            5dl1.2       ΔSma
***                    
**                    
ns                    
Jak1                    
R
e
la
ti
v
e
 e
x
p
re
s
s
io
n
 
(t
o
 m
o
c
k
)
235 
 
 
 
 
 
 
Figure 6-17. Activation of JAK1 in human and mouse cells during HSV-1 
infection. Triplicates of HFF and MRC5 or MF from three individual mice prepared 
from (A, C) C57BL/6 or (B, D) BALB/c strains were infected with wild-type (WT) or 
vhs mutant (ΔSma) at an MOI of 0.5 for eight hours. Following this, Western blotting 
analysis (WB) for JAK1 protein expression (JAK1) and activation (JAK1p) was 
performed. Images of WB are representative of three independent experiments. 
Quantification of JAK1, JAK1p and GAPDH in each band from three replicates was 
conducted by densitometry using ImageJ. A linear model was used to evaluate 
differences between human and mouse cells. The results are expressed as mean ± SEM. 
*p <0.05, **p <0.01 and ns, no significant difference.  
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Figure 6-18. HSV-1 vhs is required for different growth of HSV-1 in human and 
mouse cells. Triplicates of HFF and MRC5 or MF cells from three individual mice 
were infected with wild-type (WT) HSV-1, (A) ICP27 deletion mutant (5dl1.2) or (B) 
vhs mutant (ΔSma) at an MOI of 0.01 and were harvested at indicated time points. Viral 
titres were then measured by plaque assays. Two-way ANOVA with Tukey’s tests was 
employed to test differences between means in growth curves. The results are expressed 
as mean ± SEM. **p <0.01, ***p <0.001 and ns, no significant difference.  
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6.3 Discussion 
 
For HSV-1, several antiviral reactions, such as programmed cell death and antigen 
presentation, have been found to be differentially regulated between human and mouse 
cells (Jugovic et al., 1998; Guo et al., 2015b; Huang et al., 2015; Yu and He, 2016). 
Furthermore, microarray data from two different studies have separately showed that 
HSV-1 regulates ISGs expression in opposing directions, including Mda5, Mx and Gbp 
family members in primary mouse embryonic cells and human fibroblasts (Pasieka et 
al., 2006; Peng et al., 2008). In this chapter, the human-mouse difference during HSV-
1 infection was comprehensively investigated by RNA-seq and analysed by using a 
computational pipeline for cross-species analysis. Raw RNA-seq data from primary 
male mouse skin fibroblasts were extracted from Section 3.2.5 and compared to primary 
male human skin cells (HFF) in this chapter. Moreover, we included another commonly 
used cell line for propagation and study of HSV-1, namely MRC5, an immortalised 
male human cell line (Earnshaw et al., 1992; Harkness et al., 2014). Therefore, the 
baseline of the difference between the two human cell types could be set as a standard 
and control to more fairly evaluate the extent of differences between primary human 
and mouse cells. At the beginning of this chapter, our data showed greater viral yields 
in human cells than in mouse cells (Figure 6-1), which further encouraged us to 
thoroughly understand the molecular mechanism regulating the human-mouse 
difference in HSV-1 infection. RNA-seq analysis based on the shared orthologues 
between humans and mice consistently showed that the cross-species difference was 
larger than the difference between the two human cell types (Figure 6-5 and Figure 6-
6). Importantly, this customised pipeline found previously reported human-mouse 
differences in the apoptotic process [GO:0006915] and cell death pathways 
[GO:0008219] (Guo et al., 2015b; Huang et al., 2015), indicating fair sensitivity and 
specificity of our tailored analysis of the cross-species data.  
 
The pathway that took our immediate interest was the antiviral/ISG pathway, which 
was upregulated in mouse cells but downregulated in the two human cell types (Figure 
6-10). We then selected Jak1 as our candidate gene as JAK1 receives convergent 
signals at one of the most upstream positions of the IFN signalling pathway (Schindler 
et al., 2007; Babon et al., 2014). Initially, JAK1 was generally thought to be activated 
due to the interaction of cytokines and IFNs with their specific receptors, resulting in 
cellular signalling to recruit and subsequently activate JAKs by auto- or trans-
phosphorylation (Miyazaki et al., 1994; Bellucci et al., 2015). However, our 
preliminary data indicate that knockout of IFNAR and secreted soluble proteins in the 
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supernatant of HSV-1-infected cells were not sufficient to eliminate the difference in 
Jak1 upregulation between human and mouse cells (data not shown). These results 
suggest that the human-mouse difference in Jak1 expression is IFN-independent and 
could be due to intrinsic stimulation. In addition to cytokines, previous reports have 
revealed a binary regulation of JAK-STAT signalling by cytokine- and calcium-
dependent pathways (Sengupta et al., 1996; Wang et al., 2008a). Coincidently, HSV 
infection can trigger calcium-signalling pathways and the phosphorylation of cellular 
proteins may occur in conjunction with calcium signalling (Cheshenko et al., 2003; 
Cheshenko et al., 2013; Cheshenko et al., 2014). However, to date, there is no clear 
evidence showing whether JAK1 activation is regulated by calcium transport during 
HSV-1 infection. According to the results of our GO analysis in Figure 6-8, human and 
mouse cells react differently in ion transport [GO:0006811], cation transport 
[GO:0006812] and protein phosphorylation [GO:0006468]. The above findings suggest 
that we can further investigate the link between JAK1 phosphorylation and calcium 
signalling in primary human and mouse skin fibroblasts. For example, by treating cells 
with a cell-permeant calcium chelator to block calcium transport, we may understand 
whether calcium plays a role in the induction of phosphorylated JAK1 during HSV-1 
infection.  
 
When Jak1 was deficient, HSV-1 replicated equally well in human and mouse cells 
(Figure 6-14), indicating that Jak1 is essential for regulating the human-mouse 
difference in HSV-1 replication. Previous data from HSV-1 mutants showed that the 
decrease in JAK1 is regulated by vhs during early infection (Chee and Roizman, 2004). 
As ICP27 collectively regulates mRNA stability with vhs during HSV-1 infection, it is 
likely that ICP27 affects Jak1 upregulation as well (Brown et al., 1995; Chee and 
Roizman, 2004; Taddeo et al., 2010). Herein, our results revealed that both ICP27 and 
vhs are important for restriction of Jak1 upregulation, but only vhs can restore Jak1 in 
mouse cells to a similar level as those in the two human cell types (Figure 6-16). This 
finding correlates with the growth phenotypes of vhs mutant virus among HFF, MRC5 
and MF (Figure 6-18), indicating that vhs is a key viral gene in the human-mouse 
difference. Several mechanisms can be used to interpret the different efficiency of vhs 
in the degradation of Jak1 between human and mouse cells, although detailed 
experiments are required to provide further support for these mechanisms. Previous 
studies have suggested that the rate of vhs-mediated mRNA degradation is dependent 
on the cell type (Saffran et al., 2010; Dauber et al., 2011). A difference in vhs activity 
can be identified between cells in two close species, or even in the same species (Dauber 
et al., 2011). It has been shown that the growth defect of HSV-1 vhs mutants is 
dependent on differences in the translation machinery in the respective cell (Saffran et 
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al., 2010; Eaton et al., 2014). In addition, the efficiency of the interaction of vhs with 
cellular translation factors, including eukaryotic initiation factors (eIFs), might differ 
between human and mouse cells. This may also influence the capacity of vhs to degrade 
mRNA, as the association between vhs and eIFs guides vhs to the preferred cleavage 
sites (Feng et al., 2005; Page and Read, 2010).  
 
In addition to Herpesviridae, accumulating evidence has shown that there are human-
mouse differences in the regulation of innate immune responses by other viruses 
(Zschaler et al., 2014). Species-specific activity of antiviral genes has also been well-
documented in HIV, a virus adapted to replicate in human cells (Sawyer et al., 2004; 
Sawyer et al., 2005; McNatt et al., 2009). For instance, there is a resistance of non-
human tetherin proteins to antagonise HIV infection such that magnitude of the 
reduction in HIV yield varies depending on what species of the tetherin protein is 
overexpressed (McNatt et al., 2009). Likewise, IFN antagonism of ZIKV seems to be 
species dependent (Aliota et al., 2016; Rossi et al., 2016). In support of this, ZIKV 
infection results in the degradation of STAT2 in primary human fibroblasts, but STAT2 
protein expression is not affected in MEFs (Hamel et al., 2015). Moreover, no 
detectable virus production was found in wild-type MEFs infected with ZIKV, but 
INFAR-deficient MEFs supported ZIKV replication. These data indicate that both 
STAT2 and IFNAR are essential for maintaining intact IFN signalling during ZIKV 
infection and species-specific IFN countermeasures may further contribute to the 
control of ZIKV replication (Morrison and Diamond, 2017; Dong and Liang, 2018). In 
another case, the NS1 protein of influenza B virus counteracts host antiviral responses 
via binding to ISG15. NS1 also exhibits species-specific binding and it interacts with 
human and non-human primate ISG15, but not mouse and canine counterparts. 
Sridharan et al. (Sridharan et al., 2010) identified that the small 5-amino acid hinge 
between the two ubiquitin-like domains of ISG15 is critical for the species-specific 
binding with Influenza B virus NS1 protein. Furthermore, a recent study found that 
ISG15 plays a role in antiviral immunity in mice, but displays more complicated 
functions in humans (Speer et al., 2016). ISG15-deficient individuals exhibit a 
persistent elevation in ISG expression and resist viral infection from various virus 
families, in contrast to what has been observed in ISG15-deficient mice. The difference 
in viral susceptibility between ISG15-deficient humans and mice was further explained 
by a species-specific interaction of ISG15 with ubiquitin specific peptidase 18, a 
negative regulator of IFN-α/β signalling which downregulates the IFN-α/β reactions in 
humans, but not in mice (Zhang et al., 2015; Speer et al., 2016).  
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In summary, here we performed a comprehensive analysis of differentially regulated 
pathways between human and mouse cells during HSV-1 infection. Our customised 
pipeline for cross-species analysis of RNA-seq data showed many differences between 
the two species, including some that were already known and a previously unexplored 
difference in the IFN signalling pathway and ISGs. Furthermore, we found that HSV-1 
vhs has a species-specific immune evasion role via more effective suppression of Jak1 
in human cells than in mouse cells. These data provide new leads for further 
investigation of the differences in responses of human and mouse cell to HSV-1 
infection. They also suggest that the role of IFN and ISGs differ in significant ways 
between these species and this needs to be taken into account in interpreting mouse 
models of HSV-1 diseases.  
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Chapter 7. Final discussion 
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The work in this thesis began by considering some of the assumptions that are 
commonly made in the virology literature. The first one was that the sex of cells in 
culture is not important and the second is that species differences can be ignored, even 
if they are more often acknowledged. We present the first comprehensive analysis of 
these two factors for HSV-1. Herpesviruses are distributed worldwide and the global 
burden from HSV-1 diseases is huge (Looker et al., 2015a; Looker et al., 2015b). 
However, there are various aspects of HSV-1 infection that remain unclear. The 
outcome of infection with many pathogens differs between males and females, but the 
basis of this in HSV-1 is not well-explored. To date, most studies in vivo indicate that 
sex hormones influence the immune system and may play the role in the control of viral 
infections (Klein and Flanagan, 2016; Ghosh and Klein, 2017). These sex-determined 
differences can operate at the level of individual cells. Yet, sex is rarely considered as 
a variable in studies that aim to reveal the molecular mechanisms of viral disease in 
vitro. Therefore, we investigated the ways in which chromosomal, rather than 
hormonal, differences influence the outcome of HSV-1 infection in culture. In addition, 
given that many primary infections by HSV-1 can be asymptomatic and the neurotropic 
properties of HSV-1 make it hard to obtain information from infected humans, 
researchers extensively use mouse models to study HSV-1 diseases. However, mice are 
not a natural host for this virus and more and more papers show cross-species 
differences in response to viral infection. Therefore, it is important to have 
comprehensive knowledge of cross-species differences between mice and humans in 
HSV-1 infection. 
 
At the time we began our study (July, 2015), there were only two research articles using 
RNA-seq to study HSV-1. The first paper utilised this method to measure the viral gene 
expression of wild-type HSV-1 and IE gene mutant viruses simulating latent infection 
in immortalised human embryonic lung cells (MRC5) and primary mouse trigeminal 
neurons (Harkness et al., 2014). This study revealed that MRC5 cells have more 
restricted viral transcription than trigeminal neurons. There were also divergences in 
the cascade expression of early genes in lytic infection. Moreover, genes adjacent to 
LAT were especially actively transcribed during the latent period in neurons (Harkness 
et al., 2014). The other paper used RNA-seq to exploit ribosome profiling and 4-
thiouridine (4sU)-tagging of freshly made RNA to measure global changes in RNA 
processing and transcription during HSV-1 lytic infection in human foreskin fibroblasts 
(Rutkowski et al., 2015). The results showed that lytic infection by HSV-1 can 
specifically interrupt transcription termination of cellular genes, rather than viral ones, 
and abnormal splicing events were induced by HSV-1 infection independent of vhs or 
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ICP27 proteins (Rutkowski et al., 2015). In this thesis, we exploited RNA-seq to acquire 
whole transcriptomic changes at deeper resolution as sex-specific and/or human-mouse 
differences might be subtle during HSV-1 infection in cultures. 
 
Using a model system in which HSV-1 was used to infect primary mouse skin 
fibroblasts, we uncovered several findings that were due to cell-intrinsic differences 
between the two sexes. During low MOIs of infection (MOI=0.0001 and 0.0003), HSV-
1 was found to replicate better in male cells, suggesting that the two sexes have different 
responses to HSV-1 infection, and female cells may induce stronger antiviral responses. 
Further, serial passage of HSV-1 on male cells produced a strain of virus that replicated 
more efficiently on male than on female cells, and vice versa was also true for HSV-1 
serial passaged on female cells. The data showed that HSV-1 is able to adapt to grow 
more efficiently in cells of one sex, in as few as around 10 serial passes. This was 
surprising because HSV-1 as a dsDNA virus with a high fidelity polymerase, has been 
considered in the past to have a slow rate of evolution (McGeoch, 1987; Umene and 
Sakaoka, 1999). However, several studies now suggest that the original estimates of 
HSV-1 evolutionary rate may be too low because continuous positive selection was not 
considered and the data were not measured independently from the hypothesis of 
codivergence (Drake and Hwang, 2005; Firth et al., 2010; Hughes et al., 2010). 
 
Much less is known about the adaptive strategies of large DNA viruses as compared to 
RNA viruses. In order to counteract host immune responses, RNA viruses have high 
mutation rates and short generation time, leading to rapid adaptation and expansion of 
tropism in various animal species (Vignuzzi et al., 2006; Fitzsimmons et al., 2018). 
However, DNA viruses evolve more slowly than RNA viruses, but they generate highly 
competent lineages (Drake and Holland, 1999; Lynch, 2010). Historically, a key 
measure of the evolutionary rate of herpesviruses was from the analysis of 242 HSV-1 
samples from six different countries (Sakaoka et al., 1994; Firth et al., 2010). A 
substitution rate of 3.5 x 10-8 substitution/site/year was estimated (Sakaoka et al., 1994). 
In addition to nucleotide substitution, Elde et al. revealed that DNA viruses can adapt 
to a new host environment through intermediates of transient gene expansion (Elde et 
al., 2012), which explains a variety of observations in the gene expansion of myxoma 
virus, herpesviruses and chemically induced gene amplification in vaccinia (Slabaugh 
et al., 1989; Searles et al., 1999; Kerr et al., 2010). Although we did not find any 
evidence that the experimental evolution strategy in male and female cells induced gene 
expansion in the genome of herpesvirus, specific substitutions were identified due to 
selection pressure driven by sex. For example, sex pressure in mouse skin fibroblasts 
targeted HSV-1 glycoproteins, such as gH (T132H) in male and gE (S477L) in female 
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passage viruses .Mutations in the gE and gH have been shown to affect HSV entry and 
cell fusion (Dingwell et al., 1994; Fan et al., 2015). Interestingly, gH(T132H) in male 
passage viruses was predicted to be a frameshift mutation, which may lead to a 
conformational functional change of gH. More experiments are required to investigate 
this issue, although insertion mutations of HSV-1 gH is relatively tolerant and allow 
normal processing and transport of glycoproteins complex to the cell surface (Jackson 
et al., 2010). Furthermore, both male (D67N) and female (L344F) passage viruses have 
nucleotide changes in UL48 (VP16) as compared to the parent virus that was used for 
infection. VP16 is a transcription factor of HSV-1 that is involved in the activation of 
the viral IE genes (Triezenberg et al., 1988a; Triezenberg et al., 1988b). Based on recent 
studies, VP16 plays a role in regulation of host innate immune responses, such as 
blocking the production of type I IFNs by inhibiting NF-κB activation and interfering 
with IRF3 translocation (Xing et al., 2013; Zheng and Su, 2017). Additionally, we 
found that VP16 worked cooperatively with ICP34.5 to upregulate Xist during HSV-1 
infection. Thus, it is tempting to speculate that the mutations in female passage viruses 
may eliminate the antiviral functions of VP16. Female passage viruses received a point 
mutation in US3 (G341R) after 10 serial passages and this mutation was maintained in 
passage 30. US3 has been shown to dampen NF-κB activation, modulate virion 
packaging via VP11/12 phosphorylation and regulate phosphatidylinositol 3-
Kinase/Akt signalling activity (Eaton et al., 2014; Wang et al., 2014). However, these 
mutations need to be confirmed by Sanger sequencing in the future. Further, more 
experiments are required to assess whether these mentioned mutations are necessary in 
the sex-adapted HSV-1 viruses by reverting nucleotide changes back to the parent 
sequence and examining the growth on male and female cells. To investigate whether 
a mutation is sufficient for the adaptation, HSV-1 pICP47 recombinant virus should be 
modified to match the mutation found in the sex-adapted HSV-1 viruses, and growth 
on male and female cells should be tested. 
 
Given that evolution pressure from a specific sex leads to different mutations in the 
HSV-1 genome, and HSV-1 replicates more efficiently in male than in female cells, 
RNA-seq was utilised to identify mechanisms that may explain these observations. 
Pathway analysis revealed that the two sexes respond to HSV-1 infection distinctively 
in various ways, including cancer, metabolism and immunity. In particular, female cells 
induced cytosolic DNA-sensing pathway to a higher degree than male cells, which 
could be a potential explanation for the different growth phenotypes between the two 
sexes. We confirmed that one DNA sensor (cGAS), two RNA sensors (RIG-I and 
MDA5) and two IRFs (IRF1 and IRF7) and one signalling adaptor (TBK1) were 
upregulated to a greater degree in female cells, at both RNA and protein levels. Previous 
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reports have shown that HSV can be recognised by cytosolic DNA and RNA receptors 
(Chew et al., 2009). cGAS is a multifunctional protein that mediates various biological 
process, including cytosolic sensing, cellular senescence and cancer formation (Xiao 
and Fitzgerald, 2013; Schoggins et al., 2014; Gluck et al., 2017). For instance, HSV-1 
triggers cGAS production and subsequent activation of IRFs in both murine and human 
cell lines (Wu et al., 2013). Depletion of cGAS decreases IRF3 activation during HSV-
1 infection, and thereby, cGAS acts as a cytosolic DNA sensor that recognises HSV-1 
in infected cells. Likewise, evidence indicates that another DNA sensor, IFI16, is 
involved in multiple mechanisms to sense HSV-1 in a cell-type-dependent manner 
(Unterholzner et al., 2010; Horan et al., 2013). IFI16 can recognise viral DNA in both 
the cytoplasm and nucleus to induce type I IFN production and inflammatory cytokines, 
indicating that IFI16 is a restricting factor for HSV-1 replication (Unterholzner et al., 
2010; Conrady et al., 2012). In our RNA-seq data, IFI16 was downregulated in male 
cells but not in female cells in response to HSV-1 infection (data not shown). This 
observation in some way also supports the finding that female cells induce higher 
cytosolic sensing at the beginning of HSV-1 infection. Likewise, the connection 
between HSV-1 and RIG-I-like receptors is supported by data showing that HSV-1 
replicates more efficiently in human cells lacking a functional RIG-I (Cheng et al., 
2007). MDA5 has been reported to recognise HSV-1 and play an essential role in HSV-
1-induced type I IFNs and cytokine production (Melchjorsen et al., 2010; Xing et al., 
2012b). In this thesis, we found that both RIG-I and MDA5 were important in the 
upregulation of viperin in mouse skin fibroblasts, although neither of them were 
required for the sex difference in HSV-1 replication. Although cytosolic DNA and RNA 
sensors have specificities for different ligands, they both induce a signalling pathway 
that triggers the production of type I IFNs and ISGs (Wu and Chen, 2014; Radoshevich 
and Dussurget, 2016). Multiple cellular recognition events lead to signal transduction 
which eventually converges on TBK1 or NFκB signalling (Akira et al., 2006; Paludan 
et al., 2011). The induction of these kinases results in the activation of IRFs leading to 
the production of type I IFNs and ISGs, whose ultimate role is to restrain virus 
replication and spread through the initial establishment of an antiviral state (Ma and 
He, 2014).  
 
The general understanding is that IFN expression can act in both autocrine and 
paracrine manners to amplify ISG expression (Schoggins and Rice, 2011; Wang et al., 
2017), but ISGs can be induced directly upon viral infection in the absence of IFN 
signalling (Collins et al., 2004; Noyce et al., 2011). For example, Paladino et al. 
proposed a model for an IFN-independent response to entry of virus when a low 
multiplicity inoculation is used in primary fibroblasts. In this model, the entry of the 
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enveloped virus particles is sufficient to induce a subset of ISGs in an IFN-independent 
manner, indicating that innate antiviral pathways can act before or in the absence of 
type I IFNs in epithelial cells (Paladino et al., 2006; Iversen et al., 2016). This 
hypothesis is correlated with our findings where viperin, an ISG that has well-
documented antiviral activity against a broad spectrum of viruses (Helbig and Beard, 
2014), was induced in IFNAR knockout fibroblasts after a low multiplicity infection 
with HSV-1. In addition, we found that IRFs, including IRF1, IRF3 and IRF7, were all 
important for viperin regulation at the initial stage of HSV-1 infection in mouse skin 
fibroblasts. This confirms the existence of unidentified receptors and ligands that are 
able to activate an IRF and ISGs (Collins et al., 2004; Noyce et al., 2011). IRF1 may 
control IFN-independent signalling events leading to ISG upregulation and antiviral 
immunity given that when Irf1 was depleted in mouse fibroblasts, viperin level was 
abolished during HSV-1 infection. As cytosolic sensors themselves act substantially in 
cooperation with IRFs to upregulate ISG expression in an IFN-independent manner 
(Fitzgerald, 2011; Seo et al., 2011a; Duschene and Broderick, 2012), we then further 
investigated this hypothesis and found that IRF1 acts upstream of cytosolic sensing via 
mediation of cGAS transcription, thereby affecting viperin upregulation. This adds 
another layer of complexity in the role of cGAS in innate immunity.  
 
TBK1 is a key factor mediating the sex difference in antiviral responses to HSV-1. 
TBK1 functions as an adaptor kinase that receives upstream inputs and modulates 
downstream outputs to transduce signals in various signalling pathways, including 
innate immunity and cell proliferation (Li et al., 2011; Ou et al., 2011). Due to the 
importance of TBK1 in antiviral immunity, HSV-1 has evolved several proteins to 
inhibit TBK1-mediated pathways. Ma et al. reported that ICP34.5 inhibits TBK1 
through its N-terminus, which facilitates virus replication and neuroinvasion in vitro 
and in vivo (Ma et al., 2012). Moreover, HSV-1 US11 precludes the access of TBK1 to 
the IFN promoter, and therefore, suppresses expression of type I IFNs and ISGs in 
human cells overexpressed with US11 (Liu et al., 2018). In order to identify an 
upstream regulator of TBK1 leading to the sex difference in HSV-1 infection, we 
screened differentially regulated transcription factors on the sex chromosomes and 
identified that ZBTB33 negatively mediates Tbk1 expression, and thus, antiviral 
responses are maintained at a higher level in female cells. However, Zbtb33 seems to 
have no direct impact on the expression of Irfs, including Irf1, Irf3 and Irf7. This 
outcome arises an issue that whether downregulation of Tbk1 by Zbtb33 influences the 
activation of IRFs instead and further regulates antiviral activities (Stirnweiss et al., 
2010; Fitzgerald, 2011). To address this question in the future, we would like to 
understand the cytoplasm-to-nucleus translocation proportion of IRFs in the Zbtb33-
249 
 
deficient cells after HSV-1 infection. ZBTB33 is a methyl-DNA-binding protein and a 
zinc finger transcription factor that can interact with methylated DNA, resulting in the 
repression of transcription (Filion et al., 2006). In general, it is involved in the methyl-
dependent repression of gene transcription by recruiting corepressors, such as the 
nuclear receptor corepressor and silencing-mediator for retinoid/thyroid hormone 
receptors (Yoon et al., 2003; Raghav et al., 2012). In addition to interacting with 
methylated DNA, ZBTB33 can target CTGCNA sequences, but not hydroxymethylated 
DNA (Daniel et al., 2002; Qin et al., 2015). Thus, ZBTB33 has been implicated in the 
regulation of diverse biological functions, such as control of the cell cycle, 
inflammation and tumour cell invasion (Chaudhary et al., 2013; Pozner et al., 2016; 
Kwiecien et al., 2017). Furthermore, recent reports have also indicated its role in 
modifying immunological processes (Mino et al., 2018; Zhenilo et al., 2018). For 
example, Mino et al. showed that ZBTB33 is required for the modulation of chemokine-
induced T cell migration via mediation of actin cytoskeleton structure and adhesion 
(Mino et al., 2018). In another case, rapid ZBTB33 deSUMOylation was found to occur 
under hyperosmotic stress, which reduced the expression of proinflammatory 
cytokines, including TGFb1, CD40 and IL26 (Zhenilo et al., 2018).  
 
The X chromosome has a greater density of immunity-related genes compared to the Y 
chromosome (Bianchi et al., 2012). Based on this observation, several studies have 
suggested that females, having two X chromosomes and overexpression of some X-
linked genes, have an immunological advantage over males (Ross et al., 2005; 
Spolarics, 2007). For instance, clinical data indicate that females produce more 
antibodies in some circumstances and males are more susceptible to bacterial and viral 
infections (Fischer et al., 2015; Klein and Flanagan, 2016; Ghosh and Klein, 2017). 
However, these strong female-specific immune responses are not always beneficial and 
can sometimes cause severe immunopathology and autoimmune diseases (Fish, 2008; 
Klein, 2012). In order to equalise the expression of X-linked genes between the two 
sexes during mammalian female embryogenesis, females selectively silence 
transcription of one X chromosome in a chromosome-wide manner. This is called X 
chromosome inactivation (Pinheiro and Heard, 2017). In this process, the long non-
coding RNA Xist is required for the transcriptional silencing of one X chromosome in 
each cell (Brockdorff and Duthie, 1998; da Rocha and Heard, 2017). According to 
recent studies, long non-coding RNAs are essential regulators of gene expression via 
interactions with DNA, RNA or proteins (Zhang and Jeang, 2013; Diamantopoulos et 
al., 2018). Through interactions with transcription factors or chromatin-modifying 
complexes in the nucleus, long non-coding RNAs can alter the transcription of target 
genes or can control the stability of target mRNAs in the cytosol (Rinn and Chang, 
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2012). Besides regulation of the differentiation of immune cells, long non-coding 
RNAs also act as regulators of antimicrobial functions via mediation of 
proinflammatory signalling and regulation of ISGs (Rapicavoli et al., 2013; Ouyang et 
al., 2014). However, prior to this study, there was no indication that Xist might play a 
role in antiviral pathways. Here, we found that Xist is upregulated during HSV-1 
infection both in human and in mouse female cells (HeLa cells and female mouse skin 
fibroblasts). The induction of Xist led to downregulation of several X-linked genes that 
have been previously reported, including Hprt, Pgk1 and Mecp2 (Gayen et al., 2016; 
Lv et al., 2016; Wang et al., 2016b). Importantly, HSV-1-stimulated Xist expression 
was related to suppression of Zbtb33, and hence, it led to higher levels of TBK1 and 
antiviral responses in female cells. Finally, upregulation of Xist explains the difference 
between male and female cells in HSV-1 replication, indicating that Xist is a key factor 
in the maintenance of greater innate immune responses in female cells through 
repression of Zbtb33. We have searched for human female cell lines that can match the 
primary human male cells we used in this thesis, but in vain. This is because available 
female cells are either immortalized (cancer cell lines) or not from skin. We can pursue 
this in the future by collecting clinical skin samples from males and females with 
similar ages. 
 
In order to investigate how Xist was upregulated by HSV-1, we first ruled out the 
requirement of de novo protein expression, suggesting that viral proteins in the HSV-1 
tegument might activate for Xist upregulation after viral entry. Our initial hypothesis 
was that the strong viral transactivator VP16 might bind to the promoter region of Xist 
and therefore drives the expression of Xist. VP16 has been shown to target the 
TAATGARATTC consensus sequence found in IE promoters through interactions with 
the host factors Oct1 and HCF (Preston et al., 1984; Gaffney et al., 1985; Ace et al., 
1989; Wysocka and Herr, 2003). Indeed, our bioinformatic analysis indicated that there 
are two potential VP16-binding sites within the promoter region of Xist. However, 
expression of VP16 alone did not induce Xist level. We then examined another potential 
candidate, ICP34.5, based on a set of microarray data showing ICP34.5 is essential for 
induction of Xist (Pasieka et al., 2006). Our results showed that overexpression of 
ICP34.5 upregulated Xist. Although ICP34.5 has multiple roles during HSV-1 
infection, there is no evidence showing that it can act as a transcriptional factor (Wilcox 
and Longnecker, 2016; Manivanh et al., 2017). Hence, more detailed experiments 
investigating whether ICP34.5 plays a role in direct regulation of gene expression are 
needed to delineate this issue. Furthermore, our data indicated that the sex-related 
difference in virus replication is a virus-dependent phenomenon. While CPXV was 
found to replicate better in male cells, knockdown of Xist did not eliminate the sex-
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related difference in CPXV replication. This suggests that there are multiple 
mechanisms driving the sex-related differences in virus replication and the effect of 
Xist is specific for HSV-1.  
 
To date, there are limited publications focusing on whether viperin plays a role during 
HSV-1 infection and the results are not always comparable between these studies (Shen 
et al., 2014; Zheng and Su, 2017). Shen et al. showed that protein expression of viperin 
was abrogated during HSV-1 infection, but another study indicated that HSV-1 
infection induces a MAVS-dependent early production of viperin under similar 
infection conditions, such as MOI, infection time and cell line (Zheng and Su, 2017). 
In this thesis, we identified that viperin is highly upregulated by HSV-1 infection in 
mouse skin fibroblasts, but not in several human cell lines (HFF, MRC5 and HEK293), 
suggesting that the induction and function of viperin is cell- and species-specific. 
Besides differences in cell types and species, HEK293 cells might not be a particularly 
good cell line for study innate immune responses, because they have been found to 
express a very low level of TLR3 and lack functional O-linked glycosylation (de 
Bouteiller et al., 2005; Pohar et al., 2014; Termini et al., 2017). Our results suggest that 
murine viperin is antiviral against HSV-1, anti-HSV-1 activity requires N-terminal 
regions of the protein and induction of viperin is needed to restrict virus replication. 
The N-terminal amphipathic helix has been found to be required for its localisation to 
the cytosolic surface of the endoplasmic reticulum and lipid droplets (Hinson and 
Cresswell, 2009a; Hinson and Cresswell, 2009b; Seo et al., 2011a). This domain was 
also shown to be essential for antiviral activity against HCV and CHIKV via its 
association with different viral non-structural proteins, although the mechanism 
remains elusive (Helbig et al., 2011; Teng et al., 2012). In addition to the regulation by 
the ribonuclease function of HSV-1 vhs, we do not know yet whether there is another 
viral protein counteracting the antiviral activity of viperin by different mechanisms. 
The other caveat is that different MOIs were used for various purposes in this thesis 
and there may be an MOI-dependent manner in some cases, although they were within 
a reasonable range (0.5-2) and not too high to overwhelm cells. 
 
Humans and mice respond distinctively against virus infection (Sawyer and Elde, 2012; 
Zschaler et al., 2014). However, there is not a systemic study to identify differences 
between these two species during HSV-1 infection. In this thesis, we showed that HSV-
1 replicates more efficiently in cells of its natural host than in mouse cells. A 
computational pipeline was developed to analyse the cross-species RNA-seq data and 
we found that mouse cells upregulated more genes in the antiviral pathway driven by 
ISG. To antagonise the infection, many mammalian cells respond by launching an 
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intracellular signal transduction cascade leading to the synthesis and secretion of type 
I IFNs (Randall and Goodbourn, 2008). The binding of IFNs to IFNARs induces the 
phosphorylation and subsequent activation of JAKs, including JAK1 and TYK2, 
leading to the consequent phosphorylation of STAT1 and STAT 2. Activated STAT1, 
STAT2 and IRF9 further form the ISGF3 complex. This complex translocates to the 
nucleus and mediates transcriptional activation by interacting with interferon-
stimulated regulatory elements within promoters of ISGs. Mouse cells specifically 
upregulate several antiviral effectors that are downstream of IFN signalling, including 
Mx1, Mx2 and Eif2ak2, indicating that HSV-1 has evolved to counteract the innate 
immune responses in human cells, but not mouse cells. MX1 and MX2 proteins are 
well-documented antiviral proteins with broad antiviral activity to inhibit both DNA 
and RNA virus replication, including African swine fever virus and influenza virus 
(Pavlovic et al., 1990; Netherton et al., 2009). MX proteins belong to a family of large 
GTPases and the GTP binding domain is important for the antiviral activity of these 
proteins (Pitossi et al., 1993). EIF2AK2, also known as dsRNA-activated protein kinase 
(PKR), is another molecule induced by IFN that plays a critical role in antiviral 
responses (Garcia et al., 2006). PKR is constitutively expressed in mammalian cells and 
activated PKR can phosphorylate the alpha subunit of eIF2α. Phosphorylated eIF2α 
results in the inhibition of translation initiation, leading to a block of translation that 
impairs efficient viral reproduction and spread (Dauber and Wolff, 2009). HSV-1 US11 
protein binds to PKR, interfering with the activation of PKR and thus, inhibiting PKR-
mediated phosphorylation of eIF2α in an RNA-dependent manner (Cassady and Gross, 
2002). In a similar way, KSHV vIRFs interact with PKR, blocking PKR activation and 
phosphorylation of eIF2 α (Burysek and Pitha, 2001). HCMV prevents phosphorylation 
of PKR by utilising its dsRNA binding proteins IRS1 and TRS1. Overexpression of 
TRS1 causes a redistribution of PKR from the cytoplasm to the nucleus, and thus, 
restrains the interaction of activated PKR with cytoplasmic eIF2α, limiting the initial 
activation of PKR by dsRNA in the cytoplasm (Hakki et al., 2006). 
 
To identify the key component that influences the cross-species difference in HSV-1 
replication, we used the CRISPR knockout method and identified that JAK1 is essential 
for generating the human-mouse difference. HSV-1 has evolved various viral proteins 
to inhibit IFN-induced defence mechanisms in hosts, which ultimately establishes 
successful infection. Two well-studied viral proteins, ICP27 and vhs, can suppress 
antiviral reactions through inhibiting the JAK/STAT signalling pathway (Chee and 
Roizman, 2004; Johnson et al., 2008). ICP27 has been found to decrease cellular mRNA 
stability and inhibit host splicing machinery by interacting with spliceosome-associated 
proteins. In addition, ICP27 helps HSV-1 evade type I IFN signalling by 
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downregulating STAT1 activation and preventing the accumulation of STAT1 in the 
nucleus (Johnson et al., 2008). At the same time, HSV-1 particles contain vhs proteins 
which can trigger rapid cleavages of both cellular and viral mRNAs upon viral entry 
into the cell (Kwong and Frenkel, 1987). HSV-1 vhs causes a significant decrease in 
the accumulation of STAT2 during infection and inhibits STAT1 activation by reducing 
the expression of Jak1 (Chee and Roizman, 2004). Other herpesviruses also target the 
IFN signalling pathway. The product of open reading frame 10 of KSHV counteracts 
IFN signalling by associating with JAK1 and STAT2 (Bisson et al., 2009). As a result 
of these interactions, activation of JAK1, STAT1 and STAT2 is impaired, and 
therefore, the accumulation of ISGF3 in the nucleus is decreased. In another instance, 
HCMV reduces the basal levels of both JAK1 and IRF9, leading to interruption of 
phosphorylation of STAT1 and STAT2 (Miller et al., 1998; Miller et al., 1999).  
 
Our data also suggest that HSV-1 ICP27 and vhs are critical for inhibiting IFN 
signalling via a reduction of Jak1 expression. However, only vhs can eliminate the 
human-mouse difference in JAK1 expression both at RNA and at protein levels in 
infected HFF, MRC5 and MF cells. This also correlates with the comparable viral yields 
of vhs mutant virus between human and mouse cells. In general, the interaction of 
cytokine with its specific receptor can result in a series of signalling events which then 
activate JAKs by auto- or trans-phosphorylation (Babon et al., 2014). However, JAK-
STAT signalling can be induced through specific calcium-dependent protein kinases 
(Sengupta et al., 1996; Wang et al., 2008a). A previous study showed that the calcium 
signalling pathways plays an essential role in facilitating early entry of HSV-1 
(Cheshenko et al., 2003; Cheshenko et al., 2007). This process requires the full 
complement of key glycoproteins, including gB, gD and gH, to induce the calcium 
response and trigger focal adhesion kinase phosphorylation (Cheshenko et al., 2007). 
Indeed, we found mutations in HSV-1 glycoproteins in our experimental evolution of 
HSV-1 in mouse cells. Hare et al. discovered that both calcium signalling and 
recognition of viral genomes contribute to IRF3 activation in the absence of IFNs and 
this then enhances induction of certain ISGs upon low-levels of enveloped virus particle 
entry (Liu et al., 2012; Hare et al., 2015). These data suggest that calcium signalling 
can act as a danger signal prior to virus replication and the prototypic recognition 
response, priming the reaction to viral infection. We have preliminary results that show 
that HSV-1 infection induces JAK1 activation both in wild-type and IFNAR-/- mouse 
cells, but phosphorylation levels are significantly reduced while treating these cells with 
a cell-permeant calcium chelator (data not shown). This indicates that activation of 
JAK1 requires calcium transport in mouse cells during the initial infection prior to IFN 
stimulation. In human cells, JAK1 activation was barely detected during wild-type 
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HSV-1 infection. This may be explained by more efficient blockage of basal JAK1 
protein expression by HSV-1 in human cells compared with mouse cells, which 
subsequently leads to less JAK1 that can be induced to active forms. However, 
mechanisms driving calcium transport by HSV-1 infection, resulting in 
phosphorylation of JAK1 are still unknown and human-mouse differences in this 
pathway require more investigation. 
 
To summarise, this thesis investigated two broad but sometimes overlooked questions, 
namely, whether sex or species affect transcriptional changes in cells during HSV-1 
infection. Our findings emphasise the importance of understanding basic differences in 
each cell type used for research. The results of this study indicate that HSV-1 has 
evolved to restrain innate immune responses in its natural host via JAK signalling, but 
this does not occur in mouse cells which are commonly used to study HSV-1 
pathogenesis. In addition to the human-mouse difference, the chromosomal differences 
between the two sexes can by themselves generate different intensities of reactions 
against HSV-1, particularly in cytosolic DNA-sensing pathways. These findings define 
a sex-specific intrinsic program in the innate immune response, independent of sex 
hormones, at the initial stage of HSV-1 infection. Given that most of our observations 
were made in cell culture, further research is required, particularly with respect to in 
vivo study, to fully interpret both the human-mouse and sex differences during HSV-1 
infection. This will provide a more in depth understanding of interactions between 
HSV-1 and its host cells.  
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